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Introduction 
Epidemiology 
The incidence of cancer in Europe is increasing, with an estimated number of 3 million 
new cases a year1. Both in Europa and the US the most common form of cancer in men 
is prostate cancer (20%-29%) followed by lung cancer (15%-17%). In women, the 
most frequently diagnosed cancer is breast cancer (26%-29%), and respectively 
second (US) and fourth (Europe) in rank is lung cancer (6%-15%)1,2. Lung cancer is 
the most common cause of cancer death in men, while it is the third cause of death 
from cancer in women in Europe. Especially with the ageing of the European popula-
tion, cancer will remain a large problem in the near future. In the Netherlands the 
incidence of lung cancer is about 9000 a year3, being the second most frequent cancer 
in men and the third in women (www.ikcnet.nl). The incidence is decreasing among 
Dutch men, but is still increasing in women4. In 2003 about 8800 patients died of lung 
cancer, being the leading cancer-related death in men and the second in women 
behind breast cancer.  
 
Generally lung cancer can be divided in two main categories: non-small cell lung cancer 
(NSCLC) and small cell lung cancer (SLCL) with different clinical behaviour. NSCLC is 
the most frequent type of lung cancer and forms about 80% to 85% of all lung cancer 
cases2. Furthermore, lung cancer can also be categorized according to pathologic 
subtype. The main subtypes of malignant epithelial lung tumours are squamous cell 
carcinoma, small cell carcinoma, adenocarcinoma, large cell carcinoma and adeno-
squamous carcinoma5. In men lung cancer consists mainly of squamous cell carcinoma, 
while the major part of lung cancer in women is adenocarcinoma6. 
 
The prognosis of lung cancer is in general very poor, showing a 1-year survival of 
about 40% and a 5-year survival of 15%4,7,8. 
Diagnostics and staging 
NSCLC can be divided into several stages, based on the local extension, involvement of 
regional lymph nodes and the presence or absence of distant metastases. In general 
the TNM-classification is used for staging purposes6. In TNM the T gives information 
related to the extension of the primary tumour, the N stands for the invasion of re-
gional (lymph) nodes and the M for metastases. Currently, recommendations for the 
seventh revision of the TNM classification for lung cancer are being proposed9,10. Beside 
the TNM-system a staging system is employed (Table 1.1). Although the prognostic 
value of the current staging system has been demonstrated for surgical patients, its 
value is less clear in non-surgical patients9-11. 
 
Standard diagnostic procedures to stage lung cancer consist of a physical examination, 
an X-ray of the thorax and laboratory investigations. Furthermore, a CT-scan of the 
thorax and a bronchoscopy, together with a histological or cytological biopsy of the 
tumour and/or involved lymph nodes, is performed. 
4 | Chapter 1 
 
 
The 18F-fluoro-2-deoxy-glucose (FDG) Positron Emission Tomography (PET) is increas-
ingly used in the diagnostic procedure of lung cancer. FDG-6-phosphate (FDG-6-P04), 
the end product of FDG, is accumulated in the cell and is a measure for the rate of 
glycolysis within the tumour. The preferential accumulation of FDG in neoplastic cells 
permits differentiation between benign and malignant tissue12. FDG-PET scan has a 
higher sensitivity, specificity and accuracy for detection of lymph node involvement and 
distant metastases in NSCLC than CT scan and therefore, results in a more accurate 
staging13-15. Therefore, PET has now become a standard imaging tool in the staging of 
lung cancer, and has resulted in a reduction in the number of thoracotomies up to 
20%16. The avoidance of futile thoracotomies is very important, since this procedure 
has its morbidity. Furthermore, patients referred for radical radiotherapy or chemo-
radiation may be found to already harbour metastatic disease. The finding of meta-
stases on PET will therefore change the management from radical to palliative intent. 
Treatment modalities 
The treatment of NSCLC is dependent on both the general condition of the patient as 
well as the clinical tumour stage. For clinical stage I and II in fit patients, surgery is the 
first treatment of choice. Despite surgical resection, 50% to 60% of early stage pa-
tients relapse and will die from their lung cancer. For patients with early stage NSCLC 
with contraindications for surgery (medical inoperable patients) radiotherapy is com-
monly considered as the main treatment. In this group of patients stereotactic radio-
therapy has experienced increasing importance, with promising initial results for local 
tumour control of 80% to 95% with 2-year overall survival rates varying between 50% 
and 80%17. 
 
Stage III disease represents a very heterogeneous group of patients in which the 
optimal therapy is not clearly defined. A subset of stage IIIa patients might be consid-
ered surgical candidates after induction chemotherapy18. However, for patients with 
irresectable locally advanced tumours in a good general condition, radiotherapy alone 
or combined with chemotherapy is the principal choice of treatment. High local failure 
rates are observed in patients treated with radiotherapy alone or sequential chemo-
radiation. Therefore, several approaches have been applied to improve local tumour 
Table 1.1 Staging of non-small cell lung cancer. 
 T N M  
occult Tx N0 M0  
stage 0 Tis N0 M0  
stage IA T1 N0 M0  
stage IB T2 N0 M0  
stage IIA T1 N1 M0  
stage IIB T2 N1 M0  
 T3 N0 M0  
stage IIIA T1 N2 M0  
 T2 N2 M0  
 T3 N1, N2 M0  
stage IIIB any T N3 M0  
 T4 any N M0  
stage IV any T any N M1  
Abbreviations: T=tumour, N=(lymph) nodes, M=metastases. 
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control and survival. These strategies include escalating the radiation dose, accelerated 
radiotherapy schedules and/or concomitant administration of chemotherapy and 
radiotherapy19-23. However, even with the concurrent administration of chemotherapy 
and radiation, local relapse occurs in about 30 percent of the patients as the initial site 
of failure24-26. And although radiation dose-escalation is associated with improved local 
control and overall survival, the possibilities for dose-escalation are often limited due to 
normal tissue constraints19. 
 
In case of metastatic disease treatment mainly consists of palliative chemotherapy and 
supportive care. In this stage radiotherapy can play a meaningful role in the palliation 
of painful (bone) metastases. 
Improvement of radiotherapy in NSCLC 
Several issues contribute to the outcome in radiation treatment of NSCLC. The first one 
is the need of a correct staging; an incorrect staging will ultimately lead to under- or 
overtreatment of the patient. Therefore it is important to incorporate FDG-PET with its 
high diagnostic accuracy, in the staging procedure. Indeed, in 10% to 26% of cases, 
FDG-PET will change the intent of treatment from radical to palliative, because of the 
detection of distant metastases or locally advanced tumour, not suitable for radical 
treatment27,28. Secondly, it is important to define the target volume correctly, both for 
the primary tumour as well as for the involved lymph nodes. An incorrect defined 
target volume will lead to a geographical miss of the tumour and/or involved nodes 
during radiation, resulting in an increased risk of loco-regional recurrence. Both re-
spiratory related tumour movements as well as changes during the series of fractio-
nated radiotherapy will influence the localization and volume of the target volume, and 
should be taken into account for target volume delineation29. A third important issue 
contributing to the outcome is the total radiation dose delivered to the tumour. Not 
only the total radiation dose delivered, but also the time in which this dose is given is 
of utmost importance30,31. This is due to accelerated repopulation, which is usually 
observed about 3 weeks after start of radiotherapy32,33. Finally, in-vivo dosimetry using 
Electronic Portal Imaging Devices (EPID) and monitoring of the set-up of the patient 
are needed to assure the quality of the radiation treatment delivered34. 
Outline of thesis 
The first two chapters give an overview about the current role of PET-CT in the diag-
nostics and treatment of lung cancer. Chapter 1 contains the general introduction, 
whereas in Chapter 2 a review is given of the current status of FDG-PET in tumour 
volume definition in NSCLC in radiation treatment planning. 
 
In this thesis several questions are addressed, which ultimately might lead to     
improvement of radiotherapy and hence outcome in NSCLC. 
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What is the biological meaning of FDG-uptake on PET scan? 
The maximal uptake of FDG in the primary tumour was consistently shown to be a 
significant, independent prognostic factor for survival, both after complete resection 
and after radical radiotherapy35-38. However, the actual mechanisms by which a high 
uptake of FDG leads to a worse prognosis are not well known. A high proliferative 
activity of the tumour might be related to a higher uptake of FDG, but contradicting 
findings have been observed regarding the correlation between proliferation and the 
uptake of FDG39,40. Hypoxia might be another important factor playing a role in the 
uptake of FDG, since it leads via the Hypoxia Inducible Factor-1α (HIF-1α) pathway to 
upregulation of several pathways, including the upregulation of glucose trans-
porters41,42. Hypoxia leads to an increased rate of glycolysis, which in turn, increases 
the uptake of FDG. Moreover, hypoxia is an important cause of treatment failure in 
many tumours and has been related to a poor outcome43-46. Chapter 3 addresses the 
question whether the worse prognosis of NSCLC patients with a high FDG uptake is 
related to hypoxia. This chapter shows the results of a study, investigating the relation 
between the standardized uptake value (SUV) on FDG-PET scan and hypoxia related 
markers (HIF-1α and CAIX), a proliferation-related marker (Ki-67) and glucose trans-
porters (GLUT-1 and GLUT-3) in 102 NSCLC patients. 
 
Not only the background of a high uptake of FDG and its relation with a poor prognosis 
needs to be further investigated, but also the intra-tumour heterogeneity in the uptake 
of FDG as visualized on PET scan. This might reflect heterogeneity of ongoing patho-
physiological processes within the tumour. More insight knowledge concerning the 
biological meaning of the intra-tumour heterogeneity might allow specific targeting, 
and will lead to further individualisation of the treatment of NSCLC47. In Chapter 4 the 
feasibility to correlate the intra-tumour heterogeneity as visualized on 18F-FDG PET 
with histology in an ex-vivo model is evaluated. 
Can FDG-PET-CT scan further improve the characterization and definition of 
the target volume? 
To achieve accurate radiation treatment planning a precise and consistent delineation 
of the target volume is necessary. However, there is large interobserver variability in 
the target volume delineation in NSCLC. The accuracy of target volume delineation can 
be improved using a standardized delineation protocol. Furthermore, integration of PET 
information into target volume delineation in NSCLC results in a reduction of inter-
observer variability compared with CT-based delineation48-51. Currently, target volume 
delineation is carried out manually. PET-based automatic contouring, based on e.g. 
Signal-to-Background ratios (SBR), might further improve target volume delineation 
and reduce interobserver variability52,53. Automatic contouring would be the ultimate 
method to use both in daily clinical practice, as well as for clinical studies. Chapter 5 
describes the validation of a PET-CT scan based auto-contouring method and the 
influence of this auto-contour on interobserver variability in the delineation of the 
primary tumour and the involved lymph nodal volumes in NSCLC. 
 
Usually treatment planning is mainly based on pre-treatment images only. The gross 
tumour volume (GTV) is commonly delineated on CT and consists of the visible tu-
mour54. To include microscopic disease a margin of 5 to 8 mm is taking into account55, 
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creating the so-called clinical target volume (CTV). Furthermore, different factors like 
variations in size, shape and position of the CTV as well as uncertainties in patient 
position (set-up) are taken into account in the additional margins for the planning 
target volume (PTV)56. However, the target volume is not a static volume and in case 
of NSCLC, this will be influenced by tumour movement due to respiration as well as 
changes during fractionated radiation treatment29. A respiratory correlated CT scan 
provides information concerning the movement of the target volume due to respira-
tion57. This movement can be taken into account in the margins added from CTV to 
PTV58. Moreover, repeated imaging of the tumour during radiotherapy will contribute to 
a better definition of the target volume. Repeated PET-CT scanning can be used to 
track both changes in anatomics and tumour volume as well as metabolic changes and 
will give the opportunity to adapt treatment according to the changes. Chapter 6 and 
Chapter 7 are dedicated to the (individual) changes in tumour volume, tumour motion 
and maximal uptake of FDG during fractionated radiotherapy. 
Can the treatment of NSCLC be improved by individualization of radiotherapy? 
One of the approaches to further improve radiation treatment in NSCLC is dose-
escalation to improve loco-regional control and survival in NSCLC19,22,59-61. However, 
dose escalation is limited by damage to normal tissues, like lung and spinal cord. 
Therefore, most dose escalation studies have included selected patients. In these 
studies they usually have categorized patients in groups and moved from one esti-
mated iso-toxicity level to the next. However, the best achievable radiation schedule 
should be defined for each individual patient separately. Such a scheme would include 
the highest total tumour dose based on individualized normal tissue dose constraints 
for this patient; the so-called individualized radiation dose prescription. The last  
chapters of this thesis concern the application of an individualized maximal tolerable 
dose radiation prescription, using FDG-PET-CT for target volume delineation. Chapter 8 
describes a theoretical dose modelling study. In this study the theoretical gain using 
the concept of an individualized dose prescription, based on normal tissue dose con-
straints, is evaluated. A comparison of 5 radiation schedules, including classical frac-
tionation, hypofractionation and hyperfractionation combined with accelerated treat-
ment is performed and the effect on estimated tumour control probability and the risk 
for pneumonitis are investigated. In Chapter 9 the clinical results, both toxicity and 
outcome, of a prospective feasibility study using an individualized dose prescription are 
described. In this study the radiation dose was individually escalated until a dose-
limiting normal tissue constraint. 
 
Finally, Chapter 10 contains a discussion of the results mentioned in this thesis, their 
clinical implications and future directions. 
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Abstract 
Purpose: Positron emission tomography (PET) scan, mainly using 18F-Fluoro-
deoxyglucose (FDG) as a tracer, is currently widely accepted as a diagnostic tool in 
oncology. It may lead to a change in staging and therefore in treatment management. 
PET can also be used to define the target volume in radiation treatment planning and 
to evaluate treatment response. 
 
Materials and Methods: In this review, we focused on issues concerning the role of 
PET in target volume delineation in non-small cell lung cancer, both for the primary 
tumour and regional lymph nodes. A literature search was performed using MEDLINE. 
Furthermore, the following questions were addressed: does PET allow accurate tumour 
delineation and does it improve the outcome of radiotherapy, in terms of reduced 
toxicity or a higher tumour control probability? 
 
Results: Most studies have shown a significant alteration in the target volume in 
almost half of the patients. The addition of PET resulted mainly in a decrease in target 
volume of 20% to 25%. These changes were most often due to the exclusion of atelec-
tasis and the inclusion or exclusion of lymph nodal stations. PET reduces the inter-
observer variability in target volume delineation. Moreover, PET might improve tumour 
coverage and reduces the volume of organs at risk irradiated. 
 
Conclusion: Combined computer tomography (CT) and PET information seems to 
influence target volume delineation. Using (CT-)PET scan, interobserver variability is 
being reduced. In the field of lung cancer, incorporation of PET seems to improve 
tumour coverage and spare normal tissues, which may lead to less toxicity or the 
possibility to escalate dose. 
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Introduction 
Positron emission tomography (PET), mostly with 18F-fluoro-deoxyglucose (FDG), and 
to a much lesser extend with 11C-methionine (MET) or 11C-choline, is increasingly used 
in oncology. The preferential accumulation of these radiotracers in neoplastic cells 
permits differentiation between benign and malignant tissue. In case of FDG, the end 
product of FDG, FDG-6-PO4 is retained in the cell, and is a measure for the rate of 
glycolysis in the tumour1. FDG-PET has for many cancer sites a higher sensitivity, 
specificity and accuracy for detection of tumour involvement than computer tomo-
graphy (CT) or magnetic resonance imaging (MRI) and results in a more accurate 
staging of malignancies, both for the primary tumour, lymph nodes and distant metas-
tasis2-10. Since FDG uptake is closely related to biological characteristics of the tumour, 
treatment-induced changes resulting in tumour cell death or growth arrest, result in a 
subsequent reduction in FDG uptake, making this technique a sensitive marker of 
response. Several studies have investigated the role of PET for evaluation of treatment 
response and prediction of recurrence and/or survival after surgery, radiotherapy and 
chemotherapy, and have shown superiority for PET scan in several cases11-24. 
 
Concerning the issue whether a post-radiotherapy PET scan could predict residual 
disease and hence outcome, several studies have shown that residual FDG uptake is 
often associated with a worse treatment outcome, although the timing of scanning and 
the clinical consequences are not yet obvious in all circumstances25-32. Despite this 
being very important, both of those issues are beyond the scope of this chapter. 
 
Due to the high diagnostic accuracy of the PET, its role in radiotherapy has been 
investigated. From a theoretical point of view, the PET may influence radiotherapy by 
changing the T-, the N- and the M-staging with direct influence on treatment manage-
ment (Table 2.1)33,34.  
 
Table 2.1 Impact of (staging-) PET scan on radiotherapy treatment. 
 Changes in staging Effect on radiotherapy 
   
T-stage Larger extension of primary 
tumour (upstaging) 
Enlargement of radiotherapy fields to avoid geographical miss 
Change of radiotherapy indication from curative to palliative 
   
 Less extension of primary 
tumour (downstaging) 
Decrease in radiotherapy fields and hence decrease in radiation 
exposure of normal tissues, and thus possible allowing dose  
escalation 
Change of radiotherapy indication from palliative to curative 
   
N-stage Detection of new site of lymph 
node involvement  
(upstaging) 
Enlargement of radiotherapy fields to avoid geographical miss 
Change of radiotherapy indication from palliative to curative 
   
 Omission of enlarged lymph 
nodes, diagnosed as malignant 
on CT or MRI (down staging) 
Decrease in radiotherapy fields and hence decrease in radiation 
exposure of normal tissues, and thus possible allowing dose  
escalation 
Change of radiotherapy indication from palliative to curative 
   
M-stage Detection of distant metastases Change of radiotherapy indication from curative to palliative 
Abbreviations: T=tumour; N=(lymph) nodes; M=metastases. 
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Indeed, in 10% to 30% of cases, FDG-PET changed the intent of treatment from 
radical to palliative, because of the detection of distant metastases or locally advanced 
tumour, not suitable for radical treatment34-38. In the case of new or additional PET 
findings, pathologic confirmation is needed before changing treatment. As there is a 
more accurate differentiation between tumour and non-malignant tissue compared with 
morphological imaging techniques, the integration of PET into radiotherapy planning 
may also influence delineation of target volumes and reduce the inter- and intra-
observer variability34-51. This may also enable individualisation of radiotherapy strate-
gies, as it provides information about specific biological characteristics of tumours. It 
may then lead to altered fractionation regimes and/or combination of radiotherapy with 
targeted drugs52,53.  
The rational use of PET in radiation treatment planning depends on the qualities of 
PET(-CT). These qualities, like sensitivity, specificity, positive predictive value, negative 
predictive value and accuracy of PET and CT, are depending on the specific tumour 
site. For mediastinal lymp node staging in non-small cell lung cancer (NSCLC) both the 
sensitivity and specificity for PET(-CT) are higher than for CT alone. Whereas the CT 
has a sensitivity varying from 33% to 83%, the sensitivity is 77% to 91% for        
PET(-CT), with a specificity between 67% and 90%54-57. 
 
Methods used to determine sensitivity and specificity of PET scanning differ between 
the mentioned studies. Sometimes numbers are specific either for the primary tumour, 
lymph nodes or metastatic disease or a combination of these. To further complicate the 
issue, numbers on lymph nodes may refer to individual nodes or nodal levels. More 
recently the combination of PET-CT has been compared side-by-side with CT and PET, 
CT alone and PET alone. The PET-CT combination has consistently been shown to have 
a higher sensitivity and accuracy compared with the individual modalities. This holds 
both for the primary tumour and lymph node metastases9. It is beyond the scope of 
this chapter to discuss in depth how to use PET (or PET-CT) according to their intrinsic 
values of sensitivity and specificity. An editorial has been written on that subject58. 
 
In this study we will only address the question of how PET scan influences radiotherapy 
planning in stricto senso, i.e. how will this technique change the definition of target 
volumes in patients selected for radiotherapy with curative intent. Ideally information 
about the delineation of the Gross Tumour Volume (GTV) and/or Clinical Target Volume 
(CTV) should be given. In the case of Planning Target Volume (PTV) margins for 
movement and set-up variations are also taken into account. This makes it more 
difficult to compare these volumes between different centres, as they are dependent on 
the radiation and immobilisation techniques used. 
 
We will therefore focus on the following questions: 
 Does PET scanning allow accurate tumour delineation? 
 Does PET scanning change Gross Tumour Volume (GTV), Clinical Target Volume 
and/or the Planning Target Volume (PTV), both for the primary tumour and the   
local and regional lymph nodes? 
 Does PET scanning allow improvement of treatment outcome? 
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Materials and Methods 
A literature search was performed on MEDLINE with the key words (FDG-)PET, lung 
cancer, NSCLC, radiotherapy, radiation, oncology, cancer, treatment, therapy, plan-
ning, target volume, Gross Tumour Volume (GTV), Clinical Target Volume (CTV), 
Planning Target Volume (PTV), staging, contouring, delineation, variability, observer, 
intra-observer, interobserver, toxicity, dose escalation, recurrence, fields and permuta-
tions of these. Only articles, published before July 31st 2007, in English were studied. 
Most studies used FDG as a tracer, and in this article PET will imply FDG-PET, unless 
otherwise stated. Studies were omitted when they did not include radiotherapy   
patients, studied other radiation qualities than photons (e.g. protons), only compared 
data on staging for distant metastases, only addressed basic research questions or only 
provided data on the proportion of patients in which the indication for radiotherapy 
changed from radical to palliative intent for this was deemed being an extension of 
staging. 
Results 
Does PET scanning allow accurate tumour delineation? 
The major drawback of PET is the lack of anatomic detail. Combining PET and CT or 
MRI-scan will be needed to provide anatomical information. The exact meaning of PET 
signal is not known and in general, studies evaluating the correlation between target 
volume delineation based on PET and pathological data are missing. To date, only few 
studies in head-and-neck cancer compared PET, CT and MRI based delineation of the 
primary tumour with pathologic findings, and showed a complex relation59,60. Studies 
with similar design in NSCLC are awaited to provide a better idea about the definite 
role of PET scanning in radiation treatment planning. 
 
Integrated PET-CT-scan for treatment planning might improve the standardization of 
volume delineation when compared with CT alone. With anatomic imaging modalities, 
like CT, the boundaries of the tumour are difficult to define, especially in patients with 
atelectasis or displacement of normal tissue. Consequently, a significant interobserver 
variation is found for imaged based (CT and MRI) contouring of GTV at different  
tumour sites61-64. By adding PET-information not only the mean volume of GTV is 
reduced, but there is also a reduction of the standard deviation35. The ratio of largest 
to smallest GTV based on PET-CT information shows a narrower range compared with 
CT alone. Caldwell et al. found a decrease of this ratio in 23 out of 30 patients (77%) 
with NSCLC with a mean ratio of largest to smallest GTV for CT-alone of 2.31 and for     
PET-CT of 1.56, a significant decrease42. Co-registration of CT and PET images even 
further reduces interobserver variability compared with non-registered images in the 
delineation of lung tumours47,65. Steenbakkers et al. investigated interobserver   
variation in NSCLC, comparing the CT and CT-PET based delineation of 22 lung   
tumours by 11 radiation oncologists. They observed a reduction in observer variation 
from a standard deviation of 1.0 cm for CT to 0.4 cm for matched CT-PET. Moreover, 
they found a reduction in the mean delineation time (12 versus 16 minutes)43.  
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Although interobserver variability is still seen with (CT-)PET, it seems to be minimal-
ised compared with conventional imaging methods. 
 
Most studies using PET for target volume delineation use the visual interpretation of 
PET images. More and more automatic segmentation based on a certain intensity level, 
such as Standardized Uptake Value (SUV)-level, a percentage of the maximal SUV or 
the source-to-background ratio is used34,60,66-71. Which is the best method to be used 
still needs to be further evaluated72. One has to be aware however that SUV, defined 
as the average activity per unit volume normalized to the injected dose and patient 
body weight, is influenced by different factors making it only reliable in a standardized 
setting. Factors that interfere with SUV quantification can grossly be divided into three 
areas: first tissue activity factors such as the shape of the Region of Interest (ROI), the 
partial-volume and spill over effects, attenuation correction, reconstruction methods 
and parameters for scanner type. Secondly it is influenced by tissue state factors 
amenable for corrections such as the time of SUV evaluation and competing transport 
effects and finally by the normalization factor (body size, body surface area, lean body 
mass)73-76. As pathologic examination is the golden standard, more results comparing 
PET-findings with pathology are needed. This information will provide us with infor-
mation about the definite role of PET scanning in target volume delineation and   
radiation treatment planning. 
Does PET scanning change Gross Tumour Volume (GTV) and the Planning 
Target Volume (PTV), both for the primary tumour and the local and regional 
lymph nodes in NSCLC? 
Primary tumour 
FDG-PET scanning plays an important role to differentiate between malignant and 
benign pulmonary lesions77. Several articles have been published about the integration 
of the FDG-PET information into radiotherapy planning in NSCLC, concerning GTV 
delineation34-36,39,40,44-51. PET data were incorporated into CT-based radiotherapy treat-
ment planning by visual comparison or with image co-registration. Both an increase 
and decrease in target volumes, GTV and PTV, have been described. Most studies 
showed a treatment volume modification in about half of the patients39,44-48. Bradley et 
al. found a GTV contour change in 17 out of 24 patients (58%): an increase in 12% 
and a decrease in 46%48. Ashmalla and co-writers found in 10/19 patients (52%) a 
treatment volume modification larger than 25% in stage II-IIIB NSCLC. In half of these 
cases an increase of the GTV was observed47. Deniaud-Alexandre et al. observed a 
decrease in GTV in 21 out of 101 patients and an increase in GTV in 24 patients46, 
while Grills and co-workers observed in 48% of patients a smaller GTV and in 33% a 
larger GTV on PET compared with CT40. Looking at more quantitative information on 
the effects of integrating PET data into CT planning for NSCLC, several studies describe 
the influence on GTV and/or PTV. Although most studies show a decrease in target 
volume due to the addition of PET (mean decrease of 8% till 29%)35,48,49,78, Erdi et al. 
and Munley et al. both observed an increase in mean target volume50,51. The largest 
series published by Deniaud-Alexandre et al., showed a decrease in 20% of patients 
(mean decrease of 42%±8%) and an increase in 24% of patients (mean increase of 
26.5%±19%)46.  
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In general, the major cause for a decrease in target volume is the exclusion of atelec-
tasis, which seems easier to diagnose with PET-CT compared with CT alone. An   
increase in GTV was mainly caused the detection of additional mediastinal nodal 
disease on PET compared with CT. 
Lymph nodes 
In view of the higher diagnostic accuracy of FDG-PET compared with CT for staging the 
mediastinum54-57,79, the incorporation of PET in radiotherapy planning of patients with 
NSCLC was investigated. In the study of Vanuytsel et al. CT and PET positive nodes 
were compared with the golden standard, pathologic examination, in 988 lymph 
nodes78. They found in a subgroup of 73 patients, that on CT criteria alone the GTV 
would include all pathologic nodes in 75% of patients (55/73), while based on PET-CT 
data this was 89% (p=0.005). Kiffer et al. found in 4 out of 15 patients (26.7%) that 
the mediastinal lymph nodes showed significant FDG uptake on the PET, whilst no 
abnormality was found on CT80. Giraud et al. found similar results: in 4 out of 12 
patients, PET positive lymph nodes (in 2 cases mediastinal) were negative on CT, 
leading to a modified treatment plan81. 
 
In NSCLC most groups only irradiate the involved mediastinal lymph nodes based on 
CT scans82-84. Van der Wel et al. showed in a group of 21 patients with clinical CT stage 
N2/N3 M0 NSCLC that the GTV of the lymph nodes decreased from 13.7±3.8 cm3 based 
on CT to 9.9±4.0 cm3 on PET-CT (p=0.011)85. Moreover, it was shown that irradiating 
only PET positive mediastinal lymph nodes could be safely applied in clinical practice. 
In a phase II study, only one isolated failure occurred in a group of 44 patients86. 
These results were confirmed by Belderbos et al.87. 
 
A summary of the given literature about the influence of the PET-scan on the measured 
target volumes in NSCLC is given in Table 2.2. 
 
Table 2.2 Impact of PET on target volume in radiation treatment planning. 
 No CT based target 
volume (in cc) 
 PET(-CT) based target 
volume (in cc) 
  Conclusions 
  Primary tumour      
Vanuytsel, 
2000  
10 PTVCT  579.0   PTVPET  402   p=0.002 PTVPET was significant 
smaller than PTVCT 
Ciernik,  
2003 
6 GTVCT  36.1   GTVPET 27.8     
 
 
 PTVCT  444.4   PTVPET  399.7    Mean change in PTV of 26% 
Bradley,  
2004  
24 GTVCT  111.3   GTVPET  99.8   p=ns No difference in GTVCT and 
GTVPET in the total group 
Deniaud-
Alexandre, 
2005  
92 PTVCT  361.0   PTVPET  347.5     Increase in PTV in 25% of 
patients (mean increase of 
35%) and a decrease in 22% 
of patients (mean reduction 
of 27%) 
  Lymph nodes       
Van der Wel, 
2005  
21 GTVCT  13.7   GTVPET-CT  9.9   p=0.011 GTVPET-CT was significant 
smaller than GTVCT 
Abbreviations: No=number of patients included; GTV=gross tumour volume; PTV=planning target volume. 
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In conclusion, most studies have shown a significant alteration in the target volume in 
25% to 50% of patients with NSCLC. Mostly a decrease in target volume was noticed, 
with a change of about 20 to 25%, when adding PET information for radiotherapy 
planning. The main causes for an increase in target volume are a larger primary 
tumour and most of all inclusion of additional nodal disease. The major cause for a 
decrease in target volume was the ability of PET to exclude atelectasis. Nevertheless, 
there are no pathologic data confirming that atelectatic regions do not contain any 
tumour cells. A correlation between pathologic examination and image-based delinea-
tion has only been performed for CT, but not for PET88-90. In NSCLC, PET-CT has a high 
diagnostic accuracy for detecting mediastinal lymph nodes and adding PET information 
for radiation treatment planning will lead to modified plans. In clinical studies, it was 
shown that it was safe to only irradiate PET positive mediastinal lymph nodes86,87. 
Further research to correlate target volumes based on PET and the golden standard of 
pathology needs to be done to validate the role of PET in delineating the tumour 
volumes in lung cancer. 
Does PET scanning allow improvement in treatment? 
A better delineation of the target volume might lead to an improvement in treatment. 
In case of radiotherapy with curative intent, the dose to normal tissues is usually the 
dose-limiting factor. Using the combined information of PET and CT can probably 
decrease the dose in critical organs at risk. When looking at normal tissues few studies 
have given limited information on Dose Volume Histograms (DVH) with and without 
FDG-PET31,34,39,40,45,46,50,78,81,85. Several studies showed no statistical significant differ-
ences in the DVH concerning percent lung volume receiving 20 Gy or more (V20 lung) 
comparing plans on base of CT data only or with additional PET information34,39,45. 
However, both Giraud et al. and Vanuytsel et al. found a reduction in V20 lung. In the 
study of Giraud et al. (n=12) there was a marked reduction of the V20 lung by an 
average of 22.8%. In only 1 patient there was an increased volume (5%) of healthy 
lung irradiated, but in 4 other patients the V20 lung was decreased with a maximal 
reduction of almost 50%81. Vanuytsel et al. performed in 10 selected cases a dosi-
metric study, leading to a reduction of V20 lung of 27% (8-58%)78. Deniaud-Alexandre 
and co-workers observed an increase in V20 by PET in 15 out of 81 patients (mean 
increase of 154%) and a reduction in V20 in 22 patients (mean reduction of 19%)46. 
Van der Wel et al. showed in a modelling study, consisting of a group of 21 patients 
with NSCLC, that the use of combined CT and PET information leaded to a decrease in 
mean V20 lung from 24.9% to 22.3% (p=0.012) and in the mean lung dose (MLD) from 
14.7 Gy to 13.6 Gy (p=0.004)85. Considering the V45 and V55 oesophagus the same 
pattern was shown in this study: a decrease from 45.2% to 34.0% for V45 (p=0.012) 
and from 30.6% to 21.9% for V55 (p=0.004). However, Ceresoli et al. and Grills et al. 
did not observe a change in respectively Dmax and Dmean for the esophagus. Moreover, 
Deniaud-Alexandre et al. investigated changes in the percentage of total heart volume 
receiving more than 36 Gy in a group of 81 patients46. They observed an increase in 8 
patients and a decrease in 14 patients, while Certolosi et al. observed a non-significant    
decrease in Dmean of the heart45. Looking at the impact of dose on the spinal cord in 
NSCLC patients Mah et al. found a reduced dose on the spinal cord when adding FDG-
PET information. The ratio of the maximum cord dose for the PET-CT plan/dose for the 
CT plan varied from 0.05 to 24. A significant lower average maximum dose for the 
spinal cord was found for the PET-CT plans compared with the CT plans34. This finding 
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was confirmed by Ceresoli et al.45, while in the series published by Deniaud-Alexandre 
et al. the mean spinal dose was unchanged comparing PET-CT to CT based planning46. 
Erdi et al. calculated the Normal Tissue Complication Probability (NTCP) in patients with 
stage I-III NSCLC. No difference was seen in the highest NTCP for lung when using 
combined PET-CT planning (22%) or CT only (21%)50. Grills and colleagues observed a 
lung NTCP of 18% for the CT-based planning, compared with 15% for the PET-based 
planning40. They also investigated the esophagus NTCP and observed a NTCP of 20.2% 
for CT-based planning and 18.7% for PET-based planning. 
 
Concerning the risk of geographical miss, MacManus et al. showed that in 3 out 10 
patients CT-based planning ultimately would lead to a geographical miss if PET was not 
used39. Kiffer et al. observed that if radiation ports based on CT alone were projected 
on the PET based target volumes, this would result in an inadequate coverage in 26% 
of patients80. Moreover, van der Wel et al. investigated the theoretical gain in TCP 
using the same toxicity levels for the CT-based and the PET-CT based plans85. The dose 
could be raised from 56.0 Gy to 71.0 Gy (p=0.038), leading to an increase in esti-
mated tumour control probability (TCP) from about 13% to 18%. Using a combined 
PET-CT simulator these results were confirmed, showing a decrease in exposure to 
oesophagus and lung. An increase in dose would lead to calculated TCP’s rising from 
6.3% for CT planning to 24.0% for PET-CT planning91. 
 
In patients with NSCLC, considered for radiation treatment with curative intent, the 
assessment of tumour localization in loco-regional lymph nodes, by means of PET, 
might improve tumour coverage. In a subgroup of patients, the volume of organs at 
risk irradiated, like lung, oesophagus, heart and spinal cord, can be reduced. This may 
lead to a decrease in toxicity or accepting the same level of toxicity, this can lead to 
dose-escalation with an expected gain in tumour control probability. 
Discussion 
Using combined PET-CT information seems to influence target volume delineation. The 
main problem is that only few studies have been performed comparing delineation 
based on PET with the golden standard of pathologic examination. In head-and-neck 
cancer a larger GTV was found using PET data compared with the macroscopic exami-
nation although there was an underestimation considering the extension in the   
mucosa59. Most studies performed in NSCLC show a significant alteration in target 
volume by incorporating PET information into treatment planning31,39,45,46,50,78,81,85. PET 
seems to help in differentiating between atelectasis and tumour and in identifying 
positive mediastinal nodes. In clinical studies it was shown that irradiating only the PET 
positive mediastinal lymph nodes is safe86,87. However, more data are needed to 
further investigate the explicit role of PET in delineating gross target volumes in  
radiation treatment planning. Using (CT-)PET scan interobserver variability is still seen, 
but it seems to be minimalised compared with conventional imaging methods43,47,65. 
Preliminary results show that incorporating PET data into treatment planning, probably 
will improve tumour coverage. In a subgroup of patients, the volume of organs at risk 
irradiated can be reduced and this gives the opportunity to escalate doses without 
increasing the complication risk. However, the field of incor-porating PET data into 
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radiotherapy planning is a rapidly evolving, meaning that information provided today 
may be outdated tomorrow. 
 
However, PET scanning has some drawbacks. Ideally imaging modalities or a combina-
tion of different tools should show all tumour nodules, which are present in a patient. 
One of the problems is that at the moment no modality does adequately detect sub-
clinical disease. Margins for subclinical disease will be needed using PET, as they are 
needed in CT and MRI. The PET has a relative low spatial resolution of 6 to 7 mm. 
Although a lot of effort is put into the improvement of the spatial resolution, it is 
physically limited to about 2 mm, and microscopic disease may thus still be missed on 
FDG-PET images. Technical advances in software, image fusion and image processing 
might improve interpretation of images. 
 
One of the other shortcomings of PET scanning is that the exact borders of tumours on 
the PET are not well defined, making visual delineation error prone. Therefore, soft-
ware has been developed, which will create a contour automatically when a certain 
intensity or SUV value is given. However, the literature is not clear about the intensity 
level that should be chosen to contour a tumour, should this be 40% or 50% of the 
maximal intensity?34,48,66-72,92 Another method developed for automatic volume segmen-
tation is based on the relationship between source-to background ratio and the activity 
level as has been described by Daisne et al.69. This last method looks promising in 
relation with pathologic examination in laryngeal cancer59. A background based   
thresholding seems also feasible in the delineation of lymph nodes in NSCLC93.    
However, since e.g. scanning protocols and SUV levels are not standardised, data from 
literature still need to be validated in individual departments, before introducing them 
into clinical practice. 
 
Both organ and tumour movements influence PET findings. In using image fusion of CT 
data and PET data, it has to be taken into account, that CT data are more rapidly 
acquired, whereas a PET dataset needs a longer acquisition time, which leads to fusion 
problems. E.g. in the thoracic region respiratory motion causes image artefacts.  
Respiration-correlated (RC) acquisition of both CT and PET can tackle part of this 
problem by reducing the smearing and improving the accuracy of co-registration of PET 
and CT data. The attenuation correction will be performed more accurately and hence 
SUV will be defined more precisely. 
 
Different tracers are and will become available to identify different kind of processes 
ongoing in tissue. For example, the PET tracer 18F-fluoromisonidazole (F-MISO) allows 
non-invasive assessment of tumour hypoxia, while 3’-Deoxy-3’-18F-fluorothymidine   
(F-FLT) is developed to investigate tumour cell proliferation. Most tracers have a 
relatively short half-life, e.g. 11C has a half-life time of 20 minutes, compared with 120 
minutes for 18F. This short half-life time influences the clinical availability for centres 
without a cyclotron1. The development of new PET radiopharmaceuticals may in the 
future allow in vivo detection of tumour biological properties, like malignant potential, 
hypoxia and eventually responsiveness to treatment. This would a provide information 
leading to a further individualization of cancer treatment. 
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PET-CT may also play a role in the response of the tumour to different treatment 
modalities, both during and after treatment. Especially evaluation of response early 
during treatment will give the possibility to adapt radiotherapy to the PET findings. 
 
Molecular imaging will be part of the future of radiation treatment planning. The 
advances in technology in imaging technology and the development of new tracers, 
which can be used to evaluate in a non-invasive way biological characteristics, together 
with the possibility to spare more normal tissues or to escalate tumour dose, will lead 
to more individualized cancer treatment and hopefully to better treatment results in 
radiation oncology. 
Conclusions 
The PET is currently more and more accepted as a diagnostic tool in oncology and is 
increasingly used in defining the target volume in radiation treatment planning in 
NSCLC. Looking at issues concerning the role of PET in treatment planning, combined 
PET-CT information seems to influence target volume delineation. However, data on 
the confirmation of the relation between delineation based on (CT-)PET and pathologic 
examination are scarce. More research is needed to address the question whether PET 
does allow accurate tumour delineation in regard to pathological tumour extension. As 
to the question whether PET improves outcome of radiotherapy, theoretical studies 
show that using PET information in treatment planning can lead to sparing of normal 
tissues and, by escalating dose, to a higher tumour control probability. Additionally, 
PET can add knowledge on different biological characteristics of the tumour itself. This 
biological information might be used in the future to delineate a biological target 
volume and to adapt radiotherapy treatment, both in terms of volume as well as in 
dose. More basic research and clinical confirmation of theoretical studies are awaited, 
before the definite role of PET in radiation treatment planning becomes clear. 
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Abstract 
Introduction: The purpose of this study was to investigate the relation between the 
standardized uptake value (SUV) on FDG-PET scan and hypoxia related markers    
(HIF-1α and CAIX), a proliferation-related marker (Ki-67) and glucose transporters 
(GLUT-1 and GLUT-3) in non-small cell lung cancer (NSCLC). 
 
Materials and Methods: One hundred and two patients, scheduled for complete 
resection, received a PET scan in Leuven or Maastricht/Aachen. The maximal SUV 
(SUVmax) was correlated with survival and immunohistochemical staining patterns. 
 
Results: The actuarial survival was worse for patients showing a high SUVmax, the best 
discriminative value being 8.0 (Leuven, p=0.032) and 11.0 (Maastricht, p=0.007). 
Tumours with a high SUVmax expressed in a higher proportion HIF-1α (63.1% versus 
37.9%, p=0.024) and GLUT-1 (82.8% versus 62.5%, p=0.025), than tumours with a 
low SUVmax. No significant difference was found in the expression of CAIX, Ki-67 and 
GLUT-3. 
 
Conclusions: This study supports preclinical data that hypoxia is associated with a 
higher uptake of FDG. 
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Introduction 
TNM-stage is up till now the best prognostic indicator for survival after radical opera-
tion in NSCLC1. However, even patients with the same stage may have a very different 
survival. Pre-treatment characteristics that add prognostic information are therefore of 
interest. Non-invasive imaging modalities, like positron emission tomography (PET), 
are increasingly used in the staging and treatment of NSCLC. The maximal uptake of 
18F-fluoro-2-deoxy-glucose (FDG) in the primary tumour was consistently shown to be 
an independent prognostic factor for survival2-5. However, the actual mechanisms by 
which a high FDG uptake leads to a worse prognosis are not well known. Different 
molecular markers, representing independent pathways, like hypoxia, apoptosis and 
angiogenesis, have been associated with a high risk of recurrence and death in NSCLC 
patients6-8. 
 
Hypoxia might play an important role in the uptake of FDG, since it leads via the 
Hypoxia Inducible Factor-1α (HIF-1α) pathway to up regulation of glucose transporters, 
Carbonic Anhydrase IX (CAIX) and other target genes9,10. Preclinical studies suggest 
that hypoxic conditions correspond to a higher FDG uptake11-14. In addition hypoxia is 
an important cause of treatment failure in many tumours and both HIF-1α and CAIX 
have been related to a poor outcome6,8,15,16. 
 
Since hypoxia leads to an increased rate of glycolysis, which in turn, increases the 
uptake of FDG, we hypothesized that the worse prognosis of NSCLC patients with a 
high FDG uptake would be related to hypoxia. Therefore we investigated the impact of 
tumour hypoxia, as assessed by the expression of the endogenous hypoxia markers 
HIF-1α and CAIX, and glucose metabolism (GLUT-1 and GLUT-3) on the uptake of FDG 
on PET scan before surgery in NSCLC. 
Materials and Methods 
Study population 
The surgical specimens evaluated were taken from 102 patients with a histological 
proven NSCLC. All patients with a clinical stage I or II, who had undergone resection of 
their tumour with curative intent and had had a diagnostic PET scan, were included. All 
patients were operated on at the University Hospital Gasthuisberg of Leuven (n=56, 
November 1994 - October 1997) or the University Hospital of Maastricht (n=46, 
February 1998 - September 2002). Only adenocarcinoma, squamous cell carcinoma 
and large cell/undifferentiated carcinoma were included. FDG-PET scanning was  
performed on two different types of PET-scanners. All patients fasted for at least 6 
hours before scanning and glucose levels were checked. 
 
The first group of patients from Leuven (n=56) was scanned with a CTI-Siemens 
(Iselin, NJ) 931/08/12 PET scanner with an axial field of view (FOV) of 10.1 cm and a 
spatial resolution of 8 mm. After injection (6.5 MBq/kg, maximal 555 MBq) a 60 min 
dynamic emission study was followed by a 10 min static acquisition. Images were 
reconstructed using filtered back projection. The patients from Maastricht (n=46) were 
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scanned with an ECAT EXACT 922 (Siemens-CTI, Knoxville, TN) in Aachen with an axial 
FOV of 162 mm and a spatial resolution of 6 mm. After a median time of 60 min (range 
45-120 min) after injection (3.5 MBq/kg) 2-D whole body emission images were 
acquired. Images were reconstructed using an iterative reconstruction algorithm. For 
the determination of the Standardized Uptake Value (SUV) a Region of Interest (ROI) 
was drawn by the nuclear medicine physician on the transaxial images around the 
primary tumour. SUV was then automatically calculated as activity concentration of 
FDG uptake divided by injected dose/body weight17. To avoid partial volume effects as 
much as possible, the maximal SUV (SUVmax) within this ROI was calculated. Since the 
2 PET-scanners used in this study have different characteristics, a potential concern 
was different measurements of SUVmax on the two machines. Phantom measurements 
to compare the 2 machines could not be performed, since the CTI-Siemens was no 
longer used. Since direct comparison of the results of the 2 groups was not possible, 
we determined the best discriminating factor for survival for both groups scanned on 
the 2 separate PET scanners, as has been described by Vansteenkiste and colleagues 
and used by other authors4,5. Different cut-off levels, within an in literature most often 
mentioned range between 5 and 13, were used for this purpose. 
 
The final staging was based on the findings at pathologic examination (TNM classifi-
cation, 6th edition, 2002). Follow-up data from all patients were collected until August 
2005, using the patient’s files. If necessary, the patient’s general practitioner or  
referring specialist was contacted to complete follow-up. Since data were collected 
retrospectively, only overall survival was estimated. 
Materials 
The specimens studied were routinely processed, formalin-fixed and paraffin-
embedded. Representative histological sections of the tumour specimen were taken to 
cut tissue sections of 4 µm thicknesses and stained with haematoxylin and eosin. For 
immunohistochemical staining sections were dewaxed in xylene and rehydrated by 
passage through graded alcohols. Endogenous peroxidase was blocked by applying 
0.03% hydrogen peroxidase (20 min). If necessary antigen retrieval was achieved 
using a citrate or TE buffer and sections were pretreated with blocking normal rabbit 
(CAIX) or calf (HIF-1α) serum. The following primary antibodies were used: mouse 
monoclonal antihuman CAIX antibody M75 (Slovak Academy of Sciences, Bratislava, 
1:50, 45 min), mouse monoclonal antihuman HIF-1α antibody (BD Biosciences   
Pharmingen, 1:50, overnight), rabbit anti-GLUT-1 and anti-GLUT-3, (AB1341 and 
AB1345 polyclonal antiserum, Chemicon, Temecula, 1:500, 2 hrs) and monoclonal 
mouse antihuman MIB-1 antibody (Ki-67 antigen DAKO M 7240, 1:100, 45 min). 
As second layer Dako Envision+ (CAIX and HIF-1α) or biotinylated antibody and 
biotinylated horse-radish peroxidase complex (GLUT-1, GLUT-3 and Ki-67) were used. 
Finally all slides were developed with diaminobenzidine (DAB) and counterstained with 
hematoxylin, dehydrated and mounted. Positive and negative (primary antibody 
omitted) controls were used to check the procedures. 
 
Sections were assessed using light microscope in a blinded fashion by at least two 
observers (AvB, DR and RJvS). If discrepancies were found, a consensus was reached 
using a conference microscope. For Ki-67 at least 500 tumour cells were counted and 
the percentage of Ki-67 positive cells was noted. Tissue samples showing no or just 
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weak membranous staining for GLUT-1 and GLUT-3 were considered negative, whereas 
strong membranous staining was considered positive. For CAIX membranous (m)CAIX 
staining and nuclear staining of HIF-1α a semi-quantitive scoring method was used: 
0=<5%, 1=5-25%, 2=25-50%, 3=50-75% and 4=>75% of cells positive. Finally the 
results were dichotomized. Tumours with no or low positive staining were considered 
negative and tumours with >25% positivity were considered positive. 
Statistics 
The SPSS software (version 14.0, SPSS Inc., Chicago, IL) was used to perform statisti-
cal analysis. Results are expressed as mean±standard deviation (S.D.) and range, 
unless otherwise indicated. Survival curves were analysed using the Kaplan-Meier 
method and the log-rank test. The Chi-square test, Pearson correlation coefficient and 
the Mann Whitney U-test were used to analyse the association between the different 
categorical variables. P-values less than 0.05 were considered statistically significant. 
Ethics 
According to Dutch and Belgian law and regulations of the Medical Ethical Committees, 
no informed consent was required for this study. 
Results 
Patient and tumour characteristics 
The patient and tumour characteristics are depicted in Table 3.1. In total 102 patients, 
83 males and 19 females were included in the study. The mean follow up was 42 
months (range 1-96 months) and the 2-year actuarial survival was 68.6%. One patient 
(1.0%) died within 30 days postoperatively due to cardial problems. Most tumours 
were squamous cell carcinoma (n=58, 56.9%), while 30.4% (n=31) consisted of 
adenocarcinoma and 12.7% (n=13) of large cell carcinomas.  
 
Table 3.1 Overview of patient characteristics and tumour characteristics. 
Characteristics    
Mean age (years)  64.3  (37-85) 
Gender Male  83 (81.4) 
 Female 19 (18.6) 
Pathology Adenocarcinoma 31 (30.4) 
 Squamous cell carcinoma 58 (56.9) 
 Large cell carcinoma 13 (12.7) 
Pathologic staging group IA 26 (25.5) 
 IB 40 (39.2) 
 IIA 0 (0) 
 IIB 24 (23.5) 
 IIIA 10 (9.8) 
 IIIB 2 (2.0) 
Values are expressed as mean (range) or number (percentage). 
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PET data and survival 
For the first group of patients from Leuven a median SUVmax of 10.0 (mean 10.8,    
S.D. 5.2, range 1.7-25.4) was observed. The most discriminative cut-off point for 
survival was found at SUVmax of 8.0 (Figure 3.1a). A statistically significant worse 
survival was noted in patients having a tumour with a SUVmax≥8, compared with 
patients showing a tumour with a SUVmax<8, a 2-year survival of 56.8% and 89.5% 
respectively (p=0.032; Figure 3.2a). For the second group of patients from Maastricht, 
a median SUVmax of 12.7 (mean 14.1, S.D. 6.5, range 4.2-31.5) was found. The best 
discriminative cut-off point for this group was observed at a SUVmax of 11.0 (Figure 
3.1b). Patients with a tumour with a SUVmax>11 showed a 2-year survival of 60.6%, 
while patients with a tumour showing a SUVmax<11 showed a 2- year survival of 92.3% 
(p=0.007; Figure 3.2b). The 2 groups of the different PET scanners showing a high 
uptake of FDG were combined and referred to as high SUVmax group further on. The 
combination of the groups with a SUV<8 and <11 respectively referred to as low 
SUVmax. The combining of the groups showed a 2-year survival of 90.6% for the  
patients with a low SUVmax and 58.6% for the patients with a high SUVmax (p=0.001). 
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Figure 3.1 P-values of log rank-test for actuarial survival using different cut-off levels for SUVmax for the 
group of patients from Leuven (a) and from Maastricht  b). 
b 
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PET data and immunohistochemical staining 
All immunohistochemical staining results were associated with SUVmax levels above and 
below the above-mentioned cut off points. Figure 3.3 shows the different IHC staining 
patterns for the markers. In total, 55% of the tumours showed positive nuclear  
staining of HIF-1α. Tumour samples with a high SUVmax showed positivity for HIF-1α in 
63.1%, while only 37.9% of the samples with a low SUVmax showed nuclear staining 
(p=0.024). Of all samples positive for HIF-1α 57% were positive for CAIX, whereas 
77% of cases being positive for CAIX showed nuclear staining for HIF-1α. Although a 
correlation between HIF-1α and CAIX staining was observed (correlation coefficient 
0.363, p=0.001), no significant difference in CAIX staining was observed between the 
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Figure 3.2 Kaplan-Meier survival curve for actuarial survival for maximal SUV (tumours with a high 
SUVmax versus tumours with a low SUVmax) applying a threshold for SUVmax of 8.0 for Leuven (a) and a 
SUVmax of 11.0 for Maastricht (b). 
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high and low SUVmax groups (resp. 45.3% and 30.0% positive samples, p=0.16). For 
the proliferation-associated marker Ki-67, the mean percentage of tumour cells being 
positive was 42.7% (S.D. 21.7, range 2.7-95.2%). In tumours with a high uptake of 
FDG 44.4% of cell were positive for Ki-67, while tumours with a low SUVmax showed a 
mean percentage 39.1% (p=0.20). For the glucose transporters, in total 76.5% of the 
tumours stained positive for GLUT-1 and 44.1% for GLUT-3. The tumours with a high 
SUVmax showed in 82.9% of cases membranous staining of GLUT-1, whereas tumours 
with a low uptake only in 62.5% (p=0.025). For GLUT-3 there was no statistically 
significant difference (p=0.21). The association between SUVmax and the expression of 
the different markers and the correlation coefficients of the markers are depicted in 
Table 3.2 and Table 3.3. 
 
 
 
Figure 3.3 Immunohistochemical staining. Positive nuclear staining for HIF-1α (a), positive membranous 
staining for CAIX (b), nuclear staining of Ki-67 (c), and membranous staining positive for GLUT-1 (d) and 
GLUT-3 (e). 
a b 
c d 
e 
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Table 3.3 Correlation between immunohistochemical staining patterns. Pearson correlation coefficients 
and p-value (between brackets) of immunohistochemical staining scores. 
 HIF-1α CAIX GLUT-1 GLUT-3 
CAIX  0.36     
  (<0.01)     
GLUT-1 0.14 0.13    
  (0.19) (0.21)    
GLUT-3 0.03 0.03 -0.19   
  (0.79) (0.80) (0.85)   
Ki-67 (MIB) 0.33 0.36 0.20 0.17 
 (<0.01) (<0.01) (0.04) (0.10) 
Discussion 
Although the high FDG uptake in malignant tumours is due to an increased glucose 
metabolism, the exact mechanism by which FDG accumulates in malignant cells has 
not fully been unravelled17. Nevertheless, it was repeatedly shown that a high SUVmax is 
related to an inferior overall survival2-5,18. 
 
This report studied the molecular mechanisms that might be involved in the prognostic 
role of SUVmax in stage I or II NSCLC surgical patients. As the patients were scanned in 
two departments, we used the best discriminative cut-off level for the SUVmax of each 
PET-camera to create a high and low SUVmax group4,5. In this study we confirmed a 
worse survival for patients with a high FDG uptake compared with a low uptake (2-year 
survival of resp. 58.6% and 90.6%, p=0.001). Furthermore, we investigated the 
biological characteristics of the tumours with a high and low FDG uptake. We observed 
an association between the amount of FDG uptake and the endogenous marker of 
hypoxia (HIF-1α) and the glucose transporter GLUT-1. Although it would be of interest 
to asses the amount of variance in FDG uptake explained by the expression of hypoxia 
related markers, this was not feasible since SUVmax could not be used a continue 
variable due to the use of different scanners. Nevertheless, to the best of our     
knowledge we are the first to report an association between hypoxia related markers 
and SUVmax in lung cancer patients11,13,4. Indeed, Bos and colleagues investigated the 
correlation between different markers and the uptake of FDG in 55 breast tumours, but 
Table 3.2 Relation between different immunohistochemical staining scores and the maximal SUV (SUVmax) 
of the tumour. 
IHC staining of surgical specimen low SUVmax 
(n=32) 
high SUVmax 
(n=70) 
p-value 
HIF-1α  37.9% 63.1% p=0.024a 
(% of tumours positive)     
CAIX  30.0% 45.3% p=0.16a 
(% of tumours positive)    
GLUT-1 62.5% 82.9% p=0.025a 
(% of tumours positive)    
GLUT-3 53.1% 40.0% p=0.21a 
(% of tumours positive)    
Ki-67 (MIB) 39.1% 44.4% p=0.20b 
(mean % of cells positive)    
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found no correlation between the HIF-1α and FDG uptake19. However, in their study a 
different cut-off point for HIF-1α expression (cut-off point of 1%) was chosen. 
 
In relation to the staining for HIF-1α and CAIX, we observed similar results as Giatro-
manolaki and colleagues showing 80% of CAIX positive cells also staining positive for 
HIF-1α6. Hypoxia up regulates different genes, like CAIX, GLUT-1 and GLUT-3, through 
the HIF-1α pathway20. However, different oxygen concentrations are required for 
induction of GLUT-1 and CAIX, which might explain the lack of association between 
SUV and CAIX, while finding a positive association between SUV and GLUT-121. For 
proliferative tumour activity, Veselle and colleagues showed in a study with 39 NSCLC 
patients a correlation between Ki-67 expression and SUVmax22. In contrast, we did not 
observe a correlation between the proliferation marker Ki-67 and the SUVmax. Although 
the tumours with a high uptake showed a somewhat higher percentage of Ki-67 posi-
tivity, this difference did not reach significance (p=0.20). In line with our results, 
Chung and colleagues found no correlation of PET findings and the proliferation index, 
measured by flowcytometry, in NSCLC23. Moreover, an animal model for prostate 
cancer, showed that a higher FDG uptake was indicative of tumour hypoxia but not for 
cellular proliferation14. Although the expression of GLUT is not necessarily directly 
related to transport activity, hypoxia can increase GLUT-1 levels and glucose uptake24. 
In several tumour sites, for instance cervix, oesophagus and breast, a relation between 
expression of glucose transporters and FDG uptake has been observed. In NSCLC 
contradictory findings have been observed. While the groups of Higashi and Mamede 
observed an association between the FDG uptake and GLUT-1, others did not find this 
correlation23,25-27. We could confirm a higher expression of GLUT-1 in the high SUVmax 
tumours (83%) compared with tumours with a low SUVmax (63%; p=0.025). The use of 
a different antibodies and/or different scoring methods may account for the difference 
in outcome of the studies. 
 
In this study, a cut-off level of 8 and 11 respectively were found as best discriminative 
cut-off levels. Findings of different cut-off levels can be explained by the usage of 
different PET machines and techniques2-5. We stress that the above-mentioned cut-off 
levels are not generally applicable. To compare results between different scanners 
directly, calibrating is necessary. However, cut-off levels only represent a way to 
simplify a sliding scale in which a higher FDG uptake is associated with a worse   
survival. The goal of this study was to investigate the biological background of a high 
uptake of FDG, which is correlated with a worse outcome. Our results show that a high 
uptake of FDG is associated with a higher HIF-1α and GLUT-1 expression. This finding 
might have therapeutic implications. Both clinical and preclinical studies have described 
the role of HIF-1α in therapy resistance28. Potential hypoxia-targeted therapies, like 
blockade of HIF-1α, are under investigation20,28,29. In the future FDG-PET scans might 
be used for both selection of patients for different therapies and monitoring tumour 
response on these therapies. 
 
In conclusion, the amount of uptake of FDG on the PET scan, as measured by the 
SUVmax, is associated with the expression of HIF-1α and GLUT-1, both up regulated 
under hypoxic conditions. This study provides evidence that not only in vitro, but also 
in vivo hypoxia is associated with an increase in FDG uptake. 
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Abstract 
We evaluated the feasibility to correlate intra-tumour heterogeneity as visualized on 
18F-FDG PET with histology for non-small cell lung cancer. For this purpose we used an 
ex-vivo model. The procedure was feasible in all operated patients. We have shown 
that this method is suitable for correlating intra-tumour heterogeneity in tracer uptake 
with histology. 
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Introduction 
Positron emission tomography (PET) in oncology has evolved as a valuable tool for 
staging of disease, to predict prognosis and in the evaluation of therapy response in 
non-small cell lung cancer (NSCLC)1. Moreover, the use of PET scan in radiotherapy 
planning of NSCLC has gained great interest2,3. This success is mainly based on the 
application of the glucose analogue 18F-2-fluoro-deoxy-D-glucose (FDG). Most tumours 
exhibit enhanced glucose uptake, which might be related to a higher consumption of 
FDG, an increased hexokinase activity or a decreased phosphatase activity within the 
tumour. As tumours are heterogeneous for several biological characteristics, it is the 
ultimate aim to visualize the phenotypic or micro-environmental tumour characteristics 
by imaging4. Variations in the FDG uptake within the tumour can be assumed to reflect 
heterogeneity of ongoing pathophysiological processes. Therefore, PET might poten-
tially be used to map different areas within the tumour with specific characteristics, 
and would allow for specific targeting and hence improvement of radiation treatment 
outcome in NSCLC. Although the uptake of FDG on PET scan has been correlated with 
biological variables, like the expression of GLUT-1 and HIF-1α5-7, detailed knowledge 
about the underlying characteristics of intra-tumour heterogeneity in the uptake of FDG 
is not available8,9. Therefore, we tested an ex-vivo model to investigate heterogeneity 
in uptake of FDG within the tumour. The model was accepted to be feasible if it would 
result in good quality images showing intra-tumour heterogeneity as well as good 
quality tissue sections, which could be used for immunohistochemical staining. In this 
chapter, we describe the model used and our experience in the first patients. 
Materials and Methods 
Model 
An ex-vivo model was tested to correlate intra-tumour heterogeneity in FDG uptake on 
PET with histology. FDG enters the cell by the same membrane transport mechanism as 
glucose and is phosphorylated by hexokinase. Since FDG-6-phosphate does not  
undergo further metabolism, FDG is trapped within the cells10. The PET-CT scan of a 
surgical specimen (ex-vivo) will thus provide us information about the situation before 
operation (in-vivo), at the time of injection of the tracer. Using an ex-vivo model no 
tumour movements are encountered during scanning and this furthermore provides the 
possibility of multiple sampling. 
Description of the procedure 
Injection of FDG 
Patients fasted for at least 6 hours before the injection of the radioactive tracer 18FDG. 
Plasma glucose levels were checked and if fasting levels (<7.0 mmol/l) were meas-
ured, a small dose of FDG (1/10 of the diagnostic used dose) was injected intrave-
nously. The dose was calculated according to the weight of the patient: 
(weight*0.4+2) MBq. A low dose of FDG was chosen to limit radiation exposure to the 
patient, surgeon and pathologist. In case of an injected dose of 40 MBq the effective 
dose (‘dose to the body’) for the patient was calculated to be about 0.76 mSv     
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according to ICRP 8011. This is a small dose compared to the dose given for a diag-
nostic PET scan (340 MBq; 6.5 mSv). An effective dose of 20 μSv for the surgeon and 
pathologist per patient operated was assumed to be acceptable. In case of 25 proce-
dures a year, this would result in a maximal effective dose of 0.5 mSv a year, which 
compares well with the dose limit for radiological workers of 20 mSv per year. To 
compensate for the lower injected dose of FDG, a longer scanning time of the specimen 
was needed to achieve PET images of good quality.  
Surgery 
Surgery was performed about one hour after injection of FDG, in the standard way by a 
cardiothoracic surgeon. Once the tumour was resected the surgical specimen was 
transported directly to the pathology department and subsequential sectioned in 
parallel slices of 1 cm thickness, including the total tumour.  
PET-CT imaging 
The slices were put between Perspex plates in vertical direction to facilitate scanning 
and put on ice to guarantee the quality of the specimen for pathologic examination 
afterwards. The PET-CT scanner used was a Biograph™ (SOMATOM® Sensation 16 with 
an ECAT ACCEL PET scanner, Siemens) with a transaxial field of view of 58.2 cm, an 
axial field of view of 16.2 cm and a spatial resolution of 6-7 mm. First a spiral CT scan 
was performed, which was used for attenuation correction of PET emission images. A 
PET scan was performed in 1 bed position encompassing the total specimen with a 
scanning time of 30 minutes, to correct for the low dose of FDG injected. The complete 
PET data set was reconstructed iteratively with a reconstruction increment of 5 mm to 
provide isotropic voxels.  
Delineation of tumour heterogeneity 
The total tumour was selected as a 3-D Region of Interest (ROI) in e.soft (version 5.0, 
Siemens, Erlangen, Germany). The maximal uptake of FDG within the tumour was 
calculated and contours were created for regions with 80%, 50% and 20% of maximal 
uptake. For each scanned slice a 1:1 plot was created depicting the different contours. 
Biopsies 
The plots were printed on a transparent sheet and used to guide sampling out of the 
different regions. In each individual tumour, biopsies (small tissue blocks of about 
0.25 cm3) were taken from the regions with the highest uptake (>80%), the lowest 
uptake (<20%) and a median uptake (50%). The biopsies were paraffin-embedded. 
After sampling the surgical specimen was processed for regular pathologic examina-
tion. Biopsies were cut into tissue sections of 4 µm thickness for haematoxylin and 
eosin (H&E) staining and for further immunohistochemical staining. H&E stained slides 
were microscopically evaluated to examine whether they contained vital tumour cells, 
fibrotic tissue, inflammation and/or necrotic tissue. An example of the total procedure 
is depicted in Figure 4.1. 
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Patients 
Patients with operable NSCLC, who had not received previous chemotherapy or   
thoracic radiotherapy and did not suffer from diabetes mellitus, were studied. Five 
patients were assumed to be needed to test the feasibility. Tumours had to be histo-
logical proven NSCLC and all types except bronchiolo-alveolar cell carcinoma were 
accepted. To ensure intra-tumour heterogeneity tumours had to be PET positive on 
diagnostic imaging and at least 3 cm in diameter. 
Ethics 
All patients were treated at the University Hospital of Maastricht. This study has been 
reviewed and approved by the local Medical Ethical Committee, according to the Dutch 
law and regulations. All patients gave written informed consent before entering this 
study.  
Statistics 
SPSS software (SPSS for Windows, version 14.0, SPSS Inc., Chicago, IL) was used to 
perform statistical analysis. For the comparison of the contents of the different biopsies 
the Chi-square test for homogeneity was used. Two-tailed p-values are provided and  
p-values less than 0.05 were considered statistically significant. 
 
 
Figure 4.1 Visualization of the total procedure: total surgical specimen (a), specimen sectioned in parallel 
slices of 1 cm thickness ready to be scanned (b), delineation of tumour heterogeneity in e.soft with 
regions with 80% (pink line), 50% (green line) and 20% (red line) of maximal uptake of FDG (c) and 
biopsies from the different regions (d). 
a b 
c d 
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Results 
Patient and tumour characteristics 
The feasibility of the ex-vivo model was tested in 5 patients, 1 female and 4 male 
patients. The median age of the patients was 60 years (range 43-76 years). The 
median diameter of the tumours was 3.0 cm (range 3.0-4.8 cm). Four tumours   
consisted of a squamous cell carcinoma, where as one tumour was an adenocarcinoma.  
Feasibility 
In all cases it was feasible to slice and scan the tumour. A median dose of 36 Mbq 
(range 34-46 Mbq) was injected. The interval between injection of FDG and completion 
of the resection of the tumour varied from 2 hours to 3.5 hours (median interval 120 
minutes) and the median interval between resection and imaging was 60 minutes 
(range 30-90 minutes). A scanning time of 30 minutes was sufficient to visualize the 
tumour well. In all patients good quality images could be achieved showing intra-
tumour heterogeneity of FDG uptake. The median maximal uptake of FDG within the 
tumour was 626.6 Bq/ml (range 278.9-1037.7 Bq/ml). The surgical specimen was 
sectioned in a median number of 3 slices (range 3-4) to include the whole tumour for 
each patient. In total 23 biopsies were taken of the different regions with a median 
number of 5 biopsies (range 3-6) per tumour. In 3 out of 5 patients the highest uptake 
of FDG was observed in the peripheral zone of the tumour, while in 2 patients the 
highest uptake was centrally located. No clear relation between the localisation of the 
highest uptake and tumour diameter was observed.  In total 7 samples were biopsied 
from low uptake regions, 9 from median uptake regions and 7 from high-utake regions.  
Radiation exposure 
The median effective dose for the 5 patients was 0.68 mSv (range 0.64-0.95 mSv). For 
the surgeon the median effective dose was 9.4 μSv and for the pathologist 0.2 μSv. 
This was below the dose of 20 μSv, accepted as maximal dose for each procedure. 
Histological examination 
All biopsies showed a good quality of H&E staining. Most slices consisted of a combina-
tion of tumour cells, fibrosis, inflammatory cells and/or necrosis. In total two samples 
out of the low uptake regions (29%) showed no vital tumour cells. Although low uptake 
biopsies showed in a higher percentage mainly fibrosis (43%) as the median (11%) 
and high (0%) uptake biopsies, the distribution patterns were not significantly different 
(p=0.16, Table 4.1).  
 
Table 4.1 Distributions of microscopic evaluation for the different biopsies out of regions with a low, 
median or high uptake of FDG. 
Characteristics low uptake of 
FDG 
median uptake of 
FDG 
low uptake of 
FDG 
Mainly vital tumor (>75%) 2 1 2 
Mainly fibrosis (>75%)   3* 1 0 
Combination of vital tumour, fibrosis and/or inflammation 
or necrosis 
2 7 5 
No significant differences in distribution patterns were observed (p=0.16). * 2 samples showed no vital tumour.  
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Discussion 
Most studies correlated imaging with histology, investigated microscopic extension 
beyond CT-based borders12-14 or correlated the biological characteristics of a random 
tumour sample with the uptake of FDG of the total tumour5,7,15. Not much is known 
about the correlation between intra-tumour heterogeneity of FDG uptake and histology. 
The aim of this study was to test the feasibility to image relative intra-tumour hetero-
geneity in the uptake of FDG and the possibility to investigate the histological back-
ground of this phenomenon. Although both the removal of the tumour and the slicing 
might influence tumour architecture, FDG-6-phosphate does not undergo further 
metabolism and therefore FDG will be trapped within the cells10. The PET scan of the 
surgical specimen may thus represent the situation in-vivo. Sorensen et al. showed in 
a mice model, that in-vivo FDG PET was able to distinguish between viable tumour 
tissue and confluent areas of necrosis. This finding was verified by autoradiography and 
histological studies of the C3H mammary carcinoma16. Zhao et al. performed a study in 
7 rats, using an allogenic hepatoma cell model, to correlate intra-tumour heterogeneity 
in FDG distribution using autoradiography with the expression of several immuno-
histochemical markers9. A higher expression of FDG in the central region compared to 
peripheral zones of the tumour was observed. Applying our ex-vivo model, we    
observed in 3 out of 5 patients the highest uptake in the peripheral zone and in 2 
patients this was centrally located. We did not observe a significant difference in 
distribution patterns concerning tumour, inflammation and fibrosis in these patients. 
Zhao et al. showed a correlation between the expression of the immunohistochemical 
markers Glut-1, Glut-3, Hexokinase II and intra-tumour accumulation of FDG. The 
hypoxia related marker Hypoxia Inducible Factor-1α (HIF-1α) was only observed in the 
central regions. This indicates that the heterogeneous distribution of FDG might be 
related to hypoxia, which leads to a higher expression of the glucosetransporters.  This 
is in line with in- vitro and in-vivo studies that have demonstrated an increased uptake 
of FDG under hypoxic conditions7,17,18. Ongoing studies will investigate the relation 
between immunohistochemical staining patterns in relation to intra-tumour hetero-
geneity in FDG uptake on PET. 
Conclusions 
We demonstrated the feasibility of an ex-vivo method to correlate intra-tumour  
heterogeneity in vivo with histology in human NSCLC. This technique can also be 
applied to other tumour types and PET tracers, and can provide more insight informa-
tion in the biological correlates of intra-tumour heterogeneity. Finally, this would allow 
for specific targeting and hence improvement of treatment outcome in NSCLC.  
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Abstract 
 
Purpose: To compare the source-to-background ratio (SBR) based PET-CT auto-
delineation with pathology in NSCLC and to investigate whether auto-delineation 
reduces the interobserver variability compared with manual PET-CT based gross tumor 
volume (GTV) delineation. 
 
Material and Methods: SBR based auto-delineation was compared with macroscopic 
tumor dimensions to assess its validity in 23 tumors. Thereafter, GTVs were delineated 
manually on 33 PET-CT scans by 5 observers for the primary tumor (GTV-1man) and the 
involved lymph nodes (GTV-2man). The delineation was repeated after 6 months with 
the auto-contour provided. This contour was edited by the observers (GTVauto). For 
comparison the concordance index (CI) was calculated, defined as the ratio of inter-
section and the union of 2 volumes (A∩B)/(A∪B). 
 
Results:  The maximal tumor diameter of the SBR based auto-contour correlated 
strongly with the macroscopic diameter of primary tumors (correlation coefficient: 
0.90) and was shown to be accurate for involved lymph nodes (sensitivity 67%,  
specificity 95%). The median auto-contour based target volumes were smaller than 
those defined by manual delineation for GTV-1 (31.8 cc and 34.6 cc, respectively, 
p=0.001) and GTV-2 (16.3 cc and 21.8 cc respectively, p=0.02). The auto-contour 
based method showed higher CIs than the manual method for GTV-1 (0.74 and 0.70 cc 
respectively, p<0.001) and GTV-2 (0.60 and 0.51 cc respectively, p=0.11). 
 
Conclusions: SBR based auto-delineation showed a good correlation with pathology, 
decreased the delineated volumes of the GTVs and reduced the interobserver     
variability. Auto-contouring may further improve the quality of target delineation in 
NSCLC patients. 
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Introduction 
Thoracic radiotherapy plays an important role in the management of inoperable non-
small cell lung cancer (NSCLC). The prognosis of patients with NSCLC remains poor 
due to high rates of local failure and distant metastases1-3. Although local tumor control 
can be improved by adding chemotherapy to radiotherapy and by increasing the total 
radiation dose, normal tissue toxicity is dose limiting4-9. A precise and consistent 
delineation of the target volumes is therefore a prerequisite for accurate radiation 
treatment planning. At present, target volume delineation is not only time consuming, 
but a large interobserver variability has been observed for many tumor sites10-19. 
Delineation accuracy can be improved using a standardized delineation protocol and by 
using Positron Emission Tomography (PET) information10,11,14,20-30. To date, at least 5 
studies have investigated the role of integrating PET into target volume delineation in 
lung cancer and these have consistently shown a reduction in interobserver variation 
compared with CT-based delineation10,26,31-33. However, in all the currently used proce-
dures, target volume delineation is carried out manually. 
 
PET scan signals, based on Standardized Uptake Value (SUV) and Source-to-
Background ratio (SBR) can be utilized to automatically delineate tumors. It is con-
ceivable that these auto-delineation tools may improve the accuracy of target volume 
delineation. Different authors mentioned different fixed threshold values of maximal 
uptake, which vary from 36% to 50%, as well as a variable threshold depending on the 
SBR31,34-37. The latter method has been compared with the ‘gold standard’ of pathology 
of surgical specimens of laryngeal carcinomas, where it has shown a complex, but 
accurate relation. In this tumor site the SBR based method underestimated, like other 
imaging modalities, contralateral mucosal extension, while overestimating infiltration of 
the cartilage and extralaryngeal structures38. To the best of our knowledge, no such 
study has been performed in lung cancer. 
 
This study aimed to investigate the validity of SBR based auto-delineation, compared 
with the pathology in NSCLC, and subsequently to look at whether auto-contour based 
delineation would reduce interobserver variability in the delineation of the gross tumor 
volume (GTV) of the primary tumor and involved lymph nodes compared with conven-
tional, manual PET-CT based delineation in patients with untreated NSCLC. 
Materials and Methods 
PET-CT scan 
Included in this study were 33 consecutive patients with histological proven NSCLC 
(clinical stage Ib-IIIb), who had undergone a diagnostic whole body PET-CT scan 
(Biograph™, SOMATOM® Sensation 16 with an ECAT ACCEL PET scanner, Siemens). 
Patients fasted at least 6 hours before the start of the examination. 18F-fluoro-2-deoxy-
glucose (FDG) (MDS Nordion, Liège, Belgium) was injected intravenously, followed by 
physiologic saline (10 ml). The injected total dose of FDG was dependent on the weight 
of the patient (weight*4+20 MBq). After 45 minutes (time which is needed for uptake 
of FDG) free-breathing PET and CT images were acquired. First a topogram was made 
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from the skull to the upper region of the legs. Secondly, a spiral CT-scan with intra-
venous contrast was performed. The PET images were acquired in 5 minute bed posi-
tions (in total 7 bed positions with overlap). The CT dataset was used for attenuation 
correction of PET images. The complete data set was then reconstructed iteratively 
with a reconstruction increment of 5 mm to provide isotropic voxels. The Standardized 
Uptake Value (SUV) was used to measure the amount of uptake of FDG in a selected 
Region of Interest (ROI). For the determination of the SUV of the primary tumor, a ROI 
was drawn on the 3D-images in e.soft (version 5.0.24.5, Siemens, Erlangen, Germany)  
around the region of the primary tumor. The SUV was calculated as activity concentra-
tion of FDG uptake divided by injected dose/body weight39. To minimize partial volume 
effects, the maximal SUV (SUVmax) within this ROI was calculated. PET images were 
interpreted and reported by a nuclear medicine physician. Three series of tomograms 
(transverse, coronal and sagital) were inspected simultaneously. Any focally enhanced 
18F-FDG uptake, that projected onto a pulmonary mass or a lymph node on CT were 
classified as positive40. 
SBR based auto-delineation 
The e.soft image processing software was used to delineate volumes exceeding a 
specified threshold automatically. To determine thresholds, phantom measurements 
were performed using different source-to-background ratios, as described by Daisne et 
al.5. A spherical phantom filled with 6 spheres with volumes ranging from 0.5 to 32 ml 
was used. Each sphere was filled with 18F-FDG in different concentrations, together 
with different background concentrations to get different SBRs. The thresholds were 
determined as a percentage of the maximal uptake in the spheres, when the estimated 
volume as determined in e.soft was equal to the original volume of the sphere.   
According to these phantom measurements the threshold of FDG-PET activity varied 
from 34% to 47%. In case of an SBR >5 an 34% threshold of maximal uptake could be 
used. For each individual patient this SBR was calculated, using the lung or the homo-
lateral thoracic erector spinae muscle as relevant background depending on the  
localization of the primary tumor. The maximal SUV was measured within the primary 
tumor and the same threshold was used for both the primary tumor and the lymph 
nodes within the same patient. For all patients the maximal diameter of the SBR based 
auto-contour for the primary tumor was measured. The maximal diameter was   
measured on each slide in transversal, anterior-posterior and in cranio-caudal     
direction. For correlation with the pathological specimen the maximal diameter in any 
direction on PET scan was noted. With regard to the lymph nodal staging all lymph 
nodes showing a SBR based auto-contour were considered positive. The contour not 
necessarily needed to encompass the lymph node as a whole. 
Pathology 
Twenty-three of the 33 patients (70%) underwent a surgical resection of their lung 
tumor. In these cases the maximal diameter of the primary tumor was measured by 
macroscopic examination. In all 33 patients, histological information concerning the 
lymph nodes was available. In 6 patients information was available by mediastino-
scopy, in 24 patients by thoracotomy (in 2 patients after mediastinoscopy) and in 5 
patients by trans-esophageal fine-needle aspiration. In total 69 lymph nodes (58 
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mediastinal nodes and 11 hilar nodes) were examined, of which 9 mediastinal nodes 
showed metastases. 
Gross Tumor Volume delineation and interobserver variability 
Manual delineation based on fused PET-CT images was compared with the auto-contour 
based delineation. The PET-CT scans of all 33 patients were used for manual delinea-
tion of the primary tumor (GTV-1man) and the involved lymph nodes (GTV-2man), using 
a standard clinical delineation protocol (Figure 5.1a and Figure 5.1c). Both the PET-CT 
report and clinical information concerning these patients were provided. The primary 
tumor was delineated using the combined CT and PET information. In patients with a 
primary tumor growing into the mediastinum, only one combined GTV (GTV1+2) was 
delineated. GTV-2 only included lymph nodes that were PET positive and/or pathologi-
cally proven malignant. The protocol also included fixed window-level settings of both 
CT (lung W 1700; L –300, mediastinum W 600; L 40) and PET scan (W 30000; 
L 15000) to be used for delineation. For the final delineation of the lymph nodal areas 
the CT scan provided a better contrast with surrounding (fat) tissue and was mainly 
used for the determination of the border of the lymph node station.  
 
Five observers independently performed the delineation: 3 radiation oncologists spe-
cialized in thoracic oncology and 2 experienced residents. All observers were blinded to 
the contours delineated by the others.  
 
Target volume delineation based on PET-CT scan was repeated after 6 months, this 
time using an SBR based auto-contour provided to the observers, which they were 
asked to edit if they wished to do so both for the primary tumor (GTV-1auto), the lymph 
nodes (GTV-2auto) or the combined contour (GTV1+2auto; Figure 5.1b and Figure 5.1d). 
 
Pairs of edited auto-contours and pairs of manually outlined volumes for the different 
observers were compared by the concordance index (CI), defined as the ratio of 
intersection and the union of the 2 volumes (Figure 5.2)32,41. 
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In which A stands for the GTV of the first observer and B for the GTV of the second 
observer. The CI was computed in 3-D for all tumors for all pairs of observers. The CI 
varies between 0 (no overlapping volumes between 2 observers) and 1 (complete 
agreement on delineated volume). 
Statistics 
SPSS software (SPSS for Windows, version 14.0, SPSS Inc., Chicago, IL) was used to 
perform statistical analysis. Pearson’s correlation coefficient was used to compare 
pathology and imaging estimates of maximal tumor diameter.  
 
To compare sensitivity and specificity with regard to lymph nodal staging of the  
Nuclear Medicine report and the SBR based auto-contouring method, the areas under 
the curves of the Receiver Operating Characteristic (ROC) curves were compared using 
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the method described by Hanley and Mc Neil42.Concerning the delineations, for each 
case, each observer and each method used, the different volumes were measured. 
Results are summarized by the median and range. To assess interobserver variation 
statistically, the coefficient of variation (CV) of the GTVs for each individual patient was 
measured. The CV is defined as the standard deviation (SD) divided by the mean GTV 
of the 5 observers. Moreover, the CIs of both methods were compared using the 
Wilcoxon signed ranks test, since the data did not follow a normal distribution. Two-
tailed p-values are provided and p-values less than 0.05 were considered statistically 
significant. 
 
 
 
Figure 5.1 Example of manual (a) and auto-contour based (b) delineation of a primary tumor (GTV-1) 
and of manual (c) and auto-contour based (d) delineation of GTV-2 (lymph nodal area) delineated by the 
five observers. Arrows indicate changes in interobserver variation in delineation between the two 
methods. 
 
 
 
 
 
Figure 5.2 Concordance index: intersection of volume A and B divided by the union of volume A and B. 
 
a b
c d 
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Results 
SBR based auto-contour compared with pathology 
In order to check validity the PET automatic SBR based delineation of the primary 
tumor was compared with macroscopic examination of the surgical specimen (n=23). 
The maximal diameter of the tumor on macroscopy was compared with the maximal 
diameter of the PET auto-contour as estimated by e.soft (SBR based). A strong correla-
tion was found between these two parameters (Pearson correlation coefficient 0.90; 
Figure 5.3). 
 
In general the maximal diameter of the auto-contour slightly underestimated the 
maximal diameter found at macroscopic examination. The accuracy of the threshold 
based auto-contouring for hilar and mediastinal lymph node delineation was compared 
with the report of the PET scan (based on visual inspection, department of Nuclear 
Medicine). Compared with the gold standard of pathology, the auto-contouring method 
showed a sensitivity of 66.7% (95% confidence interval: 35.1%-88.3%) and a   
specificity of 95.0% (95% confidence interval: 85.8%-98.8%), whereas the report of 
the department of Nuclear Medicine showed a sensitivity of 55.6% (95% confidence 
interval: 26.6%-81.2%) and a specificity of 88.3% (95% confidence interval:    
77.5%-94.5%) (AUC of ROC curve auto-contouring 0.81, AUC of ROC curve Nuclear 
Medicine 0.72, p=0.28). 
SBR based delineation compared with manual delineation 
For 30 patients a GTV-1 was delineated, whereas for 3 patients with a tumor growing 
into the mediastinum a GTV-1+2 was delineated. In 10 patients additional lymph 
nodes, GTV-2, were contoured. In all patients the GTVs were delineated both manually 
and by editing the SBR based auto-contour. The results concerning volume are   
depicted in Table 5.1. 
 
The edited auto-contour of the primary tumor, GTV-1auto (median 31.8 cc) was smaller 
than the manually contoured GTV-1 (median 34.6 cc, z=-3.36, p=0.001). Similar 
results were found for the small group of tumors growing into the mediastinum   
(median GTV-1+2auto 45.2 cc and GTV1+2man 66.4 cc), although this difference was not 
significant (z=-1.60, p=0.11). The median volume of delineated lymph nodes, GTV-2, 
was also significantly smaller using the auto-contour based method than the manual 
method (z=-2.40, p=0.017). The median volume of GTV-2auto was 16.3 cc compared 
with GTV-2man 21.8 cc. For the individual observers, the changes in volumes for GTV-1, 
GTV-1+2 and GTV-2 showed similar results, although not all individual changes did 
reach significant levels (Table 5.1). To investigate whether the inter-observer agree-
ment of the delineated volume would change using the auto-contouring method, we 
compared the coefficient of variation (CV) of the 2 methods for the different delineated 
volumes. The CV of the auto-contour based method was significantly lower than of the 
manual method for the primary tumors (z=-3.76, p<0.001). The median CV was 0.15 
for GTV-1auto and 0.22 for GTV-1man. The changes in CV for each individual delineated 
GTV-1 is depicted in Figure 5.4. No significant change in CV was observed for GTV-1+2 
(z=-0.0, p=1.0) and GTV-2 (z=-2.55, p=0.80) between the 2 methods. 
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Table  5.1 Mean, median volume and range of Gross Tumor Volumes (GTV) for the manual and auto-contour 
based methods. 
  mean median range mean median range   p-value 
 
  GTV-1man   GTV-1auto   
all observers 75.3 34.6 2.1-343.7 69.0 31.8 2.1-324.9 0.001  
observer 1 78.7 35.7 1.8-353.7 64.8 30.6 2.1-312.4 <0.001  
observer 2 69.4 33.7 1.1-320.9 62.7 30.1 1.4-298.4 0.43  
observer 3 63.0 33.9 1.7-310.0 65.0 29.5 1.6-309.1 0.29  
observer 4 81.1 36.4 2.9-378.6 73.5 38.4 3.0-338.3 0.002  
observer 5 84.3 38.9 2.9-355.4 78.8 37.2 2.5-366.3 0.12  
 
  GTV-2man   GTV-2auto   
all observers 108.4 66.4 40.7-218.0 89.3 45.2 34.3-188.5 0.11  
observer 1 113.6 88.9 45.2-206.8 64.8 30.6 2.1-312.4 0.11  
observer 2 95.9 40.9 38.5-208.3 62.7 30.1 1.4-298.4 0.11  
observer 3 87.7 34.9 31.6-196.6 65.0 29.5 1.6-309.1 0.11  
observer 4 126.3 94.4 42.2-242.4 73.5 38.4 3.0-338.3 0.11  
observer 5 118.3 75.4 43.6-235.8 78.8 37.2 2.5-366.3 0.11  
 
  GTV-1+2man   GTV-1+2auto   
all observers 26.3 21.8 4.9-94.7 89.3 16.3 4.1-67.1 0.017  
observer 1 28.1 21.2 4.7-107.7 21.0 14.9 4.0-77.3 0.009  
observer 2 24.9 22.5 4.1-79.1 16.8 17.1 1.0-34.2 0.21  
observer 3 22.8 18.0 3.1-86.5 19.9 15.1 4.0-69.6 0.09  
observer 4 27.1 26.8 6.7-98.7 23.1 19.6 4.8-79.5 0.11  
observer 5 29.6 21.8 5.9-101.7 24.2 17.6 4.5-75.2 0.03  
Volumes are in cc for primary tumors (GTV-1, n=30), primary tumors growing into the mediastinum (GTV-1+2, 
n=3) and for lymph nodal areas (GTV-2, n=10). Volumes are calculated for the total group of observers (mean of 
5 observers for all patients) and for each individual observer. P-values of Wilcoxon signed ranks test. 
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Figure 5.3 Maximal diameter of primary lung tumor assessed by PET scan (SBR based automatic delinea-
tion) compared with maximal diameter of tumor on macroscopic examination of the surgical specimen 
(n=23). Pearson correlation coefficient=0.90, r2=0.82. The solid line (___) represents the linear fit and 
the dotted line  (---) the reference line. 
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To investigate whether the inter-observer agreement of the delineated volume would 
change using the auto-contouring method, we compared the coefficient of variation 
(CV) of the 2 methods for the different delineated volumes. The CV of the auto-contour 
based method was significantly lower than of the manual method for the primary 
tumors (z=-3.76, p<0.001). The median CV was 0.15 for GTV-1auto and 0.22 for    
GTV-1man. The changes in CV for each individual delineated GTV-1 is depicted in  
Figure 5.4. No significant change in CV was observed for GTV-1+2 (z=0.0, p=1.0) and 
GTV-2 (z=-2.55, p=0.80) between the 2 methods. 
 
Evaluation of the interobserver variation using the concordance indices (CIs) showed 
similar results. The auto-contour based method showed higher CIs than the manual 
based method. For GTV-1 the auto-contour based method had a median CI of 0.74, 
compared with a CI of 0.70 for the manual method (z=-4.16, p<0.001). Although the 
CI for GTV-2 also showed an increase, this difference was not significant. The CI for 
GTV-2 showed a median of 0.60 for the auto-contouring method compared with 0.51 
for the manual method (z=-1.58, p=0.11). No difference was observed between the 
CIs of GTV-1+2 (z=-1.07, p=0.29; Table 5.2). 
Discussion 
The delineation of target volumes, as well as organs at risk is a very critical step in 
high-precision radiation treatment planning43. Both good image quality as well as a 
good delineation protocol is crucial for target volume delineation. Different methods of 
PET(-CT) based contouring have been described in literature10,21,34-37,44. Visual inter-
pretation and threshold based methods, using a fixed threshold, an SBR based or 
gradient based method, have been used to delineate tumors. Although the SBR based 
methods show a good agreement with pathologic-anatomic structures, these methods 
should be validated individually for each PET scanner used35. Nestle et al. compared 4 
different PET-based delineation methods (visually, threshold of 40% of maximal SUV, 
SUV of 2.5 and a tumor-to-background algorithm) with CT-based volumes37. In this 
study the threshold of 40% was the only volume, which did not correlate with          
CT-based volume. However, no correlation with the macroscopic tumor diameter was 
attempted to validate the different methods. Actually, only few studies have compared 
the accuracy of imaging to pathology. For head-and-neck cancer Daisne et al. showed 
that automatic delineation on PET using the SBR-method was accurate in delineating 
laryngeal tumors38. Although the GTVs of the surgical specimen were on average 
smaller than the GTVs obtained by PET, CT and MRI, there was an overestimation of 
extralaryngeal extension and an underestimation of superficial spread of the tumor 
using the different imaging modalities. Comparing the 3 modalities, FDG PET showed 
the highest specificity. Although it is important to validate auto-delineation software in 
lung cancer as well, to date, no such a study has been performed in NSCLC. In the 
present study, we showed that the SBR based auto-contouring method was accurate in 
localizing the involved nodal areas. The specificity of 95% is comparable with published 
data on PET scan. The sensitivity of 67%, found analyzing the small number (9/69) of 
positive lymph nodes in our study, is also in line with values described in literature, 
which range from 66% to 83%45-47.  
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It could be expected that a subpopulation of tumors, e.g. larger tumors, show a higher 
sensitivity of lymph nodal auto-contouring. However, due to the limited number of 
positive nodes this could not be tested in this study. We also observed a good corre-
lation (correlation coefficient 0.90) between the maximal diameter on PET-scan using 
the SBR based auto-contouring method and the macroscopic tumor diameter on the 
surgical specimen for 23 operable lung cancers, although this is admittedly a fairly 
crude measure. A prospective study to further investigate the accuracy of PET-CT in 
the delineation of lung tumors, including shape and location of the tumor, compared 
with pathologic delineation is ongoing48. In the current study free-breathing PET-CT 
images were used for the delineation, showing smearing of the PET signal due to tumor 
motion. In the prospective study respiratory correlated imaging will be performed, 
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Figure 5.4 Coefficient of variation (CV) of GTV-1 for each individual patient for both the manual method 
(black bars) and the auto-contouring based method (grey bars). 
Table 5.2 Mean, median volume and range of coefficient of variation (CV) and concordance index (CI) for 
the manual and auto-contour based methods. 
  mean median range mean median range   p-value 
 
 CVmanual CVauto-contour  
GTV-1 0.21 0.22 0.02-0.48 0.17 0.15 0.03-0.37 <0.001  
GTV-1+2 0.23 0.24 0.12-0.30 0.22 0.19 0.05-0.50 0.8  
GTV-2 0.21 0.13 0.09-0.42 0.21 0.12 0.06-0.47 1.0  
 
 CImanual CIauto-contour  
GTV-1 0.70 0.70 0.51-0.84 0.74 0.74 0.57-0.88 <0.001  
GTV-1+2 0.63 0.69 0.42-0.78 0.67 0.69 0.49-0.84 0.29  
GTV-2 0.51 0.51 0.33-0.70 0.59 0.60 0.43-0.85 0.11  
CVs and CIs for primary tumors (GTV-1, n=30), primary tumors growing into the mediastinum (GTV-1+2, n=3) 
and for lymph nodal areas (GTV-2, n=10) are calculated for the total group of observers (mean of 10 observer 
pairs for all patients). p-values of Wilcoxon signed ranks test. 
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which might further improve depiction of the real tumor volume and therefore can lead 
to a change in cut-off levels and/or segmentation methods used for auto-contouring. 
 
Another important issue in target volume delineation is the interobserver variability. 
Therefore several authors investigated the influence of integrating PET into target 
volume delineation in lung cancer. Caldwell et al. found a reduction in the ratio of 
largest to smallest GTV using PET-CT co-registered data compared with CT alone in a 
group of 30 patients, delineation being performed by 3 observers31. A reduction in 
interobserver variation using matched PET-CT compared with CT was noted by     
Steenbakkers et al. and by Ashmalla and co-authors10,33. Fox et al. looked at the 
influence of registration of PET-CT images on the concordance. They showed an im-
proved concordance using registered PET-CT images compared with side-by-side 
images (CI of 0.70 and 0.61 respectively)32. In our study, we found a CI of 0.70 for the 
primary tumor using manual delineation on PET-CT fused images and a further   
improvement of conformity (CI 0.74) using the SBR based auto-contouring method       
(p<0.001). The fact that the CIs were significantly lower than 1.0, the value reached 
for perfect concordance reflects that individual observers were allowed to edit the auto-
contour based delineation to their wished contour. The edited contour will clearly be 
influenced by the delineation the way the observers are used to delineate, as has been 
performed in the manual method. However, we did observe an increase in CIs and also 
a significant decrease in CV among observers of the GTV-1 using the auto-contouring 
based method compared with the manual method (p<0.001). This shows that there 
was less variation in the volume of GTV-1 delineated using this auto-contour based 
method compared with the standard manual way. Although our study set also included 
surgical patients, the mean volumes for the primary tumor in this series is comparable 
with other studies. The mean volume for GTV-1man was 75.3 cc (range 2.1-343.7 cc) in 
our study, while tumors in the Steenbakkers’ study had a mean volume of 69 cc (range 
4-307 cc) and in Caldwell’s study of 90.5 cc (range 12-360 cc)29,31. We therefore 
believe our data are representative for NSCLC patients, including patients referred for 
radiotherapy. 
 
In our study we found a non-significant improvement in agreement between the 
observers in nodal volume delineation (CIman 0.51 and CIauto 0.60, p=0.11). For the 
lymph nodal areas we observed somewhat lower CIs for the lymph nodal areas than for 
the primary tumor. However, in the literature, no separation between nodal volumes 
and volumes of the primary tumors were made, thus we cannot compare the present 
data with those of others. 
 
The ultimate goal is a precise delineation of the tumor and a higher agreement   
between observers together with an accurate auto-contouring method will ultimately 
lead to better target volume delineation. One of the advantages of the auto-contour 
method is that it directly gives a possible delineation solution, which is visualized on 
screen for the radiation oncologist, who then only has to edit the contour. Another 
advantage of the auto-contour based delineation might be a reduction of the time 
needed to delineate. Steenbakkers et al. reported that including a PET scan in target 
volume delineation reduced the mean delineation time from 16 minutes to 12 minutes 
(p<0.001)33. Although delineation time needed was not recorded in our study, there 
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was a general feeling among the observers that editing the automatic contour was less 
time consuming than manual delineation based on PET-CT starting from scratch. 
 
In conclusion, the use of a source-to-background ratio based automatic delineation 
showed a good correlation with macroscopic and histological examination in NSCLC, 
both for the maximal diameter of the primary tumor as well as for the involved lymph 
nodes. The SBR based automated contour reduced the interobserver variability, since 
lower CVs and higher CIs were found using the auto-contour based delineation. This 
approach may thus improve target volume delineation in daily practice radiation 
oncology. 
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Abstract 
Purpose: To investigate the change in tumor volume, motion and breathing frequency 
during a course of radiotherapy, for locally advanced non-small cell lung cancer. 
 
Materials and Methods: Twenty-three patients underwent CT-PET and Respiration 
Correlated CT scans prior to treatment, which was repeated in the first and second 
week following the start of radiotherapy. Patients were treated with an accelerated 
fractionation schedule, 1.8 Gy BID, with a total tumor dose depending on pre-set dose 
constraints for the lungs and the spinal cord. 
 
Results:  A striking heterogeneity of tumor volume changes was observed at all time 
points. In some patients the volume decreased >30% (3/23) in others the volume 
increased >30% (4/24) but for the majority of patients (16/23) the tumor volume only 
changed slightly (<30%). No significant changes in average tumor motion or breathing 
frequencies were seen during treatment. Although quite some changes in individual 
tumor motion were seen, only in one patient would this have led to an increase of the 
internal margin >1 mm in one direction, one week after the start of treatment, and in 
three patients for one direction, 2 weeks after the start of the  treatment. 
 
Conclusions: A large variability of changes in tumor volume between the patients was 
observed. This underscores the need for repeated imaging during the course of radio-
therapy. However, the changes in tumor motion are small, which indicates that   
repeated respiration correlated CT does not appear to be necessary. 
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Introduction 
Radiation therapy, alone or in combination with chemotherapy or surgery, is important 
in the treatment of lung1. Nowadays, target volume delineation is often based on 
sophisticated imaging techniques such as CT and FDG-PET scans, as this improves the 
diagnostic accuracy and may allow radiation dose escalation2-5. Breathing induced 
tumor motion and hence appropriate margins can be taken into account using 4D CT 
information from respiration correlated CT (RC-CT) scans. Incorporating this temporal 
information in radiotherapy planning could also lead to a more accurate delineation of 
the gross tumor volume. In general, smaller margins can be applied which would make 
dose escalation or a decrease of normal tissue exposure possible6. However, radiation 
treatment planning is based on imaging taken at a single time-point before the start of 
radiotherapy, and therefore any changes of tumor motion, tumor volume or breathing 
frequency during the course of fractionated radiotherapy are not incorporated in the 
treatment planning process. 
 
Few data on volume changes during radiotherapy for lung cancer patients have been 
reported7-10, showing conflicting results. Moreover, the evolution of the tumor motion 
during radiotherapy was only reported in stereotactic radiotherapy for stage I NSCLC 
patients10, although this information is important for Adaptive RadioTherapy (ART). We 
therefore investigated the changes of tumor volume, tumor motion and breathing 
frequency during the first 2 weeks of an accelerated course of radiotherapy in patients 
with locally advanced non-small cell lung cancer (NSCLC). 
Materials and Methods 
Patients 
Twenty-three patients with histological or cytological proven non-small cell lung cancer 
(NSCLC) (UICC stage II-III) were included in this study, from December 2004 until 
September 2005. Twenty patients received three cycles of Carboplatin and Gem-
citabine chemotherapy before radiotherapy, had a WHO performance status 0-1 and a 
good lung function (FEV1 ≥50% and DLCO ≥50%). Three patients did not receive 
chemotherapy due to medical reasons. The response to induction chemotherapy was 
evaluated using the RECIST-criteria11. No concurrent chemotherapy was given. Patients 
were treated using our current standard CT-PET simulation, radiation treatment plan-
ning, and fractionation schedule, as described below. 
 
The Medical Ethics Committee according to the Dutch law approved the trial. All pa-
tients gave written informed consent before entering this study. 
Radiotherapy simulation 
Patients were simulated in radiotherapy position on a dedicated CT-PET-simulator with 
both arms above the head and on an immobilization and patient laser marker system. 
Radiotherapy technologists trained specifically for this purpose always carried out the 
simulation. The CT-PET scanner used was a Siemens Biograph™ (SOMATOM®     
Sensation 16 with an ECAT ACCEL PET scanner). An intravenous injection of 18F-Fluoro-
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Deoxy-Glucose (FDG) (Tyco Health Care, Amsterdam, The Netherlands) of 
(weight*4+20) MBq was followed by 10 ml physiologic saline. After a 45 minutes 
uptake period, during which the patient was encouraged to rest, PET and CT images 
were acquired. A spiral CT with intravenous contrast was performed covering the 
complete thoracic region. 
Radiotherapy planning 
Radiotherapy planning was performed on a XiO (Computerized Medical Systems, 
St Louis, Missouri) treatment planning system, using inhomogeneity corrections, based 
on a convolution algorithm. For all patients, the Gross Tumor Volume (GTV) and the 
Planning Target Volume (PTV) were defined, based on CT-PET data, obtained prior to 
radiotherapy (i.e. post chemotherapy in case of induction chemotherapy). The Clinical 
Target Volume (CTV) was defined as the GTV with a 5 mm margin incorporating 
microscopic disease. This CTV was subsequently expanded with 1 cm to draw the PTV 
to incorporate the internal respiratory motion and setup errors. For the volume com-
parison in this study, the CT-GTV was defined as the primary tumor on lung window 
(W 1600, L -800). Contouring of the lungs was carried out automatically by the treat-
ment planning system. For the calculation of the mean lung dose (MLD), the volume of 
both lungs excluding the GTV was used12. The spinal cord was drawn throughout the 
whole CT scan and was considered to be at the inner margin of the bony spinal canal. A 
3D conformal treatment plan was calculated on the PTV for all patients according to 
ICRU 50 guidelines13. Dosimetric values were calculated on the basis of dose-volume 
histograms and dose distributions on each axial CT plan. 
Radiation dose and normal tissue constraints 
For each patient, the radiation dose was escalated to a mean lung dose (MLD) of 19 Gy 
while respecting a maximum spinal cord dose of 54 Gy. There were no esophageal 
dose constraints. As the tumor dose was delivered in 1.8 Gy fractions, a maximum 
deviation of the constraints of ±4% was allowed. Radiotherapy was always delivered 
twice a day (BID), with a minimum of 8 hours between the two fractions, and given 5 
days per week. 
Respiration Correlated CT scans (RC-CT) 
For the patients who gave informed consent for this study, the CT-PET was im-
mediately followed by a respiration correlated CT, using offline correlation of the 16 
slice spiral CT scan of the CT-PET system. This had been modified to enable a low pitch 
(minimum 0.1), in combination with a respiratory signal obtained by a pressure sensor 
in a chest belt (AZ-733V, Anzai Medical Corporation, Tokyo, Japan). The raw CT data 
were reconstructed in 10 phases, from 0% to 100% in steps of 10% of the respiration 
period starting at end inspiration. In-house developed software with Matlab (Mathworks 
Inc, Natick, MA) was used to measure the motion of the lesion in all three orthogonal 
directions. 
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Study design 
During the course of radiotherapy, the patients underwent a repeat CT-PET scan and a 
respiration correlated CT in treatment position, one and two weeks after the start of 
treatment. At all time points, the primary tumor was delineated using the free-
breathing CT rather than on a single phase of a respiration correlated CT, as respiration 
correlated CT data was not available in all patients. This approach assumes that no 
blurring of the moving tumor occurs in the free-breathing CT. This assumption was 
checked and found to be valid as the high-speed 16 slice CT scan protocol, effectively 
‘freezes’ the tumor in a single phase during a free-breathing CT. The tumor was deline-
ated for each patient by the same physician to avoid inter-observer variability. To 
study the intra-observer variability, all pre-treatment CT-scans were delineated twice 
by the same physician, as was the case for ten patients for all time points, with at least 
a 3 month time interval. 
 
Due to technical and logistical problems, a complete image dataset at all three time 
points, was not available for all patients. We missed a CT-PET dataset for one patient 
one week after the start of treatment and for three patients, two weeks after the start 
of treatment. 
Statistics 
We determined the tumor volumes prior to, and 1 and 2 weeks after start of the 
treatment, based on the GTVs drawn on the free-breathing CT. In addition, we used 
the respiration correlated CT to quantify the tumor motion at all 3 time points. Tumor 
motion was expressed as a 3D vector14, which is the quadratic sum of the motions in 
the three orthogonal directions. Finally, breathing frequency was recorded at all three 
time-points during the respiration correlated CT. All results are expressed as the 
mean±standard deviation (SD). Statistical differences between paired parameters from 
the three time points were evaluated using the Wilcoxon signed rank test. Differences 
were considered to be significant when the p-value was less than 0.05. 
Results 
Patient characteristics 
The patient characteristics are shown in Table 6.1. The mean values of the total tumor 
dose (TTD) and the corresponding mean lung dose (MLD) were 61.7±9.8 Gy (range 
46.8-79.2 Gy) and 16.4±3.4 Gy (range 6.8-20.8 Gy) respectively. The GTV of the 
primary tumor before radiotherapy was 87.5±137.7 cm³ (range 0.4-660.2 cm³). The 
first repeat scan was made after the patient received on average a dose of 20.4±4.1 Gy 
(about 11 fractions) and the second scan after 38.3±5.1 Gy (about 21 fractions; Table 
6.2). 
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Volume changes of the primary tumour 
A striking heterogeneity of the changes in volume of the primary tumor during radio-
therapy was observed. Using an arbitrarily chosen cut-off level of 30%, four patients 
(17%) showed an increase of the tumor volume of >30%, for sixteen patients (70%) 
the volume change varied <30% while for three patients (13%) the volume decreased 
>30%. In Figure 6.1 these patients are indicated with a dotted line for the patients 
with a large increase in tumor volume, a dashed line for those patients with a large 
decrease and a solid line for the rest of the patients. Although the average volumes do 
not reflect the individual changes, we observed a significant increase in average tumor 
volume in the patients (n=22) for which data at the first and second time point was 
available, from 90.9±139.9 cm³ to 99.2±130.4 cm³ from the start of radiation to week 
1 (p=0.049). For time point at week 2, we missed the CT information for three pa-
tients. In the remaining 20 patients the tumor decreased on average from 
94.7±146.3 cm³ to 86.4±109.8 cm³ from the start of radiation to week 2 (p=0.940; 
Table 6.2 and Figure 6.1). No significant difference in tumor volume changes was 
observed between patients with stable disease and partial response to induction 
chemotherapy. For the 43 delineations, which were performed twice, we found an 
average intra-observer variability of 1.2%±4.4%, with a maximum deviation of 9.5%. 
 
Table 6.1 Patient characteristics. 
Patient no. Age 
(years) 
Gender Stage Location of the 
primary tumor 
Response to 
chemotherapy 
TTD 
(Gy) 
MLD 
(Gy) 
OTT 
(days) 
1 52 F T1N3M0 RLL PR 54.0 17.6 17 
2 54 M T3N2M0 RML SD 54.0 19.3 20 
3 75 M T3N2M0 RUL PR 54.0 15.2 20 
4 71 F T3N1M0 RUL no chemo 64.8 20.7 23 
5 71 M T2N3M0 RUL PR 54.0 14.7 23 
6 61 M T1N3M0 RML PR 68.4 14.9 22 
7 71 M T2N3M0 LLL PR 54.0 16.0 19 
8 77 M T4N2M0 RUL PR 61.2 17.6 22 
9 74 F T2N0M0 RLL no chemo 54.0 16.3 20 
10 79 F T4N0M0 RLL PR 57.6 18.3 23 
11 57 M T1N3M0 LUL PR 64.8 8.5 27 
12 68 M T4N0M0 RUL PR 54.0 6.8 20 
13 63 M T4N0M0 RLL SD 64.8 17.3 24 
14 59 F T2N2M0 RML PR 46.8 20.0 16 
15 55 M T4N2M0 LUL SD 79.2 16.4 29 
16 52 F T2N3M0 LLL PR 54.0 15.6 20 
17 50 F T4N2M0 LLL PR 61.2 20.8 21 
18 71 M T4N2M0 RUL PR 79.2 13.6 29 
19 61 F T2N2M0 RML PR 57.6 19.0 21 
20 62 M T2N2M0 RUL PR 68.4 18.8 27 
21 80 M T2N0M0 LLL no chemo 61.2 15.2 21 
22 56 M T4N2M0 LUL SD 79.2 17.8 30 
23 54 M T2N3M0 LUL SD 79.2 16.1 30 
         
Mean 64.0         61.7 16.4 22.8 
SD 9.6         9.8 3.4 4.1 
Abbreviations: TTD=Total Tumor Dose; MLD=Mean Lung Dose; OTT=Overall Treatment Time; F=Female; M=Male; 
Response to chemotherapy: PR=Partial Remission; SD=Stable Disease (RECIST criteria);RLL=Right Lower Lobe; 
LLL=Left Lower Lobe; RUL=Right Upper Lobe: LUL=Left Upper Lobe; RML=Right Middle Lobe. 
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Figure 6.1 The CT volumes, relative to the volume prior to treatment, were plotted versus the dose. The 
thick black line is the average relative CT volume together with the standard deviation. The dotted lines 
represents the patients where the tumor increased more than 30%, the dashed lines those patients with a 
decrease of more than 30%. 
Table 6.2 Evolution of the Gross Tumor Volume of the primary tumor during radiotherapy. 
Patient no Volume before 
RT (cm3) 
Corresponding dose after 
one week of RT (Gy) 
Volume after 
one week of 
RT (cm3) 
Corresponding dose after 
two weeks of RT (Gy) 
Volume after 
two weeks of 
RT (cm3) 
1 7.9 19.8 4.7 37.8 5.2 
2 660.2 18.0 580.3 34.2 455.9 
3 53.1 18.0 65.9 NA NA 
4 26.6 19.8 14.7 37.8 2.8 
5 97.3 18.0 155.0 36.0 134.6 
6 7.5 19.8 4.3 34.2 5.0 
7 28.1 16.2 43.8 37.8 36.4 
8 3.5 19.8 5.9 41.4 6.0 
9 64.9 27.0 35.8 NA NA 
10 12.2 NA NA 36.0 10.8 
11 0.4 19.8 0.5 NA NA 
12 63.2 23.4 64.6 37.8 72.3 
13 67.2 19.8 88.6 48.6 42.2 
14 272.2 23.4 323.8 41.4 288.9 
15 92.9 19.8 104.3 37.8 84.0 
16 79.0 21.6 99.7 39.6 83.8 
17 92.9 19.8 153.5 37.8 121.1 
18 7.3 21.6 6.2 32.4 6.4 
19 101.9 16.2 131.2 41.4 80.1 
20 24.2 19.8 28.0 37.8 26.7 
21 107.7 14.4 114.7 27 105.3 
22 73.0 18 75.9 39.6 65.0 
23 69.0 34.2 79.9 50.4 95.8 
      
Mean 87.5 20.4 99.2 38.3 84.4 
SD 137.7 4.1 130.4 5.1 109.8 
One week of RT vs prior to RT: p=0.04; two weeks of RT vs one week of RT: p=0.00; two week of RT vs prior to 
RT: p=0.94. Abbreviations: no=number;RT=Radiotherapy; NA=Not Assessed because of technical problem. 
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Changes of the motion of the primary tumor 
Tumor motion, expressed as a 3D vector, which is the quadratic sum of the motion in 
the three orthogonal directions and the breathing frequency are shown in Table 6.3 
and Figure 6.2. 
 
On average, the total vector motion changed from 7.8±4.8 mm initially to 7.8±5.9 mm 
and 8.0±5.6 mm one and two weeks after the start of the radiotherapy respectively. All 
differences compared with the initial tumor motion were not statistically different from 
each other (p=0.969 and p=0.582 respectively). 
 
Table 6.3 3D-Vector motion and breathing frequency before and during the radiation treatment.  
Patient no Before RT After one week of RT After 2 weeks of RT 
 3D Vector BPM 3D Vector BPM 3D Vector BPM 
5 7.7 22.2 9.2 22.2 8.2 25.5 
6 8.1 15.5 11.0 12.0 16.0 17.6 
7 4.5 24.0 2.9 23.1 3.9 21.6 
12 0.5 14.0 0.7 15.0 1.6 12.6 
14 16.3 17.5 21.0 17.6 17.8 19.0 
15 4.2 12.9 7.3 23.5 4.7 17.1 
16 9.5 19.2 6.2 25.5 8.2 21.1 
17 4.2 21.6 3.1 21.6 4.0 24.5 
19 11.4 22.2 7.4 20.3 9.8 16.1 
20 4.5 16.9 1.6 16.3 2.5 16.7 
21 15.6 19.7 15.8 17.9 15.1 17.9 
22 7.0 16.0 6.9 15.4 4.6 9.9 
       
Mean 7.8 18.5 7.8 19.2 8.0 18.3 
SD 4.8 3.6 5.9 4.1 5.6 4.5 
3D-vector: one week of RT vs prior to RT: p=0.969; two weeks of RT vs prior to RT: p=0.582. BPM: one week of 
RT vs prior to RT: p=0.799; two weeks of RT vs prior to RT: p=0.875. Abbreviations: no=number; BPM=Breathing 
cycles per minute. 
 
 
Figure 6.2 3D-Vector motion, which is the quadratic sum of the motion in three orthogonal directions, 
plotted versus the dose. The thick black line represents the average tumor motion, together with the 
standard deviation. 
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When we looked at the individual differences for the motion for all directions compared 
with the initial motion, we observed a maximal absolute difference of 4.5 mm and 
6.4 mm one and two weeks after the start of radiotherapy. The maximal difference 
between week 2 and week 1 after the start of radiotherapy was 5.4 mm. In Figure 6.3 
a histogram of these differences is shown. 
 
If we use the peak to peak amplitude divided by four, as used for the internal margin 
in Van Herk’s margin recipe15, only for one patient, for one direction the internal 
margin increased more than 1 mm one week after the start of radiotherapy. Two 
weeks after radiotherapy the internal margin should have been changed for three 
patients with more than 1 mm (Figure 6.3). 
 
 
Figure 6.3 Histogram of the differences (mm) in motion amplitude between all time points. The 
differences for all three orthogonal directions are shown. 
Change of the breathing frequency 
The breathing frequency was not statistically different at the three time points. On 
average, the frequency changed from 18.5±3.6 breathing cycles per minute (BPM) to 
19.2±4.1 BPM and 18.3±4.5 BPM (p=0.80 and p=0.88 respectively). 
Discussion 
For high precision radiation therapy, it is important to have, during a course of   
radiation therapy, knowledge of the changes of several parameters, such as the tumor 
volume and tumor motion. We observed a large heterogeneity of the changes in tumor 
volume in our patient population. Only a few patients (3/23) showed a large systematic 
decrease (>30%) in tumor volume, whereas in the majority of patients (16/23), the 
tumor volume only slightly changed (<30%). We even found a large increase in tumor 
volume for four out of 23 patients. The clinical impact of these volume changes and 
how to adapt treatment is however still unclear. Further clinical and planning studies 
need to be done to clarify this problem. 
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So, in contrast to other investigator7,8, no significant decrease in the tumor volume 
during the first two weeks of radiotherapy was found. Several differences between the 
reported studies and our study may explain the differences. In contrast to the present 
study, in the studies of Kupelian et al.8 and Erridge et al.7, patients were treated with a 
conventional fractionation scheme (2 Gy/day) delivered over an overall treatment time 
of more than 40 days. In our study, all patients received an accelerated schedule in 
which 1.8 Gy per fraction was delivered BID, 5 days per week. It may be that the 
decrease of the tumor volume by radiation-induced cancer cell death was offset by 
treatment-induced inflammation, which once again increased the volume. The net 
result may be a stable volume. Comparable results in tumor volume changes on CT 
scans in the first two weeks due to radiotherapy have been described when high doses 
per fractions (7.5-20 Gy) are used in stereotactic radiotherapy for stage I NSCLC9,10. 
We may get more insight in the internal tumor processes by analyzing the FDG   
distribution in the tumor during the course of radiation. Unfortunately it is still too early 
to correlate these changes in tumor volume with outcome. These analyses will however 
be the subject of another paper. 
 
To the best of our knowledge, this is the first study dealing with the changes of the 
motion and the breathing frequency of patients with locally advanced (Stage II-III) 
NSCLC during a course of radiotherapy. Underberg et al.10 described similar findings for 
Stage I NSCLC treated with hypofractionated stereotactic radiotherapy. Although we 
found no significant changes, on average, in tumor motion and breathing frequency, 
during the first two weeks of radiotherapy, in some patients quite a wide variation was 
seen. However, even for the largest difference in tumor motion, the clinical implication 
on the size of the PTV and hence on the treatment fields is limited, since only a fraction 
of this motion is used for PTV expansion to account for the tumor motion. Only for one 
patient, for one direction the internal margin increased more than 1 mm one week 
after the start of radiotherapy. Two weeks after radiotherapy the internal margin 
should have been changed for three patients with more than 1 mm (Figure 6.3). In this 
patient group, the respiration correlated CT information will not influence the internal 
margin that needs to be taken. 
 
In conclusion, our results clearly show that, at least when an accelerated radiotherapy 
schedule is given, changes in the volume of the primary tumor do occur during the first 
two weeks of radiotherapy. A large variability among the patients was observed, 
indicating that repeated imaging during the course of radiotherapy is necessary to 
know the changes in GTV and to be able to individualize radiation treatment. In  
contrast, repeated respiration correlated CT imaging during radiotherapy does not 
appear to be necessary as the changes in tumor motion are small, and will not lead to 
a change in treatment. 
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Abstract 
 
Purpose: 18F-fluoro-2-deoxy-glucose (FDG) uptake on PET scan is a prognostic factor 
for outcome in NSCLC. We investigated changes in FDG uptake during fractionated 
radiotherapy in relation to metabolic response with the ultimate aim to adapt treatment 
according to early response. 
 
Materials and Methods: Twenty-three patients, medically inoperable or with ad-
vanced NSCLC, underwent four repeated PET-CT scans before, during and after radio-
therapy. Changes in maximal Standardized Uptake Value (SUVmax) were described. 
Patients were treated with accelerated radiotherapy with a total tumour dose depend-
ing on normal tissue dose constraints. 
 
Results:  The most striking result was the large intra-individual heterogeneity in the 
evolution of SUVmax. For the total group a non-significant increase in the first week 
(p=0.052), a decrease in the second week (p=0.023) and after radiotherapy 
(p=0.005) was observed. Different time trends were shown for responders (no change 
during radiotherapy) and non-responders (48% increase during first week, p=0.023 
and 15% decrease in the second week, p=0.042). Non-responders had a higher SUVmax 
on all time points investigated. 
 
Conclusions: Time trends in SUVmax showed a large intra-individual heterogeneity and 
different patterns for metabolic responders and non-responders. These new findings 
may reflect intrinsic tumour characteristics and might finally be useful to adapt   
treatment. 
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Introduction 
Thoracic irradiation plays an important role in the management of advanced non-small 
cell lung cancer (NSCLC). Although the prognosis of these patients has improved, local 
tumour control is still not achieved in the majority of the patients1-3. Local tumour 
control can be improved by increasing the total radiation dose and the addition of 
chemotherapy to radiotherapy, but normal tissue toxicity, like esophagitis and radiation 
pneumonitis, is dose limiting4-9. A more individualized prediction of response to a 
specific therapy is needed in order to avoid needless treatment or to be able to propose 
an alternative therapy if possible10-12. Methods to describe tumour characteristics 
include imaging techniques, like positron emission tomography (PET). In different 
tumour sites pre- and post treatment PET scans have been correlated to outcome13-15. 
Indeed, the maximal uptake of 18F-fluoro-2-deoxy-glucose (FDG) in the primary lung 
tumour as measured on a PET-scan before treatment was consistently shown to be a 
significant, independent, prognostic factor for survival in NSCLC, both in case of  
surgical resection and radical radiotherapy16-21. On the other hand a post-treatment 
PET scan can predict residual disease and hence outcome in NSCLC22-26. 
Although there is a paucity on data dealing with the evolution of FDG uptake during 
fractionated radiotherapy, it is logic to study these time trends as an early predictive 
parameter, as has been shown for chemotherapy26-30. We hypothesized that changes in 
uptake might reflect early tumour response during radiotherapy, which might finally 
allow further individualization and adaptation of treatment before therapy is       
completed31. 
 
The aim of the current study was to describe changes in the uptake of FDG on PET 
scans during a course of radiotherapy in patients with NSCLC and to investigate 
whether there are differences in time trends in FDG uptake between metabolic    
responders and non-responders. 
Materials and Methods 
Study population 
From December 2004 to September 2005, 23 patients with medically inoperable or 
locally advanced NSCLC were enrolled in a phase I study. Patients with localized, 
histologically confirmed NSCLC, a WHO-performance sore of 0 or 1, a weight loss of 
<10% in 6 months and a reasonable lung function (a FEV1 >50% of predicted value 
and a DLCO ≥50%) were eligible. In case of previous chemotherapy, radiotherapy was 
started after a minimum of 14 days after the last chemotherapy course. The response 
to induction chemotherapy was evaluated using the RECIST-criteria32. No previous 
radiotherapy to the chest was allowed. Patients were not eligible if they had any other 
concomitant malignant disease, a recent severe cardiac disease or active peptic 
esophagitis. 
PET-CT-scan 
As part of this phase I study repeated PET-CT scans (before start of radiotherapy, on 
day 7 and day 14 during radiotherapy and 70 days after radiotherapy) were performed 
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in radiotherapy position on a dedicated PET-CT-simulator with both arms above the 
head and using a laser marker system. The PET-CT scanner used was a Biograph™ 
(SOMATOM® Sensation 16 with its ECAT ACCEL PET scanner, Siemens). Patients were 
fasting for at least 6 hours before the examination. FDG (MDS Nordion, Liège, Belgium) 
was injected intravenously and followed by physiologic saline (10 ml). The injected 
total activity of FDG depended on the weight of the patient: (weight*4+20) MBq. After 
a rest period of 45 minutes (time needed for uptake of FDG) PET and CT images were 
acquired. The CT-scan performed was a spiral CT-scan of the whole thorax, with 
intravenous contrast. The PET images were acquired in 5-minute bed positions, while 2 
or 3 positions were needed to scan the whole thoracic region. The Standardized Uptake 
Value (SUV) was used to measure the amount of uptake of FDG in a selected Region of 
Interest (ROI). For the determination of the SUV of the primary tumour, a ROI was 
drawn on the 3D-images in e.soft (version 5.0.24.5, Siemens, Erlangen, Germany) 
around the region of the primary tumour. SUV was calculated as activity concentration 
of FDG uptake divided by injected dose/body weight33. To avoid partial volume effects 
as much as possible, the maximal SUV (SUVmax) within this ROI was calculated and 
used for correlations. 
Treatment description 
All patients enrolled in this phase I study were irradiated using an individualized 
prescribed maximal tolerated dose (MTD). This total tumour dose (TTD) was based on 
normal tissue constraints instead of a classic fixed prescribed dose. For the lungs a 
mean lung dose (MLD) of 19.0 Gy and for the spinal cord a maximal dose of 54.0 Gy 
were used as dose constraints for normal tissues. The maximal allowed TTD was 79.2 
Gy or lower if any of the normal dose constraints were reached. The margin from GTV 
(gross tumour volume) to CTV (clinical target volume) was 5 mm and for the PTV 
(planning target volume) another 10 mm for the primary tumour and 5 mm for lymph 
nodes was added. No elective nodal irradiation was carried out. A 3D conformal  
treatment plan, using three to six coplanar 10 MV photon fields, was calculated accord-
ing to the ICRU guidelines34. Calculations were performed using an XiO treatment 
planning system (Computer Medical System, Inc.) with a FFT convolution algorithm for 
inhomogeneity corrections35. Patients were irradiated on a linear accelerator (Elekta SL 
15, Crawley, United Kingdom). Radiotherapy was delivered twice daily, with at least an 
8-hour interval (BID scheme) and with a fraction size of 1.8 Gy. Results concerning 
toxicity and outcome of this phase I study will be reported separately. 
Assessment of metabolic response 
Metabolic response was measured 70 days after radiotherapy by means of a PET-CT 
scan. This scan was compared with the pre-treatment scan, following the recommen-
dations of the EORTC (Table 7.1)36. The total group was divided in responders, showing 
complete metabolic response (CMR) or partial metabolic response (PMR) and          
non-responders with stable metabolic disease (SMD) or progressive metabolic disease 
(PMD). 
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Statistics 
The SPSS software (version 14.0, SPSS Inc., Chicago, IL) was used for statistical 
analysis. Results are expressed as mean±SD (standard deviation) for individual results 
and as mean±SE (standard error of the mean) for groups. The paired student’s t-test 
was used to compare the SUVmax on different time points, whereas the Mann-Whitney 
U-test and the Fisher’s exact test were used to compare the different groups. Follow-up 
was updated and frozen at July 1st of 2006. Survival estimates were calculated using 
the Kaplan-Meier method and comparison of the survival curves were made using the 
log rank test. Patients lost to follow-up were censored. Two-tailed p-values are   
provided and p-values less than 0.05 were considered statistically significant. 
Ethics 
This study has been reviewed and approved by the local Medical Ethical Committee, 
according to the Dutch law and regulations. All patients gave written informed consent 
before entering this study. 
Results 
Patient characteristics 
The patient characteristics are depicted in Table 7.2. Three patients did not receive 
chemotherapy, while 20 patients received platinum based chemotherapy (Cisplatin or 
Carboplatin, with Gemcitabin). As a result of induction chemotherapy 15 patients 
showed a partial remission and 5 patients showed stable disease. The median interval 
between the last course of chemotherapy and start of radiotherapy was 35±16 days 
(range 14-56 days). The average total tumour dose (TTD) given was 62.5±9.7 Gy 
(range 46.8 Gy-79.2 Gy) in an overall treatment time (OTT) of 22 days (range 17-30 
days). The first PET-CT scan was performed before start of radiotherapy (median        
9 days before start of radiotherapy, range 4-13 days), the second on day 7 of radio-
therapy (at a median dose of 19.8±4.1 Gy) and the third on day 14 of radiotherapy   
(at a median dose of 37.8±5.1 Gy). The fourth PET-CT scan was performed 70 days 
after the last day of radiotherapy (median 71±12 days). Because of logistic reasons or 
technical problems with the PET-scan no PET information was available for 1 patient on 
day 7 and for 4 patients on day 14 of radiotherapy. For 3 patients no PET scan was 
available after radiotherapy, in one because of technical reasons and in two patients 
because of early death after radiotherapy due to a myocardial infarction and a    
pulmonary infection. The median follow-up (FU) from start of RT was 9.2±3.8 months. 
Table 7.1 Definition of metabolic response on PET-CT scans 70 days after radiotherapy. 
 EORTC criteria 
CMR Complete resolution of FDG uptake in tumor, not distinguishable from surrounding tissue 
PMR Reduction of more than 25% in SUV 
SMD Changes in SUV of less than 25% 
PMD Increase of SUV of more than 25% or new (metastatic) lesions 
Abbreviations: EORTC=European Organization for Research and Treatment of Cancer; CMR=complete metabolic 
response; PMR=partial metabolic response; SMD=stable metabolic disease; PMD=progressive metabolic disease; 
SUV=standardized uptake value. 
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Table 7.2 Patient characteristics.  
patient 
no 
age 
(years) 
sex cTNM pathology localization of 
primary tumor 
induction 
chemotherapy 
OTT 
(days) 
TTD     
(Gy) 
1 51 F T1N3M0 adenoca RLL yes 21 54 
2 54 M T3N2M0 large cell ca RML yes 21 54 
3 75 M T3N2M0 large cell ca RUL yes 21 54 
4 71 F T3N1M0 scc RUL no 28 64.8 
5 70 M T2N3M0 adenoca RUL yes 21 54 
6 61 M T1N3M0 scc RML yes 27 68.4 
7 71 M T2N3M0 adenoca LLL yes 20 60 
8 77 M T4N2M0 large cell ca RUL yes 22 61.2 
9 74 F T2N0M0 large cell ca RLL no 20 54 
10 79 F T4N0M0 large cell ca RLL yes 24 57.6 
11 57 M T1N3M0 large cell ca LUL yes 30 64.8 
12 68 M T4N0M0 adenoca RUL yes 21 54 
13 62 M T4N0M0 scc RLL yes 24 64.8 
14 59 F T2N2M0 large cell ca RML yes 17 46.8 
15 55 M T4N2M0 adenoca LUL yes 30 79.2 
16 52 F T2N3M0 scc LLL yes 21 54 
17 54 F T4N2M0 large cell ca LLL yes 22 61.2 
18 71 M T4N2M0 large cell ca RUL yes 30 79.2 
19 61 F T2N2M0 large cell ca RML yes 21 57.6 
20 62 M T2N2M0 large cell ca RUL yes 27 68.4 
21 84 M T2N0M0 scc LLL no 22 61.2 
22 57 M T4N2M0 large cell ca LUL yes 30 79.2 
23 54 M T2N3M0 large cell ca LUL yes 30 79.2 
Abbreviations: no=number; scc=squamous cell carcinoma; PR=partial remission as response to induction 
chemotherapy; SD=stable disease as response to induction chemotherapy; OTT=overall treatment time of 
radiotherapy; TTD=total tumour dose; CMR=complete metabolic response; PMR=partial metabolic response; 
SMD=stable metabolic disease; PMD=progressive metabolic disease.  
Time trends in maximal SUV 
There was a large heterogeneity in the changes in SUVmax of the primary tumour during 
the radiation treatment between patients (Figure 7.1). Out of the 22 patients who had 
a PET-CT at day 7 of radiotherapy, 4 patients (18%) showed a decrease of more than 
25% of the SUVmax, whereas 41% (9/22) showed an increase of more than 25%. The 
remainder (9/22) showed a stable SUVmax (<25% change) compared with pre-
treatment values. 
 
For the whole patient group, the SUVmax was on average 7.3±0.8 (range 0.6-16.1) 
before start of radiotherapy, which increased to 8.9±1.2 (range 1.3-23.1) on day 7 of 
treatment (p=0.052). In the second week, a significant decrease was observed to a 
SUVmax of 8.1±1.0 (range 2.1-17.8; p=0.023). Seventy days after treatment the 
SUVmax further decreased to a mean level of 4.8±3.3 (range 1.2-13.4), a significant 
decrease compared with day 14 of treatment (p=0.001) and compared with pre-
treatment levels (p=0.005; Figure 7.2a).  
 
For the whole patient group, the SUVmax was on average 7.3±0.8 (range 0.6-16.1) 
before start of radiotherapy, which increased to 8.9±1.2 (range 1.3-23.1) on day 7 of 
treatment (p=0.052). 
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In the second week, a significant decrease was observed to a SUVmax of 8.1±1.0  
(range 2.1-17.8) (p=0.023). Seventy days after treatment the SUVmax further     
decreased to a mean level of 4.8±3.3 (range 1.2-13.4), a significant decrease     
compared with day 14 of treatment (p=0.001) and compared with pre-treatment levels 
(p=0.005; Figure 7.2a). 
 
Analysing the subset of patients (n=16), who received a PET-CT scan at all time points 
during radiotherapy, similar results were obtained: SUVmax before radiotherapy 7.0±0.9 
and at day 7 9.7±1.5 (p=0.023), day 14 8.0±1.1 (p=0.022) and 70 days after radio-
therapy 4.7±0.8 (p=0.002). 
Metabolic responders versus non-responders 
In 20 patients a PET-CT scan was performed 70 days after treatment. In 1 patient 
(with visually a CMR) no SUVmax could be calculated, due to a software problem. Eleven 
patients (55%) showed a metabolic response 70 days after radiotherapy (7 patients 
CMR and 4 patients PMR), while 9 patients (45%) showed no response (2 patients 
SMD, 7 patients PMD). Concerning the PMD group, 4 patients had metastatic disease 
and 3 patients showed loco-regional progression. 
 
Patients with a metabolic response 70 days after thoracic irradiation had a significantly 
longer overall survival (estimated survival of 100% after 9 months of follow-up) 
compared with the patients with stable or progressive disease (estimated survival of 
62.5% after 9 months of follow-up) (p=0.005; Figure 7.3). No difference was observed 
between total radiation dose prescribed (p=0.4) and the overall treatment time of 
radiotherapy (p=0.2) between metabolic responders and non-responders. 
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Figure 7.1 The absolute maximal SUV (standardized uptake value) plotted versus time (before RT, day 7 
and day 14 during RT and 70 days after RT) for all individual patients with a PET-CT scan at day 70. 
 metabolic responders 
 metabolic non-responders 
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In the group of metabolic responders no change in SUVmax was observed during the 
course of radiotherapy. Only after radiotherapy a mean decrease of 46% of the SUVmax 
was observed from 5.0±0.8 on day 14 during radiotherapy to 2.7±0.4 70 days after 
radiotherapy (p=0.017; Figure 2b and Table 3). In contrast to this finding, the group of 
non-responders showed a significant increase of the SUVmax in the first week of radio-
therapy. In this group the SUVmax before treatment was on average 8.9±1.1 and 
increased to 13.2±1.7 in the first week (p=0.023). In the second week a decrease was 
observed to an average level of 11.5±1.3 (p=0.042), with a further decrease after 
radiotherapy to a mean of 6.9±1.2 (p=0.016). Similar results were obtained for the 
subset of patients with a PET-CT scan on day 0, 7 and 14: for the responders SUVmax 
did not change during radiotherapy (before radiotherapy: 5.1±1.1, day 7: 5.3±0.8, 
day 14: 4.6±0.8), while for the non-responders the SUVmax increased during the first 
week and decreased again during the second week of radiotherapy (before radiother-
apy: 8.9±1.2, day 7: 14.0±1.7 (p=0.01) and day 14 11.5±1.3 (p=0.042). Not only a 
difference in time trends in SUVmax was observed between responders and              
non-responders, but the non-responders also showed a significant higher SUVmax than 
the responders at all time points investigated (Figure 7.2 and Table 7.3). The number 
of patients in this study was however too small to test the predictive value of the time 
trends in SUVmax in relation to metabolic response. 
Influence of induction chemotherapy 
In total 20 patients received induction chemotherapy, of which 18 patients were 
evaluable 70 days after irradiation. The group of patients achieving a partial remission 
after induction chemotherapy (13/18) showed in higher percentage metabolic response 
after radiotherapy (metabolic response rate: 62%) as patients showing stable disease 
as result of the induction chemotherapy (metabolic response rate: 20%), although this 
difference was not significant (p=0.29). The time patterns of the SUVmax in relation to 
metabolic response as described above for the total group were similar in patients 
having received induction chemotherapy. This excludes the possibility that the 3 
individuals, who did not receive systematic treatment, would have influenced the 
overall results. 
 
Table 7.3 Maximal SUV (mean±SE) before start of radiotherapy, on day 7 and 14 during radiotherapy and 
70 days after radiotherapy.  
 Total group Metabolic responders Metabolic non-
responders 
 
Maximal SUV mean SD (no) mean SD (no) mean SD (no) p-value 
Before start of RT 7.3 3.8 (23) 5.1 3.1 (11) 8.9 3.2 (9) 0.020  
Day 7 of RT 8.9 5.7 (22) 4.8 3.4 (10) 13.9 5.2 (9) 0.001  
Day 14 of RT 8.1 4.3 (19) 5.0 2.4 (9) 11.5 3.6 (8) <0.001  
70 days after RT 4.5 3.2 (19) 2.7 1.4 (10) 6.5 3.6 (9) 0.002  
Results for the total group, for patients showing a metabolic response (CMR or PMR) or no metabolic response 
(SMD or PMD) on radiotherapy 70 days after irradiation. P-value of Mann-Whitney U-test to compare the group of 
metabolic responders and non-responders. Abbreviations: RT=radiotherapy; SD=standard deviation; no=number. 
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Figure 7.2 Average change in maximal SUV for the total group of patients (a) and for metabolic responders 
(complete and partial metabolic response) versus non-responders (stable metabolic disease and progressive 
metabolic disease) (b), *indicates a significant difference. Abrreviations: SUV=standardized uptake value; 
SE=standard error 
 metabolic responders 
 metabolic non-responders 
a 
b 
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Discussion 
Until now the PET-scan is mainly used before start of radiotherapy for staging pur-
poses, to delineate the primary tumour and/or mediastinal lymph nodes and after 
therapy to assess the remission status22,25,37-45. Similar to early response measure-
ments during chemotherapy, FDG-PET scans performed in the beginning of radio-
therapy might give information on the later tumour response26,29,30,46. However, only 
limited data on this subject is available in literature27,8. We therefore assessed in the 
present study the time trends of FDG uptake during radiation treatment in NSCLC. A 
striking result was the large heterogeneity in the SUVmax in serial PET-scans between 
the individual patients. While some patients showed an increase, others show a stable 
or decreased FDG uptake after 1 week of radiation. This confirms the findings of Erdi et 
al., who described serial PET-scans during radiation therapy in 2 NSCLC patients28. 
Their first patient showed a decrease in SUVmax during and after radiotherapy, whereas 
the other patient showed first a decrease followed by an increase in SUVmax after 40 
days. De Geus-Oei et al. investigated repeated FDG-PET scans in patients treated with 
ARCON (accelerated radiotherapy with carbogen and nicotinamide) for head-and-neck 
cancer and also showed very heterogeneous changes in SUVmax after hyperoxygenation 
with a median interval of 2 days between the 2 scans27. 
 
Investigating the time trends we observed for the total group a trend in increase of the 
SUVmax (p=0.052) during the first week of radiotherapy, followed by a significant 
decrease in the second week of treatment and in the first 70 days after treatment. 
Only few other authors described repeated (CT-)PET scans during radiation therapy. 
Geets et al. described re-imaging with FDG PET scan during radiation treatment in 
head-and-neck patients47. After an average dose of 46 Gy, 18 patients received a 
repeat PET-scan, which was hard to interpret due to inflammation. In our patients with 
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Figure 7.3 Actuarial analysis of overall survival (Kaplan-Meier) in months for metabolic responders (n=11) 
and non-responders (n=9), classified according to EORTC-criteria. P-value of log-rank test. 
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NSCLC we did not encounter this problem. De Geus-Oei et al. showed in 22 patients 
with head-and-neck tumours a median decrease of relative change of SUV max of 4%, 
comparing the PET scan after hyperoxygenation to the baseline scan27. Lin et al. 
described repeated PET-scans during treatment in cervical patients, but no results 
concerning the (maximal) SUV were investigated in this study8. In both the study of Lin 
and Geets, most patients received concurrent chemo-radiation, while in the study of de 
Geus-Oei et al. patients were treated with ARCON. 
 
By using the EORTC criteria to evaluate the metabolic response after 70 days to  
compare the time trends of the SUVmax of responders and non-responders, we could 
confirm the findings of Mac Manus et al. that patients showing a metabolic response 
after radiotherapy had a better overall survival than the non-responders (p=0.005)25.  
A significant difference in the time trends of SUVmax during radiotherapy between 
metabolic responders and non-responders was found. Metabolic non-responders had a 
higher SUVmax at all time points investigated and showed a significant increase in 
SUVmax during the first week of irradiation followed by a decrease. In contrast, the 
responders showed a stable SUVmax during irradiation. The number of included patients 
was however too small to calculate the predictive value of the changes in SUVmax 
during a course of radiation. 
 
The question thus remains what causes the observed time trends and their relation 
with subsequent response. A first hypothesis is that the increase of SUVmax during the 
first week is due to inflammation, since a rather high median dose of 19.8±4.1 Gy  
(1.8 Gy BID) was already delivered at the time point of the first repeat PET-CT scan. 
Radiation is known to be a potent inducer of inflammation in several tissues49-51. 
However, this cannot explain the differences in metabolic responders and non-
responders, since one would also expect inflammatory changes in the group of    
responders. Another possibility is that the SUVmax provides information related to 
intrinsic biological characteristics of the tumour, such as tumour hypoxia. As hypoxia is 
strongly related to therapy resistance and the occurrence of metastases, this hypothe-
sis is particularly attractive. The prognostic importance of the FDG uptake before 
therapy further underscores this hypothesis17-21. Hypoxia might play a role in the 
uptake of FDG, since it leads via the Hypoxia Inducible Factor-1α (HIF-1α) pathway to 
up regulation of glucose transporters. However, contradictory findings concerning the 
relation between FDG uptake and hypoxia have been published52-59. 
 
Although the radiation dose (range between 46.8 Gy and 79.2 Gy in this study) could 
have influenced the response rate, a dose-response relation could not be established in 
this series, presumably due to the limited number of patients4,6. Another possibility is 
that the response on induction chemotherapy may also affect the subsequent response 
to radiation. However, this could not be shown in our study. To fully exclude the 
influence of induction chemotherapy it would have been best to perform the first     
PET-CT scan before start of any treatment. Although most of our patients underwent a 
PET(-CT) scan before starts of chemotherapy, most of these scans were performed at 
different PET(-CT) scanners in affiliated hospitals. Since maximal SUV of different 
scanners cannot be compared directly, we were not able to encompass maximal SUV 
before start of chemotherapy into our results. 
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Lastly, the overall treatment time of radiotherapy might influence response after 
radiotherapy60. We did not find such a correlation between OTT of radiotherapy and the 
metabolic response rate, but this may be due to a short OTT (less than 5 weeks) in all 
patients. However, like for radiation dose, a difference in OTT could not explain why a 
change in FDG uptake on day 7 could affect response after 70 days. Our present 
working hypothesis is that the difference in time trends of SUVmax as observed between 
responders and non-responders might reflect a complex relationship between several 
factors, like changes in blood flow as well as changes in the extracellular compartment, 
together with several intrinsic tumour properties, which all contribute to the uptake of 
the FDG tracer. Further in-depth studies, including analysis of several plasma markers 
at different time points, to address this question are ongoing. 
 
In conclusion, a large heterogeneity in changes in SUVmax was observed during thoracic 
radiation. Differences in time trends of SUVmax during radiotherapy were found between 
metabolic responders and non-responders. Further research addressing the question 
whether these time trends can predict response, the biological meaning of the different 
time trends and whether it finally might enable individualized adjustments of treatment 
is ongoing. The final goal being prediction of response early during the course of 
radiotherapy to enable early adjustments, like prescribing a higher total dose,    
adjusting the fractionation scheme or adding another form of treatment. 
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Abstract 
Purpose: Local tumor recurrence remains a major problem in patients with inoperable 
non-small cell lung cancer (NSCLC) receiving radiotherapy. We investigated the  
theoretical gain in estimated tumor control probability (TCP) from using an         
individualized maximal tolerable dose (MTD) prescription, both for conventional and 
accelerated fractionation schemes. 
 
Materials and Methods: For 64 NSCLC patients, 5 treatment plans were compared 
dependent upon normal tissue dose constraints for lung and spinal cord. The first two 
employed a classic fractionation (2 Gy/day, 5 days/week) to a total dose of 60 Gy 
(QDclassic) or determined by individualized MTD (QDMTD). The third scheme assumed a 
hypofractionated schedule of 2.75 Gy fractions (QDhypofr), whilst the fourth and fifth 
were based on hyperfractionation and acceleration, (1.8 Gy twice daily, either BIDclassic 
or BIDMTD). TCPs for the groups of patients were estimated. 
 
Results: The mean biological equivalent dose in 2 Gy fractions for tumor, corrected for 
accelerated repopulation (EQD2,T) was significantly higher for the BIDMTD scheme 
(62.1 Gy) than for any other scheme (QDclassic 47.5 Gy, QDMTD 52.0 Gy, QDhypofr 56.9 Gy 
and BIDclassic 56.9 Gy, p<0.001). While both dose-escalation (QDMTD) and hypo-
fractionation (QDhypofr) resulted in an increase in mean estimated TCP of respectively 
5.6% (p<0.001) and 14.6% (p<0.001) compared with QDclassic, the combination of 
escalation and acceleration (BIDMTD) improved the mean estimated TCP with 26.4% 
(p<0.001). 
 
Conclusions: This planning study shows a large gain in estimated TCP using an MTD 
scheme with 1.8 Gy fractions BID compared with other fractionation schedules. Clinical 
studies implementing this concept are ongoing. 
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Introduction 
Although the prognosis of patients with inoperable lung cancer has improved, local 
tumor control is still not achieved in a large proportion of patients1-4. Approaches to 
improve loco-regional control and survival include the addition of chemotherapy and 
increasing the radiation dose1,4-9. Several authors have reported dose-escalation 
studies in non-small cell lung cancer (NSCLC)5,7,8,10-12. Kong et al. analyzed 109   
patients with stage I-III NSCLC and showed a better overall survival and local control 
rate in the highest dose group7. Mathematical modeling suggested that a high dose, 
probably above 84 Gy in daily 2 Gy fractions, is needed to achieve 50% or more tumor 
control probability (TCP)13. 
 
However, in addition to the total tumor dose (TTD), the overall treatment time (OTT) in 
which the radiation treatment is given is an important determinant of outcome as 
demonstrated in the continous, hyperfractionated, accelarted radiotherapy (CHART) 
trial3. This study showed an absolute improvement in 2-year survival and an increase 
in local tumor control comparing 54 Gy in 12 consecutive days (1.5 Gy three times 
daily) with a conventional scheme of 30 2-Gy fractions, once daily in 6 weeks. In the 
continous hyperfractionated accelarated radiotherapy-weekend less (CHARTWEL) trial 
60 Gy in 2.5 weeks (three daily fractions of 1.5 Gy) was compared with 66 Gy in 6.5 
weeks (2 Gy once daily)14. In this study both arms showed an equal overall survival, 
supporting that a similar survival could be obtained with a lower TTD when the OTT is 
shortened. 
 
Concurrent chemo-radiation leads to an increase in overall survival compared with 
sequential therapy, but at the cost of a much greater incidence of acute toxicity, 
mainly esophagitis9,5-19. This gain in survival has mainly been attributed to an     
improvement in local tumor control17,18. Nevertheless, local relapse remains the initial 
site of failure in about one-third of the patients16-18. 
 
It has been estimated that the best local control rate could be achieved by delivering 
the highest possible dose in an OTT of <5 weeks20. However, dose-escalation is limited 
by damage to normal tissues. Dosimetric factors, such as the relative volume receiving 
a certain dose (e.g. the V5-V65) and the mean lung dose (MLD) appear to be useful for 
estimating the probability to develop radiation pneumonitis21,22. Several authors  
performed phase I/II studies to evaluate the feasibility of escalating dose based on 
bins using different modes to assess lung injury in different risk groups5,11,23-25. 
 
We hypothesized that the best achievable radiation schedule would include the highest 
TTD based on individualized normal tissue dose constraints, delivered in an OTT of 
<5 weeks. Hypofractionated schedules, as well as hyperfractionated schedules    
combined with acceleration (2 fractions daily) are methods to deliver a high TTD within 
a short OTT. A hypofractionated schedule is more convenient for the patient. However, 
a schedule with two fractions daily might lead to a relative sparing of normal tissues or 
could allow high dose irradiation of tumors next to critical organs. 
 
The aim of the current study was to investigate the theoretical gain in TCP using the 
concept of an individualized dose prescription, based on normal tissue dose constraints. 
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Several fractionation schedules, including classic fractionation, hypofractionation and 
hyperfractionation combined with accelerated treatment are compared in NSCLC 
patients. 
Materials and Methods 
Patients 
Radiotherapy plans from 64 consecutive patients with medically inoperable or locally 
advanced NSCLC stage I-IIIB, enrolled in different trials at MAASTRO clinic, were 
retrieved from archive for this planning study26-28. The clinical stage distribution was: 
stage IA in 2 cases, 6 patients with IB, 1 patient with IIB, 24 patients with IIIA and 31 
patients with IIIB. The treatment plans were calculated using an individualized pre-
scribed maximal tolerable dose (MTD) based on normal tissue dose constraints for lung 
and spinal cord. Because most patients had great vessels and/or the main bronchi 
included in the target volume, we applied a maximal allowed TTD. Based on the study 
of Marks et al. the maximal allowed TTD were12: 76.0 Gy in 2.0 Gy fractions once daily, 
66.0 Gy in 2.75 Gy fractions once daily and 79.2 Gy in 1.8 Gy fractions twice daily. 
Radiotherapy planning 
To investigate both the role of dose-escalation as well as decreasing OTT by twice daily 
irradiation or hypofractionation, we calculated five different treatment plans for each 
patient. A three-dimensional conformal treatment planning was performed, that was 
individually optimized to reach the highest possible TTD within the normal tissue 
constraints. For a given patient, all five plans used the same beam arrangement. All 
plans were in accordance with the International commission on Radiation Units and 
Measurements guidelines29: 
 
1. The first plan (QDclassic) was a classic dose prescription of 60 Gy, once daily 2 Gy 
fractions (QD) or a lower TTD if the normal tissue dose constraints were reached 
at a lower dose. 
2. The second plan (QDMTD) was calculated based on an individualized, maximal 
tolerable dose depending on normal tissue dose constraints with a maximum TTD 
of 76 Gy in 2.0 Gy fractions once daily. 
3. The third plan (QDhypofr) was based on a hypofractionated schedule of 2.75 Gy 
fractions once daily till a maximal TTD of 66 Gy30,31 applying the same dose      
constraints. 
4. The fourth plan (BIDclassic) was calculated to investigate the contribution of 
acceleration, based on an TTD of 61.2 Gy (EQD2,T=60.2 Gy) in 1.8 Gy fractions 
twice daily. 
5. The fifth plan (BIDMTD) combined the effect of dose escalation and acceleration. 
The same constraints as in QDMTD were applied. The TTD was prescribed in 1.8 
Gy fractions, BID, 5 days a week, to a maximal TTD of 79.2 Gy. 
 
For all plans we used a normalized mean lung dose (nMLD) of maximal 19.0±1.0 Gy as 
the constraint. Based on published data, this constraint was estimated to yield a 
probability of ≥grade 2 pneumonitis of about 15% (maximum 20%)21. For the spinal 
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cord a maximal dose of 54±0.5 Gy (in biological equivalent dose in 2 Gy fractions, 
EQD2,M) was accepted32. No specific dose constraint for the esophagus was used as 
acute esophagitis was not considered to be dose-limiting when radiation alone was 
delivered. 
 
Contouring of the lungs was done automatically by the treatment planning system 
(XiO, CMS, St. Louis, MO). The spinal cord was considered to be at the inner margin of 
the bony spinal canal. Radiotherapy planning was performed using inhomogeneity 
corrections based on a convolution algorithm. Both normal tissue contours as well as 
target volumes were outlined on each slice. The gross tumor volume (GTV) was the 
primary tumor on CT and lymph nodes positive on PET scan or proven to be positive on 
mediastinoscopy or biopsy. For the delineation of the primary tumor on CT the window-
level (W-L) setting for lung (W 1700; L -300) was used, whereas for the anatomical 
delineation of PET positive nodes the mediastinal W-L setting (W 600; L 40). No elec-
tive nodal irradiation was carried out5,33. The clinical target volume (CTV) was defined 
as the GTV plus a 5 mm margin. For the planning target volume (PTV) another 10 mm 
margin was added for the primary tumor and a 5 mm for the lymph nodal areas. 
 
The linear quadratic model was used to calculate the biological equivalent dose for 
tumor in 2 Gy fractions (EQD2,T), corrected for the overall treatment time: 
 
( ) prolifrefT DTTdDEQD ⋅−−++⋅= )(2 )(,2 βα βα  
Where D is the total radiation dose, d the dose per fraction, T the overall OTT. An α/β 
ratio of 10 Gy was used for tumor34. As we assumed a 3-week lag period before start of 
accelerated repopulation, Tref was chosen at 21 days. Before day 21 (T<Tref) repopu-
lation was assumed to be zero (Dprolif=0); after day 21 (T>Tref) the dose recovered per 
day in 2 Gy equivalent fractions (Dprolif) was assumed to be 0.6 Gy35. 
 
To assess the maximal dose for the spinal cord (EQD2,M) for the schemes with once 
daily fractions (QDclassic ,QDMTD, QDhypofr) the standard linear quadratic model was used 
(α/β ratio of 2 Gy), assuming that sufficient time was allowed for complete repair 
between fractions. However, for the BID schemes (BIDclassic, BIDMTD) the incomplete 
repair linear quadratic model was used34,36. 
 
)(2
)()1(.,2 βα
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+
++= mM HdDEQD
 
 
where D is the total radiation dose and d the dose per fraction. An α/β ratio of 2 Gy 
was used for spinal cord, and the amount of unrepaired damage was expressed by the 
factor Hm. For the spinal cord a repair half-time of 3.8 hours was assumed37. Both 
incomplete repair between fractions (8-h interval), as well as incomplete repair   
overnight (16-h interval) was taken into account38. 
 
For the normal lung tissue the mean lung dose, defined as the average dose through-
out the lungs, was used as a dose constraint21. The MLD takes into account both the 
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dose delivered as well as the volume irradiated, since the MLD transforms an inhomo-
geneous dose distribution into an equivalent uniform irradiation of the whole lung. 
However, the normalized mean (biological) lung dose (nMLD) could not be calculated 
directly for all patients, but was estimated from the mean physical lung dose similar to 
the method reported by Kwa et al.21 The following relation between the nMLD and the 
mean physical dose was obtained from a fit of data from 102 patients treated in our 
department. 
 
nMLD = 0.90 * mean physical lung dose   
 
where nMLD is calculated with an α/β ratio of 4 Gy for pneumonitis35. For the calcu-
lation of the mean physical lung dose, the volume of both lungs minus the GTV was 
considered9. 
Tumor Control Probability (TCP) calculations 
For TCP calculations, after a dose D, a logistic dose-response curve was assumed40: 
 
γ4
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where D50 is the dose needed for a 50% TCP and γ is the normalized slope of the 
sigmoid dose response curve near D50. For calculations a D50 of 70 Gy, an γ of 2.0 and 
for D the EQD2,T corrected for accelerated repopulation were used20. The TCP calcula-
tions did not take into account dose inhomogeneities within the PTV and/or incidental 
irradiation of nodal areas outside the GTV13. TCP calculations provided are thus merely 
an estimation of the TCP and are principally used for comparing the different sched-
ules. 
Risk estimation for pneumonitis 
Following Kwa and colleagues21, the risk of pneumonitis (≥grade 2) was estimated 
using the Lyman–Kutcher–Burman model41-43: 
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In this equation D is the nMLD as mentioned above and D50 is the nMLD which would 
result in a 50% risk to develop pneumonitis, being 31.8 Gy and m=0.43 and with an 
offset value (c) of 0 according to Kwa et al.21. 
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Statistics 
The SPSS software (version 15.0, SPSS Inc., Chicago, IL) was used for statistical 
analysis. Results are expressed as mean±standard deviation (SD) for TTD, EQD2,T, 
EQD2,M and nMLD, whereas mean±standard error of mean (SEM) is applied to TCP 
estimations and risk estimation for pneumonitis. Since the data did not show a normal 
distribution, the Wilcoxon Signed Ranks Test was used to compare the results. P-values 
less than 0.05 were considered statistically significant. 
Ethics 
As this was a modeling study, patients were diagnosed and treated according to 
department guidelines. Patient data were anonymized. The study was approved by the 
Institutional Review Board. 
Results 
Dose (TTD and EQD2 tumor) 
For both the individually escalated (MTD) schemes a significant higher mean TTD could 
be delivered: QDMTD 66.6±9.2 Gy and BIDMTD 65.3±11.3 Gy compared with classical 
and hypofractionated schedules: QDclassic 58.3±3.6 Gy, QDhypofr 57.5±8.7 Gy and 
BIDclassic 58.4±5.1 Gy (all p<0.001; Table 8.1). Out of the 14 patients (21.9%) not able 
to receive 60 Gy in the QDclassic scheme, 4 were limited by the nMLD at a TTD below 60 
Gy. For QDhypofr and QDMTD the maximal dose could be reached in 24 (37.5%) and 22 
patients (34.4%), respectively. The spinal cord dose was the limiting factor in half of 
the QDMTD plans (n=32) and in 40% (n=26) of the QDhypo schedules. 
 
Comparing the biological equivalent dose, corrected for accelerated repopulation, in 
2 Gy fractions (EQD2,T) for tumor we observed a mean EQD2,T of 47.5±2.3 Gy for 
QDclassic compared with 52.0±5.3 Gy for QDMTD (p<0.001). The mean EQD2,T was higher 
for the hypofractionated schedule (56.9±6.9 Gy), than for the other once daily 
schemes (p<0.001). The accelerated schemes showed a mean EQD2,T of 56.9±3.8 Gy 
(BIDclassic) and 62.1±8.5 Gy (BIDMTD). The latter was significantly greater than for all 
other schemes (p<0.001; Table 8.1). 
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Dose to normal tissues (EQD2 myelum and nMLD) 
Table 8.1 shows the EQD2,M and nMLD for all schemes. For the spinal cord, the mean 
EQD2,M BIDclassic (44.7±0.9 Gy) was significantly higher than the EQD2,M QDclassic 
(42.1±10.8 Gy, p<0.001). No significant difference was observed for the nMLD com-
paring these schemes (BIDclassic 11.8±4.5 Gy and QDclassic 12.0±4.5 Gy, p=0.28). The 
nMLD was significant higher for the BIDMTD compared with QDhypofr (mean nMLD 
13.0±4.5 Gy and 11.5±4.3 Gy, respectively, p<0.001). The spinal cord dose was also 
somewhat higher for the BIDMTD schedule (mean EQD2 myelum 48.8±9.5 Gy and 
47.2±9.7 Gy respectively, p<0.001). Both MTD schemes showed higher EQD2,M and 
nMLDs compared with the classic schemes (Table 8.1 and Figure 8.1). 
Tumor control probability (TCP) 
For the QDMTD scheme an estimated TCP to a mean value of 10.1%±0.7% was found 
(Table 8.1 and Figure 8.1). This is a limited, though significant increase compared with 
QDclassic (mean TCP of 4.5%±0.1%; p<0.001). Applying QDhypofr and BIDclassic, both could 
further improve the estimated TCP to a mean level of respectively 19.1%±1.4% 
(p<0.001) and 16.9%±0.7% (p<0.001 compared with QDclassic and p=0.046 compared 
with QDhypofr). The calculated TCP increased even further for the BIDMTD scheme, show-
ing an estimated mean TCP of 30.9%±2.4% (p<0.001 compared with all other 
schemes). Comparing the estimated TCP of BIDMTD and QDclassic, this resulted in a mean 
increase in TCP of 26.4%±2.4%. 
Table 8.1 Findings for five different radiotherapy plans. 
 QDclassic QDMTD QDhypo BIDclassic BIDMTD 
 60 Gy/2.0 GyQD MTD/2.0 GyQD MTD/2.75GyQD 61.2Gy/1.8 GyBID MTD/1.8 GyBID 
      TTD      
 Mean±SD 58.3±3.6 Gy 66.6±9.2 Gy 57.5±8.7 Gy 58.4±5.1 Gy 65.3±11.3 Gy 
 Range (42.0-60.0 Gy) (42.0-76.0 Gy) (33.0-66.0 Gy) (37.8-61.2 Gy) (37.8-79.2 Gy) 
 EQD2 tumor (corrected for repopulation) 
 Mean±SD 47.5±2.3 Gy 52.0±5.3 Gy 56.9±6.9 Gy 56.9±3.8 Gy 62.1±8.5 Gy 
 Range (37.2-48.6 Gy) (37.2-57.4 Gy) (35.1-63.5 Gy) (40.8-59.0 Gy) (40.8-72.5 Gy) 
      EQD2 spinal cord      
 Mean±SD 42.1±10.8 Gy 47.1±9.9 Gy 47.2±9.7 Gy 44.7±10.9 Gy 48.8±9.5 Gy 
 Range (7.9-54.5 Gy) (9.5-54.5 Gy) (9.3-54.4 Gy) (8.3-54.4 Gy) (9.2-54.4 Gy) 
      nMLD      
 Mean±SD 12.0±4.5 Gy 13.3±4.5 Gy 11.5±4.3 Gy 11.8±4.5 Gy 13.0±4.5 Gy 
 Range (2.7-20.0 Gy) (3.2-20.0 Gy) (2.7-20.0 Gy) (2.8-19.9 Gy) (3.0-19.9 Gy) 
      Estimated TCP      
 Mean±SE 4.5%±0.1% 10.1%±0.7% 19.1%±1.4% 16.9%±0.7% 30.9%±2.4% 
 Range (0.6%-5.1%) (0.6%-17.0%) (0.4%-31.5%) (1.3%-20.3%) (1.3%-56.9%) 
Abbreviations: QDclassic=classic dose prescription of 60 Gy, once daily, in 2-Gy fractions; QDMTD=calculated 
according to individualized MTD depending on normal tissue dose constraints, with maximal TTD of 76 Gy in 2.0-
Gy fractions once daily; QDhypo=hypofractionated schedule of 2.75-Gy fractions once daily to a maximal TTD of 66 
Gy; BIDclassic=TTD of 61.2 Gy (EQD2,T=60.2 Gy) in 1.8-Gy fractions, twice daily; BIDMTD=combined effect of dose 
escalation and acceleration, with same constraints as in QDMTD and TTD prescribed in 1.8-Gy fractions, twice daily, 
5 d/wk, to a maximal TTD of 79.2 Gy; TTD=total tumor dose; MTD=maximal tolerable dose; SD=standard 
deviation; SE=standard error; EQD2,T =equivalent dose in 2-Gy fractions corrected for accelerated repopulation to 
compare tumor effect (α/β ratio=10 Gy); EQD2,M=equivalent dose in 2-Gy fractions for spinal cord (α/β ratio=2 
Gy, for BIDclassic and BIDMTD, corrected for incomplete repair); nMLD=normalized mean lung dose (nMLD); TCP= 
tumor control probability. 
Individualized radiotherapy based on normal tissue constraints: in silico | 109 
 
 
Although for the total group both dose escalation as well as acceleration showed a gain 
in the estimated TCP, this is not necessarily the case for each individual patient. In 15 
(23.4%) of 64 patients no dose-escalation could be performed due to the fact that the 
maximal tolerable dose was already reached at a TTD of 60 Gy or lower. 
 
In 18 (28.1%) of 64 patients, a lower TTD had to be prescribed for the BIDMTD scheme 
compared with the QDclassic scheme, because of the spinal cord constraint. However, 
only in 1 patient (1.6%) the BIDMTD scheme would have resulted in a mainly unchanged 
estimated TCP compared with QDclassic (gain of 0.7%). For the other 63 patients a gain 
in TCP was expected applying a combination of dose escalation and an accelerated 
fractionation schedule (Figure 8.2). 
 
In the group of patients, where TTD was not limited by the spinal cord dose, a larger 
gain in estimated TCP could be achieved compared with those patients, in which the 
spinal cord dose was the limiting factor (gain in TCP 39.8%±17.7% versus 
15.3%±11.1%, respectively, p<0.001). However, both the TCP as well as the change 
in TCP showed no significant dependence on the clinical stage of disease. 
 
Figure 8.3 illustrates the improvement in therapeutic index as a result of dose-
escalation (Figure 8.3a; QDMTD versus QDclassic), as a result of acceleration (Figure 8.3b; 
BIDclassic vs. QDclassic) and the combination of both (Figure 3c; BIDMTD scheme compared 
with QDclassic). 
 
The gain in estimated TCP (ΔTCP) was plotted as function of the change in nMLD 
(ΔnMLD) comparing the different schemes. In 18 patients (28.1%) the BIDMTD scheme 
resulted in a lower nMLD compared with QDclassic (Figure 3c; dots left of line re-
presenting a delta nMLD of zero). Even these patients showed a gain in mean esti-
mated TCP of 6.4%±0.8%. 
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Figure 8.1 Calculations of biologic equivalent dose in 2-Gy fractions, corrected for accelerated prolifera-
tion (EQD2,T) for tumor effect, spinal cord (EQD2,M), and tumor control probability (TCP) (in percent-
ages) estimations for all five schemes. Results expressed as mean±standard deviation for EQD2,T, 
EQD2,M, and nMLD and mean±standard error of mean for estimated TCP. *Significant difference.  
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Estimated risk of pneumonitis 
The QDclassic scheme resulted in a mean estimated risk of pneumonitis of 8.3%±0.6%, 
whereas this was 9.9%±0.6% for the QDMTD (p<0.001). For the accelerated schemes 
the mean estimated risk for pneumonitis was 8.3%±0.6% and 9.5%±0.6% for respec-
tively BIDclassic and BIDMTD (p<0.001). No significant difference was observed comparing 
BIDclassic and QDhypofr (8.3%±0.6% and 7.9%±0.6%, respectively, p=0.06). Moreover, 
the estimated risk for pneumonitis for the BIDMTD compared with QDclassic was slightly 
higher for the total group of patient applying BIDMTD (9.5%±0.6% and 8.3%±0.6% 
respectively, p<0.001). 
Discussion 
The purpose of this study was to estimate tumor control probabilities and the     
therapeutic index in a planning study comparing an individualized dose prescription 
based on lung and spinal cord constraints, with a classic non-escalated dose schedule. 
We showed that using an individualized dose prescription, a large gain in estimated 
TCP could be expected. With respect to the dose escalation in once daily fractions, the 
mean TTD in once daily 2.0 Gy fractions could be increased from 58.3 Gy (QDclassic) to 
66.6 Gy for the QDMTD scheme resulting in a mean estimated gain in TCP of 5.6%. 
Moreover, applying an accelerated scheme resulted in a greater benefit (mean gain in 
estimated TCP of 12.4%, comparing BIDclassic with QDclassic). The hypofractionation 
schedule resulted in a significant increase in mean estimated TCP of 14.6% compared 
with QDclassic. However, although the hypofractionation schedule is more convenient for 
the patient and the radiotherapy department, this scheme was still not able to catch up 
with the gain of the twice daily hyperfractionated, accelerated schedule (BIDMTD    versus 
QDhypofr, 30.9% and 19.1% respectively, p<0.001). These favorable results could be  
E
st
im
a
te
d
 T
C
P
 (
%
)
60
50
40
30
20
10
0
Individual patients (n=64)
 
Figure 8.2 Gain in estimated tumor control probability (TCP) for all 64 individual patients comparing the 
classic scheme (QDclassic □) and the maximal tolerable dose scheme in twice-daily fractions (BIDMTD ●). 
Individualized radiotherapy based on normal tissue constraints: in silico | 111 
 
 
obtained since no effect of accelerated repopulation was expected to occur when the 
OTT was kept below 3 weeks20. The TTD needed to achieve a 50% tumor control 
probability is about 77 Gy for the accelerated scheme, which gives an EQD2,T of 
70 Gy13,20. For the classic schedule a much higher dose compared is needed to achieve 
the same control rate. In this study a radiation plan with an EQD2,T of at least 70 Gy 
was feasible for 20 patients (31.3%). 
 
In this study we applied a maximal allowed TTD, since the majority of patients had 
stage III disease. Our maximal TTD for the BIDMTD schedule of 79.2 Gy in 1.8 Gy 
fractions gives a comparable equivalent dose for tumor in 2 Gy fractions, corrected for 
the overall treatment time (EQD2,T) with a scheme of 100 Gy in once daily fractions of 
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Fig. 8.3 Gain in estimated tumor control probability (ΔTCP) in relation to change in normalized mean lung 
dose (ΔnMLD) comparing two different schedules: (a) ΔTCP from dose escalation comparing classic 
scheme (QDclassic) and maximal tolerable dose scheme in once-daily fractions (QDMTD), (b) ΔTCP from 
acceleration comparing classic scheme (QDclassic) and hyperfractionated, accelerated classic scheme 
(BIDclassic), and (c) ΔTCP from combination of dose escalation and acceleration comparing classic 
scheme (QDclassic) and hyperfractionated, accelerated classic scheme to maximal tolerable dose 
(BIDMTD). 
a b 
c 
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2.0 Gy or a hypofractionated schedule of 92.25 Gy in once daily fractions of 2.25 Gy. 
Moreover, unlike some of the other dose-escalation studies5,24, we also included  
patients with involved supraclavicular nodes (N3 disease) and tumors located in the 
direct proximity of the spinal cord and great vessels, which inevitably leads to the 
inclusion of organs at risk into the planning target volume. Marks et al. defined in a 
group of stage III NSCLC the maximal tolerable dose at 80 Gy, since above this dose 
complications like bronchial or tracheal stenosis, brocho-esophageal fistula and   
obstructions of the pulmonary artery are more frequently seen12. However, in a subset 
of patients, like patients with stage I or II N0 disease, it might be safe to further 
escalate dose. One way to achieve this is by treating this subgroup of patients with 
extracranial radiosurgery. 
 
Concerning late effects we observed a somewhat higher mean EQD2,M (late effects 
spinal cord, α/β ratio of 2 Gy) for the MTD schemes (47-49 Gy) compared with the 
classical schemes (42-45 Gy, p<0.001). A spinal cord dose of 54 Gy, the dose    
constraint used in this study and in daily clinical practice at our department, probably 
leads to an incidence of radiation myelopathy of 5% or less32,44. With regard to lung 
injury, a higher mean nMLD was seen in the MTD schemes (13 Gy) compared with the 
classical schemes (12 Gy). This could result in a limited increase in the proportion of 
patients developing radiation induced lung injury. In this modeling study we used the 
model of Lyman to calculate the pneumonitis risk and applied a D50 of 31.8 Gy and no 
offset value, as described by Kwa et al. for the total group of patients21,43. Applying the 
Lyman model we observed a limited increase in estimated risk for pneumonitis for the 
BIDMTD schedule (9.5%) compared with the QDclassic scheme (8.3%, p<0.001) and 
compared with the hypofractionated schedule (7.9%, p<0.001). We realize that the 
risk for grade 2 or higher pneumonitis calculated for the accelerated schemes might be 
an underestimation, since like for tumors, there is evidence in literature for a time 
factor for pneumonitis with an estimated dose recovery of 0.44 Gy/day35. Since no 
model is currently available taking this recovery into account when assessing the MLD 
based risk estimation for pneumonitis, we used the model without adjustment for 
overall treatment time. Although the current model is based on nMLD, a better predic-
tor of radiotherapy induced lung injury is needed45. The prediction should probably not 
only be based on dosimetric parameters, but should also take into account patient-
related factors, like lung function and smoking habits. 
 
One of the limitations of a modeling study is that there are uncertainties in risk   
estimates as expressed above. The risk estimates depend on several radiobiological 
parameters, such as α/β and D50. We applied literature-based values for these para-
meters, and therefore we believe that the results for TCP and risk for pneumonitis are 
the best possible estimates, based on current available data. Clinical studies are 
needed to verify these results. 
 
Although the results of clinical studies have to be awaited, no major impact on late 
effects is expected since several authors already have shown that it is safe to escalate 
dose with regard to toxicity5,11,23-25. In contrast to late toxicity, a clinically relevant 
increase in acute esophagitis is expected escalating the total tumor dose to 79.2 Gy. In 
a dose escalation study performed by Belderbos et al., and confirmed by other authors, 
about half of the patients (48/88) had grade 1 or 2 acute esophagitis, while no grade 3 
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or higher occurred23,24,46-48. Since acute esophagitis is thus not dose limiting, when no 
concurrent chemo-radiation is administered, no constraint for the esophagus was taken 
into account in this study. 
 
One could argue that the concurrent chemo-radiation is the standard treatment for 
patients with locally advanced NSCLC, because of improved survival rates9,15,17. How-
ever, the combined schedules also give rise to rather high toxicity levels9,15,17,22,46,49. 
Moreover, a large number of patients with co-morbidity cannot profit from concurrent 
schemes, and we therefore believe that optimizing non-concurrent radiation strategies 
are still very valuable. These patients may potentially benefit from a combination of 
radiation dose escalation and acceleration. 
 
Our results suggest that using a personalized maximal tolerable dose scheme, given in 
twice daily fractions of 1.8 Gy can increase tumor control probability from 4.5% for the 
classic scheme of 60 Gy in 2.0 Gy fractions once daily, to 30.9% for the new scheme. A 
further improvement in both the prediction of radiation induced lung injury, as well as 
the prediction of tumor response might give the opportunity to further individualize 
radiation treatment in NSCLC patients. The results of this in silico trial should be 
confirmed in a phase II trial. The results of such a trail, ongoing in our department, are 
awaited. 
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Abstract 
Purpose: Local recurrence is a major problem after (chemo-)radiation for NSCLC. We 
hypothesized that for each individual patient, the highest therapeutic ratio could be 
achieved by increasing the total tumor dose (TTD) to the limits of normal tissues, 
delivered within 5 weeks. We report the first results of a prospective feasibility trial. 
 
Materials and Methods: Twenty-eight patients with medically inoperable or locally 
advanced NSCLC, WHO-performance score of 0-1, and a reasonable lung function 
(FEV1 >50%) were analyzed. All patients underwent irradiation using an individualized 
prescribed TTD, based on normal tissue dose constraints (mean lung dose 19 Gy; 
maximal spinal cord dose 54 Gy) up to a maximal TTD of 79.2 Gy, in 1.8 Gy fractions 
twice daily. No concurrent chemo-radiation was administered. Toxicity was scored 
using the CTCAE-criteria. An FDG-PET-CT scan was performed to evaluate (metabolic) 
response 3 months after treatment. 
 
Results:  Mean delivered dose was 63.0±9.8 Gy. The TTD was most often limited by 
the MLD (32.1%) or spinal cord (28.6%). Acute toxicity was generally mild; only 1 
patient experienced grade 3 cough and 1 patient grade 3 dysphagia. One patient 
(3.6%) died of pneumonitis. For late toxicity 2 patients (7.7%) had grade 3 cough or 
dyspnea; none had severe dyshagia. Complete metabolic response was obtained in 
44% (11 of 26 patients). With a median follow-up of 13 months, median overall  
survival was 19.6 months, with a 1-year survival of 57.1%. 
 
Conclusions: Individualized maximal tolerable dose irradiation based on normal tissue 
dose constraints is feasible, and initial results are promising. 
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Introduction 
For patients with inoperable and/or locally advanced (stage III) non-small-cell lung 
cancer (NSCLC), radiotherapy alone or combined with chemotherapy is the principal 
choice of treatment. Conventionally, radiation doses of 60 to 66 Gy are delivered. 
However, these schedules give rise to local failure in the majority of patients resulting 
in 2-year local tumor control rates of less than 20%1,2. Several approaches have 
therefore been applied to improve local control, including increasing the radiation dose 
and/or the concomitant administration of chemotherapy1,3-6. In several randomized 
studies higher locoregional control rate was associated with an improved survival7-9. 
However, even with concurrent chemo-radiation local relapse still occurs in about one 
third of the patients as their initial site of failure8-10. Moreover, concurrent schedules 
give rise to increased levels of toxicity6,10,11 and therefore are not applicable to patients 
with co-morbidity12. We therefore believe that optimizing non-concurrent chemo-
radiation strategies are still very valuable. 
 
Several investigators have reported radiation dose escalation studies in NSCLC3-5. 
Delivery of higher doses up to a total tumor dose (TTD) of 94.5 Gy was associated with 
improved local control and overall survival3. Using a mathematical model it was sug-
gested that a dose of 84 Gy might be needed to achieve a 50% tumor control proba-
bility (TCP) in patients with locally advanced NSCLC13. However, the TTD that can be 
given is mainly limited by damage to normal tissues, such as lung, esophagus and 
spinal cord. Dosimetric factors, such as the mean lung dose (MLD), have been corre-
lated with the probability to develop radiation pneumonitis14-16. As a consequence, 
phase I/II studies were initiated to evaluate the feasibility for dose escalation based on 
bins using different modes to assess lung injury in the several risk groups3,17,18. These 
trials supported the feasibility of this approach. The dose that can be delivered safely is 
obviously related to the radiation technique and the imaging modalities used to   
delineate the target volume. Earlier, we showed that the use of 18F-fluoro-2-deoxy-
glucose (FDG) Positron Emission Tomography-Computer Tomography (PET-CT) scans 
for target volume delineation in NSCLC decreased radiation exposure of the esophagus 
and lung, and thus allowed for significant radiation dose escalation and an estimated 
increase in TCP19,20. In prospective studies, selective irradiation of only FDG-PET 
positive mediastinal nodes, did not increase the incidence of isolated nodal failures3,21. 
In addition to the mentioned factors, overall treatment time (OTT) of radiotherapy is 
considered an important factor for local tumor control2. 
 
In most dose escalation studies patients have been stratified to escalating radiation 
dose levels depending on assignment to different risk groups for the development of 
radiation pneumonitis. We hypothesized that the best achievable radiation schedule 
would include the highest TTD based on individualized normal tissue dose constraints, 
delivered in an OTT of less than 5 weeks22. The theoretical gain of such a scheme was 
estimated to be 25% in tumor control probability compared with a classical scheme of 
60 Gy in 2 Gy fractions in 6 weeks23.The main objective of this study is to evaluate the 
feasibility of an individualized maximal tolerable dose radiation prescription, using an 
accelerated schedule, in patients with inoperable and/or locally advanced NSCLC. 
Results of the 29 patients enrolled in this prospective feasibility study with respect to 
toxicity and outcome are reported here. 
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Materials and Methods 
Patient eligibility 
Patients eligible for this study had medically inoperable (stage I or II) or locally   
advanced (stage III) histologically or cytologically confirmed NSCLC. Inclusion criteria 
were: WHO-performance sore of 0 or 1, a weight loss of less than 10% in 6 months 
and a reasonable lung function (a forced expiratory volume in 1 second (FEV1) ≥50% of 
predicted value and a carbon monoxide diffusing capacity (DLCO) ≥ 50%). No concur-
rent chemo-radiation was allowed. Induction chemotherapy was allowed for stage III 
patients and consisted of three courses of Gemcitabine (1250 mg/m2 on day 1 and 8), 
in combination with Cisplatin (75 mg/m2 on day 1) or Carboplatin administered at the 
Calvert formula for a target area concentration curve (AUC) of 5 mg/ml.min (day 1)24. 
Cycles were repeated every 21 days, and standard dose-reduction rules were applied if 
indicated. An interval between the last course of chemotherapy and start of radiother-
apy of at minimum 14 days was mandatory. No previous radiotherapy to the chest was 
allowed. Patients were not eligible if they had any other concomitant malignant dis-
ease, recent severe cardiac disease or active peptic esophagitis. 
Radiotherapy treatment planning 
In all patients a treatment planning PET-CT scan before the start of radiation was 
obtained in radiotherapy position on a dedicated PET-CT-simulator with both arms 
above the head and using a laser marker system. The PET-CT scanner used was a 
Biograph™ (SOMATOM® Sensation 16 with an ECAT ACCEL PET scanner, Siemens AG, 
Forchheim, Germany). Patients fasted for at least 6 hours before the examination.    
18F-fluorodeoxyglucose (MDS Nordion, Liège, Belgium) was injected intravenously and 
followed by physiologic saline (10 ml). The injected total activity of FDG depended on 
the patient weight: (weight*4+20) MBq. After a rest period of 45 minutes images were 
acquired. The CT-scan performed was a spiral CT-scan of the whole thorax with intra-
venous contrast. The PET images were acquired in 5-minute bed positions, whereas 2 
or 3 positions were needed to scan the thoracic region. 
 
Delineation based on fused PET-CT images was performed by the radiation oncologist 
using a standard clinical delineation protocol. The protocol included fixed window-level 
(W-L) settings of both CT (lung W 1700; L –300, mediastinum W 600; L 40) and PET 
scan (W 30000; L 15000) to be used for delineation. For all patients a Gross Tumor 
Volume (GTV) was defined based on FDG PET-CT data. The total tumor volume   
consisted of the primary tumor (GTV-1), which is the (post-chemotherapy) CT based 
volume (lung window), and the initial PET-positive lymph nodal areas (GTV-2). PET 
negative nodes proven to be malignant on mediastinoscopy or transesophag-
eal/transbronchial fine needle aspiration were also included in the GTV. For the final 
delineation of the lymph nodal areas, the CT scan provided a better contrast with 
surrounding (fat) tissue and was mainly used for the determination of the border of the 
lymph node station. No elective hilar of mediastinal irradiation was carried out. The 
Clinical Target Volume (CTV) was defined as the GTV with a margin of 5 mm, whereas 
another 10 mm margin for the primary tumor and 5 mm for the lymph nodal areas was 
added for the Planning Target Volume (PTV). 
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Contouring of the lungs was done automatically by the treatment planning system 
(XiO, Computer Medical System Inc., St. Louis, Missouri, USA). For the calculation of 
the MLD, the volume of both lungs minus the GTV was considered25. The spinal cord 
was drawn throughout the whole CT scan and was considered to be at the inner margin 
of the bony spinal canal. Both normal tissue contours as well as target volumes were 
outlined on each slice. 
 
A three-dimensional conformal treatment plan using three to six coplanar 10 MV 
photon fields, was calculated according to the International Commission on Radiation 
Units and Measurements (ICRU) guidelines26. Calculations were performed using a XiO 
treatment planning system with a fast fourier transform (FFT) convolution algorithm  
for inhomogeneity corrections. Patients were irradiated on a linear accelerator    
(Elekta SL 15, Crawley, United Kingdom). Treatment verification was performed using 
electronic portal imaging device (EPID) measurements27. A shrinking action level 
protocol was used to control setup errors. The EPID images were also used for in vivo 
dosimetry measurements. 
Treatment description 
All patients enrolled in this study underwent irradiation using an individualized pre-
scribed maximal tolerated dose (MTD). The TTD was based on normal tissue con-
straints instead of a classic fixed prescribed dose. The radiation dose was individually 
escalated until a dose-limiting normal tissue constraint was reached. For the lungs, a 
maximal MLD of 16.0±1.0 Gy for the first three patients and 19.0±1.0 Gy for all other 
patients was allowed, accepting a theoretical probability of grade 2 pneumonitis  
(Radiation Therapy Oncology Group; RTOG-criteria) of at maximum 20%15. For the 
spinal cord a maximal dose of 54.0±0.5 Gy, for the main bronchi (when both main 
bronchi were in the high-dose region) a maximum of 70.2 Gy and for the plexus 
brachialis a dose constraint of 61.2 Gy was applied28-31. No specific dose constraint for 
the esophagus was used, because acute esophagitis was not considered to be dose-
limiting when radiation alone was delivered11. Based on the results of Marks et al.     
we accepted a maximal allowed TTD of 79.2 Gy31. Radiotherapy was delivered twice 
daily, with a fraction size of 1.8 Gy, because of the relative sparing of normal tissues23. 
An interval of at least 8-hours between the two fractions was respected. 
Toxicity and tumor response 
Acute toxicity was scored before start of radiotherapy (baseline) and weekly during 
radiation treatment. After the last fraction patients were followed up weekly until acute 
toxicity decreased and afterwards at 2-month intervals, consisting of history and 
physical examination. Acute and late toxicity was scored according to Common   
Terminology Criteria for Adverse Events v3.0 (CTCAE) (Table 9.1). A post-treatment 
FDG-PET-CT scan was performed to evaluate metabolic response on PET according to 
European Organization for Research and Treatment of Cancer (EORTC) criteria and 
response on CT according to Response Evaluation Criteria in Sold Tumours (RECIST) 
criteria32,33. This PET-CT scan was performed 70 days after the last fraction of radio-
therapy, since it has been shown that metabolic response on PET assesed at this time 
point is related to overall survival34,35. 
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Statistical analysis 
The SPSS software (SPSS for Windows, version 15.0, SPSS Inc., Chicago, IL) was used 
for statistical analysis. Accepting a maximal incidence of 20% of grade 3 pneumonitis 
as primary endpoint (according to CTCAE v3.0-criteria), a number of 29 patients was 
calculated to be included. If at maximum 3 out of 29 patients (10.5%, upper limit of 
one-sided 95% confidence interval: 19.7%) would develop grade 3 pneumonitis the 
schedule would be considered to be safe for the primary endpoint. Results are    
expressed as mean±standard deviation (SD), unless otherwise stated. Crude      
incidences of pulmonary complaints (cough and dyspnea), esophageal dysphagia and 
skin dermatitis (maximum score) according to CTCAE v3.0-criteria were calculated for 
Table 9.1 Acute and late toxicity according to CTCAE version 3.0 criteria. 
Grade 1 2 3 4 5 
Acute toxicity      
Cough Symptomatic, 
non-narcotic 
medication only 
indicated 
Symptomatic 
and narcotic 
medication 
indicated 
Symptomatic 
and significantly 
interfering with 
sleep or ADL 
    
Dyspnea Dyspnea on 
exertion, but can 
walk 1 flight of 
stairs without 
stopping 
Dyspnea on 
exertion but 
unable to walk 1 
flight of stairs or 
1 city block 
without stopping 
Dyspnea with 
ADL 
Dyspnea at rest; 
intuba-
tion/ventilator 
indicated 
Death 
Dysphagia Symptomatic, 
able to eat 
regular diet 
Symptomatic 
and altered 
eat-
ing/swallowing, 
iv fluids <24 hrs 
Severely altered 
eat-
ing/swallowing; 
iv fluids, tube 
feeding or TPN 
≥24 hrs 
Life-threating 
consequences 
Death 
Dermatitis Faint erythema 
or dry desqua-
mation 
Moderate-briske 
erythema; 
patchy moist 
desquamation, 
mostly confined 
to skin folds and 
creases; 
moderate edema 
Moist desquama-
tion other than 
skin folds and 
creases; 
bleeding induced 
by minor trauma 
or abrasion 
Skin necrosis or 
ulceration of tull 
thicknees 
dermis; 
spontaneous 
bleeding from 
involved site 
Death 
Late toxicity      
Pneumonitis Asymptomatic, 
radiographic 
findings only 
Symptomatic, 
not interfering 
with ADL 
Symptomatic, 
interfering with 
ADL; O2 
indicated 
Life-threating ; 
ventilatory 
support indicated 
Death 
Pulmonary fibrosis 
(radiographic changes) 
Minimal 
radiographic 
findings (or 
patchy or 
bibasilar 
changes) with 
estimated 
radiographic 
proportion of 
total lung 
volume that is 
fibrotic of <25% 
Patchy or bi-
basalar changes 
with estimated 
radiographic 
total lung 
volume that is 
fibrotic of 25-
<50% 
Dense or wide-
spread in-
flitrates/consolid
ation with 
estimated 
radiographic 
proportion of 
total lung 
volume of 50-
<75% 
Estimated 
radiographic 
proportion of 
total lung 
volume that is 
fibrotic is ≥75%; 
honeycombing 
Death 
Abbreviations: CTCAE=Common Terminology Criteria for Adverse Events; ADL=activities of daily living; TPN=total 
parenteral nutrition. 
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the acute phase (90 days from start of radiotherapy) and pneumonitis and pulmonary 
fibrosis for the late phase (>90 days from start of radiotherapy). Progression-free 
survival (time between start radiotherapy and first evidence of local or distant    
recurrence, in case of death without recurrence patients were censored) and overall 
survival (time between start of radiotherapy and death due to any cause) were calcu-
lated according to the Kaplan-Meier method. Patients still alive at the time of analysis 
were censored at the last day of follow-up. Follow-up data from all patients were 
collected until April 1, 2007. At this date, 13 months after the inclusion of the last 
patient, data were analyzed. 
Ethics 
This study was reviewed and approved by the local Medical Ethical Committee,   
according to the Dutch law and regulations. All patients gave written informed consent 
before inclusion. 
Results 
Patient and treatment characteristics 
Between December 2004 and March 2006, a total of 29 patients (20 men and 9 
women) were enrolled in the study. One patient was not treated according to the study 
protocol, but received inappropriately our standard protocol, a classical once daily 
scheme of 60 Gy in 30 fractions in 6 weeks, and was excluded from further analysis. 
Patient and tumor characteristics of all 28 patients are listed in Table 9.2. Concerning 
lymph nodal status 7 patients had cN0, 1 patient cN1, 11 patients cN2 (3 pathologically 
confirmed) and 9 patients cN3 (4 pathologically confirmed). 
 
Median follow-up for the total group of patients was 13.9 months (range 0.8-24.2 
months), with a median follow-up of 17.2 months (range 9.6-23.0 months) for patients 
still alive at the time of analysis. 
 
Twenty-four patients (86%) received induction chemotherapy, consisting of three 
courses of Gemcitabine in combination with Cisplatin or Carboplatin. Seventeen out of 
the 24 patients (70.8%) who received chemotherapy had a partial response after three 
cycles, with no complete remissions observed. The remainder showed stable disease. 
The median interval between the last day of chemotherapy and the first day of  radio-
therapy was 35 days. 
 
Mean TTD was 63.0±9.8 Gy (range 46.9-79.2 Gy) in 1.8 Gy fractions twice daily in a 
mean OTT of 24±4 days. In 5 out of 28 patients (17.9%, all stage IIIB) the maximal 
allowed TTD of 79.2 Gy could be delivered. 
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Only 1 patient (3.6%) received a dose below 50 Gy (46.9 Gy) and 11 patients (39.2%) 
received a dose between 50 and 60 Gy.The maximal TTD was most often limited by the 
MLD (32.1%), and secondly by the spinal cord dose (28.6%), or both (10.7%). In 3 
patients (10.7%) other structures were dose limiting: the main bronchii and plexus 
brachialis. In 3 patients, a major protocol violation was encountered. Two patients with 
limited lung function (FEV1 <50% of predicted value and/or a DLCO <50%) were 
included in the study, and in one patient the TTD was not escalated up to the maximal 
allowed dose. Eight minor protocol violations were observed, including 6 patients with a 
maximal spinal cord dose of more than 54.5 Gy (range 55.1-57.1 Gy) and 2 patients 
with an MLD above 20 Gy (20.7 Gy and 20.8 Gy, respectively). 
Toxicity 
Acute toxicity during the first 3 months was scored for all 28 patients (Figure 9.1). 
Most patients experienced only mild acute toxicity. Regarding pulmonary complaints, 
almost 70% of patients (n=19) experienced increased cough, but only 6 patients 
required narcotic medication (e.g. codeine) during fractionated radiotherapy. One 
patient (3.6%) developed grade 3 cough toxicity. Dyspnea was less frequently    
observed; only 4 patients (14.3%) had a grade 1 or 2 dyspnea toxicity score. One 
patient (3.6%) died 51 days after radiotherapy due to pneumonitis (grade 5 toxicity). 
Acute esophageal toxicity was generally mild, although most patients (85.7%) had 
symptomatic dysphagia grade 1 or 2. Only 1 patient (3.6%) developed severe swal-
lowing symptoms (grade 3), requiring temporarily tube feeding. No grade 2 or higher 
dermatitis was observed during or after radiotherapy. 
 
Table 9.2 Patient, tumor and treatment characteristics.  
Characteristic 
Mean age (years)  65.0 (50-80)  
Gender Male  19 (68)  
 Female 9 (32)  
WHO performance score 0 20 (71)  
 1 8 (29)  
Clinical stage I 2 (7)  
 II 0 (0)  
 IIIA 7 (25)  
 IIIB 19 (68)  
Histology 
Squamous cell 
carcinoma  9 (32)  
 Adenocarcinoma 5 (18)  
 Large cell carcinoma 14 (50)  
Induction chemotherapy Yes 24 (86)  
 No 4 (14)  
Mean GTV in cc Primary tumor 93.9 (0.4-660.2)  
 Lymphnodes 25.2 (0-155.0)  
Mean total tumor load in cc  119.2 (12.2-674.4)  
Mean TTD in Gy  63.0 (46.8-79.2)  
Mean MLD in Gy  16.6 (6.8-20.8)  
Mean Maximal spinal cord in Gy  46.3 (6.8-57.3)  
Mean OTT in days  24.4 (17-31)  
Values expresses as mean (range) or number (percentage). Abbreviations: GTV=gross tumor volume; TTD=total 
tumor dose; MLD=mean lung dose; OTT=overall treatment time. 
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Two patients died within 90 days. One patient died of a myocardial infarction within 
one week after the last fraction of radiotherapy (tumor in right upper lobe, mean heart 
dose 20.9 Gy). The other patient died of an acute respiratory distress syndrome based 
on pneumonitis, as described. The total dose prescribed for this last patient with an 
impaired lungfunction (FEV1 104% and DLCO 38%) was 61.2 Gy with an MLD of 
15.5 Gy. 
 
With a median follow-up of 13.9 months, 26 patients were available to assess late 
toxicity. Seventy days after radiotherapy radiographic changes were shown in 92% of 
patients (n=24) on CT (73% in <25% and 19% in >25% of the lungs). However, only 
one third of patients (10 of 26 patients) had clinical symptoms (≥grade 2 pneumoni-
tis). Two patients (7.7%) had severe symptoms of cough and dyspnea interfering with 
activities of daily living (grade 3 pneumonitis), whereas in 4 patients corticosteroids (in 
3 out of 4 inhalation corticosteroids only) were prescribed. Regarding dysphagia, 
3 patients (11.5%) had swallowing symptoms 2 to 9 months after radiotherapy. Two 
patients had mild symptoms, but were able to eat a regular diet. One patient with 
grade 2 dysphagia developed simultaneous a locoregional recurrence, which might 
explain the complaints. 
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Figure 9.1 Maximum toxicity score of acute toxicity within 90 days (a) and late toxicity after 90 days (b) according 
to CTCAE-criteria version 3.0 (Table 9.1). 
b 
a 
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Outcome 
At the time of analysis, 15 patients (53.6%) had died. The median overall survival was 
19.6 months (range 0.8-26.3 months) with an estimated 1-year and 2-year survival 
rates of 57.1% and 47.1% respectively, as shown in Figure 9.2a. 
 
At a median follow-up of 13 months, the incidence of loco-regional tumor progression 
was 35.7% (n=10). Only 2 patients (7.1%) had isolated local recurrence as first site of 
relapse, both showing an in-field recurrence. There was no isolated nodal recurrence. 
In 4 of 10 patients loco-regional progression was simultaneously (within 1 month) with 
distant metastases. In 3 out of these 4 patients, loco-regional progression was not 
located within the original radiation fields. About 40% of patients (11 of 28) developed 
distant metastases during follow-up. Median progression free survival was 10.2 months 
(range 0.8-23.6 months) with estimated 1-year and 2-year progression free survival 
rates of 53.8% and 27.1%, respectively (Figure 9.2b). 
PET and CT response 
A follow-up PET-CT scan was performed in 26 out of 28 patients 70 days after radio-
therapy to evaluate tumor response. Two patients died within 70 days after radio-
therapy and in 1 patient only CT data were available, due to a technical problem with 
the PET scanner. The PET-CT showed in 15 patients (60%) a metabolic response, 
consisting of a complete metabolic response in 11 patients (44%) and a partial   
metabolic response in 4 patients (16%). Three patients (12%) showed stable disease, 
while 7 (28%) patients showed progressive disease. According to the RECIST criteria 
13 patients (50%) showed a response, consisting of one (4%) complete response and 
12 (46%) partial responses (response on PET vs. CT; p<0.01). In all 7 patients (28%) 
showing progressive metabolic disease on PET, this was confirmed on CT. All these 
patients showed metastatic disease, in three combined with local or loco-regional 
progression. 
Discussion 
The main purpose of this study was to evaluate the feasibility of individualized dose 
prescription based on normal tissue dose constraints, basically an MLD of 19 Gy for 
lung and a maximal dose of 54 Gy for the spinal cord. The radiation dose was delivered 
in twice-daily fractions of 1.8 Gy with an 8-hour interval between fractions. First results 
of this prospective trial are promising, showing that this approach can be applied safely 
with acceptable toxicity. Mainly mild acute lung toxicity was observed; although in 1 
patient pneumonitis was the cause of death shortly after radiotherapy. Acute esophag-
eal toxicity was generally mild. In a dose escalation study performed by Belderbos et 
al., about half of the patients (48/88) had grade 1 or 2 acute esophagitis11. Similar 
esophageal toxicity results were observed by Kong and colleagues18. We encountered a 
greater percentage (86%) of symptoms of dysphagia grade 1 or 2 during radiotherapy. 
About half of the patients had problems swallowing and therefore a change in diet (e.g. 
soft diet). However, only 1 patient (3.6%) developed severe swallowing symptoms 
(grade 3), requiring tube feeding. No patient had an interruption of radiation treatment 
due to dysphagia symptoms. 
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The greater proportion of esophageal complaints might be explained by our accelerated 
schedule, as Saunders et al. found similar results in the Continous Hyperfractionated 
Accelerated Radiation (CHART) study36. In our study acute esophagitis was not dose 
limiting. Therefore, our policy not to include a specific dose constraint for the eso-
phagus, when no concurrent chemoradiation was administered, is supported by these 
results. 
 
Radiation pneumonitis can be scored using different toxicity scoring systems, resulting 
in a large heterogeneity in literature. We used the CTCAE v3.0 scoring system, while 
other authors used the Southwest Oncology Group (SWOG) criteria3,18. These two 
scoring methods differ, e.g. in their description of grade 2 radiation pneumonitis 
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Figure 9.2 Actuarial overall survival (a) and progression free survival (b). Abbreviations: RT=radiotherapy. 
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(SWOG grade 2, oral corticosteroids prescription; CTCAE grade 2, symptomatic, not 
interfering with ADL). Clinically significant radiation pneumonitis is usually seen in 13 
to 37% of patients treated for lung cancer with radical radiotherapy37. In our study we 
observed in 10 of 26 patients at risk (38.4%) a clinical (CTCAE v3.0 ≥grade 2) pneu-
monitis. Most patients had mild symptoms, not interfering with ADL (30.8%), whereas 
only 1 patient (4%) needed oral steroid prescription (grade 2 according to SWOG 
criteria). Two of the 10 patients (7.7%) had a grade 3 pneumonitis (CTCAE v3.0), 
indicating symptomatic pneumonitis, interfering with ADL and/or oxygen indicated. 
These results are in line with the results of other dose-escalation studies3,18,36. Kong et 
al. found minimal symptoms in 28.4% of patients, while 11% needed corticosteroid 
treatment and 5% had grade 3 pneumonitis (SWOG criteria)18. Similar results were 
observed by Belderbos et al.3. Moreover, our results are below the maximal acceptable 
incidence of 20% of grade 3 pneumonitis we used as primary endpoint. 
 
Previous studies have shown that local tumor control was dependent on the radiation 
dose3,4,38. A mean tumor dose of 63.0 Gy (range 46.9-79.2 Gy) in a mean OTT of 24 
days could be delivered without undue toxicity. The present schedule is biologically 
equivalent to approximately 80 Gy delivered in once-daily fractions of 2 Gy and the 
side-effects are within range as predicted in an in silico trial by our group23. In our 
study the maximal allowed TTD of 79.2 Gy could be prescribed in 5 patients (18%). We 
observed only 2 isolated local recurrences (7%), while the incidence of loco-regional 
tumor progression was 35.7% (n=10). In 4 patients loco-regional progression was 
simultaneous detected with distant metastases. Moreover, there was no isolated nodal 
recurrence, confirming that it is safe to apply selective nodal irradiation based on PET-
scan3,21. Thus, although one third of all patients (n=10) received 54 Gy or less because 
of normal tissue dose constraints and a mean dose of 63.0 Gy could be given in a short 
OTT, our results are similar to the literature, in which much higher doses were required 
to obtain the same local tumor control3,39. This confirms the therapeutic gain that can 
be expected by reducing the OTT, e.g. applying an accelerated schedule, compared 
with conventionally fractionated schedules. The present schedule thus allows delivery 
of high biological radiation doses in a less selected patient population. In addition, a 
large proportion of our study patients usually would not be considered for dose-
escalation studies or even radical radiotherapy, due to tumor localization close to the 
spinal cord, resulting in inclusion of the spinal cord in the PTV and/or inclusion of large 
lung volumes. 
 
Although not the aim of this study, we observed a promising outcome, with a 1-year 
survival rate of 57% and an estimated 2-year survival rate of 47%. A median overall 
surivival of almost 20 months is in line with other dose-escalation study results2-4. 
However, we could achieve this with lower total radiation doses given in an accelerated 
schedule and in patients otherwise not to be considered for high dose radiotherapy. 
Interestingly, the present results as well as those of others suggest that overall  
survival rates could be achieved with sequential chemotherapy and high-dose radiation 
schedules that are similar to concurrent chemoradiation schemes, but with less acute 
toxicity8,9,40-42. This does not come as a surprise, since the increased survival of   
patients undergoing concurrent chemoradiation is caused by a better local tumor 
control and not a decreased incidence of metastatic disease7-9. 
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Because a large proportion of patients with lung cancer has significant co-morbidity12, 
they are excluded from concurrent chemo-radiation schemes. We therefore believe that 
optimizing non-concurrent radiation strategies is still very valuable. These patients may 
potentially benefit from an individualized prescription of radiation treatment given in a 
schedule that combines the principles of dose escalation and acceleration. 
 
In conclusion, individualized maximal tolerable dose irradiation based on normal tissue 
dose constraints is feasible, and first results for 28 patients seem promising. A phase II 
trial is ongoing in our department to further assess the gain of this individualized 
radiation treatment. 
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Discussion 
Non-small cell lung cancer (NSCLC) is one of the most frequent cancers diagnosed1,2. 
Many patients are diagnosed in an advanced stage of the disease. Although resection is 
regarded as the treatment with the highest probability of long-term remission and 
cure, only about 25% of NSCLC tumours are suitable for potential curative resection3. 
Lung cancer has in general a poor prognosis, with a 5-year overall survival of about 
15%2,4,5. Whereas the treatment of choice for early stage NSCLC is surgery, inoperable 
and locally advanced disease is mainly treated with radiation alone or radiotherapy 
combined with chemotherapy. The main problem of radiotherapy in NSCLC is the high 
risk of local tumour failure. Moreover, a high number of patients develop distant 
metastases, and therefore it is associated with a poor overall survival. Several issues 
need to be solved, which might contribute to improvement of radiation treatment 
outcome in NSCLC. Among these are: a correct delineation of the target volume, the 
prescription of an adequate total radiation dose to increase tumour control and an 
adequate delivery of the dose taking into account tumoural changes during radiother-
apy. The aim of the work described in this thesis was to optimize radiation treatment in 
NSCLC, and the role of PET-CT into achieving this goal. 
Target volume delineation 
Radiation dose delivery is preceded by treatment planning. Generally a CT scan is used 
for target volume delineation. The advantage of CT-based planning is that a CT gives 
detailed information of the anatomy of the patient; it shows the relation between 
tumour and healthy tissue and allows for the correction of tissue inhomogeneities in 
radiation treatment planning. An adequate delineation of the target volume is a pre-
requisite for a precise radiation treatment. If the delineation is not performed correctly, 
it will influence the total chain of radiation treatment. Moreover, geographical miss of 
the tumour during radiotherapy will inverse the probability of loco-regional control. 
First of all, delineation accuracy can be improved using a standardized delineation 
protocol. Such a protocol should include fixed window-level settings for both the 
primary tumour and mediastinal lymph nodes. 
 
Nowadays PET(-CT) is increasingly used as pre-treatment scan in radiotherapy6-21. PET 
has a high accuracy for mediastinal staging in NSCLC compared with CT; PET shows a 
sensitivity of about 80%-90% and a specificity of 70-90%, compared with a sensitivity 
of CT between 30% and 80%22-25. Therefore, the use of PET to determine the nodal 
target volume will improve target volume delineation. Moreover, PET might be used to 
determine the border between tumour and atelectatic lung tissue. The introduction of 
PET into target volume delineation has therefore changed the volume and localization 
of the delineated gross tumour volume (GTV)7,9,10,15,16,18-20. 
 
In addition the introduction of PET into target volume delineation in lung cancer has 
consistently shown a reduction in interobserver variation compared with CT-based 
delineation12,18,26-28. In the currently used procedures, target volume delineation is 
mainly carried out manually. In contrast to CT, PET signals are very suitable for auto-
mated segmentation. Several methods have been described to achieve this. The most 
often used auto-segmentation methods are based on a certain intensity level, e.g. a 
fixed standardized uptake value (SUV) or a percentage of the maximal SUV11,15,29-34. 
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SUV is defined as the average activity per unit volume normalized to the injected dose 
and patient body weight, and is influenced by several factors. Among the factors that 
interfere with SUV are the volume and shape of the Region Of Interest (ROI), the 
partial-volume effect, attenuation correction and reconstruction methods35-39. SUV is 
also influenced by the time of evaluation of PET images and by the normalization 
factor. Therefore, the usage of absolute SUV for auto-segmentation is only reliable in a 
standardized setting and findings cannot be generally applied due to inter-institutional 
differences. More sophisticated methods for automated segmentation are the source-
to-background (SBR) method, three segmentation methods-thresholding, Sobel edge 
detection, the background-subtracted relative-threshold level (RTL) method and the 
gradient-based watershed approach32,40-43. Yet, most of the above mentioned methods 
are only validated in phantom studies. Therefore, it is not totally clear which is the best 
method to be used in clinic, and this still needs to be further evaluated. As pathologic 
examination is the golden standard, ideally these methods need to be validated with 
histology. Until now, this is only done in laryngeal tumours, for both the SBR method 
and the gradient-based segmentation method41,44. In this thesis the SBR method for 
NSCLC has been validated and showed a good correlation with pathology for both the 
primary tumour as well as for the lymph nodal areas. Moreover, PET based automatic 
delineation will further reduce interobserver variation in target volume delineation 
(Chapter 5). Auto-contouring can therefore improve daily practice target volume 
delineation and will facilitate and standardize target volume delineation in multi-
institutional studies. 
Margins 
Not only precise target volume delineation but also the margins used for clinical target 
volume (CTV) and planning target volume (PTV) are of critical importance. The CTV is 
created by adding a certain margin to the GTV to allow for microscopic extension45. 
These margins are based on the correlation between pathologic examination and 
image-based delineation. Giraud et al. compared the pre-treatment CT-based diameter 
of the tumour with the diameter at histological examination in 70 NSCLC patients46. 
They observed that a 5 mm margin from GTV to CTV will cover about 80% of micro-
scopic extension in case of adenocarcinoma and 91% for squamous cell carcinoma. To 
encompass all microscopic disease in at least 95% of patients, a margin of 8 mm for 
adenocarcinoma and 6 mm for squamous cell carcinoma was needed. Additional 
studies investigated the relation between tumour size on CT and histology47,48. Grills 
and colleagues observed in a 35 patient study that CT underestimated tumour size and 
they found that a CTV margin of 9 mm was needed to cover microscopic extension for 
90% of cases47.  In contrast, Chan et al. found in a pilot study of 5 patients that the 
CT-based GTV overestimated the area of microscopic disease, resulting in no margin 
needed from GTV to CTV48. However, in this study for most patients only bidimensional 
pathologic measurements were available and no information was given regarding the 
window-level settings used for CT, which certainly influences CT-based diameters as 
shown by Grills et al.47. Currently a study is performed to gain more insight into the 
exact position of PET and CT in tumour border definition compared with actual micro-
scopic extension in NSCLC, taking into account the lung deformation due to surgery49. 
 
Only limited information is available for the margins needed for lymph nodes. Yuan and 
colleagues reviewed nodal extracapsular extension in 243 patients and found that the 
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extent of extracapsular extension was in 95% less than 3 mm50. The CTV for lymph 
nodes to encompass extracapsular node extension should therefore be at least 3 mm. 
 
For radiation treatment planning an additional margin is added to create the PTV. 
Whereas CTV covers the microscopic extension, the margin used for PTV covers geo-
metric uncertainties as well as general tumour motion51. A standard planning CT is a 
free-breathing CT, which is a snapshot in time and therefore, does not take into ac-
count respiratory movement of the tumour. A respiratory correlated CT (RC-CT) is a CT 
scan during which the respiration signal is recorded and therefore gives information 
about the tumour motion in all directions during respiration52-54. To correct adequately 
for tumour motion due to respiration, a RC-CT should be used to assess the extent of 
tumour motion due to respiration, and to calculate an individual adapted margin to 
compensate for this movement52. 
Biological meaning of FDG uptake on PET 
It was repeatedly shown that a high SUVmax is correlated with an inferior overall sur-
vival in NSCLC, both in patients treated with surgery as well as radiotherapy55-59. The 
semi-quantitative SUV is a representation of the underlying tumour metabolism, 
although the exact mechanism by which glycolysis is upregulated within the tumour 
has not fully been unravelled35. Proliferative tumour activity might play a role in the 
amount of uptake of 18F-fluoro-2-deoxy-glucose (FDG). Veselle et al. and Nguyen et al. 
showed a correlation between Ki-67 expression and SUVmax , although this finding was 
not observed by others56,60-62. Contradictory findings have also been observed, re-
garding the (over)expression of the glucose transporters and the uptake of FDG in 
NSCLC56,60,63-65. These differences in findings might partially be explained the use of 
different methods, antibodies, scoring methods and cut-off levels used in the studies. 
Another candidate, which might play an important role in the FDG uptake, is hypoxia. 
Stabilization of the Hypoxia Inducible Factor-1α (HIF-1α) pathway under hypoxic 
conditions will lead to the upregulation of glucose transporters, the vascular endothelial 
growth factor (VEGF), carbonic anhydrase IX (CAIX) and other target genes66,67. 
Preclinical studies, both in tumour cell lines and in animal models, suggest that hypoxic 
conditions correspond to a higher FDG uptake62,68,69. In a mouse model the uptake of 
FDG in a Von Hippel Lindau (VHL) knockdown tumour was two-fold increased compared 
with controls70. This might indicate that HIF plays a role in the uptake of FDG, since 
carcinomas with mutations in the VHL-gene show a high expression of HIF. We   
confirmed that hypoxia, as expressed by HIF-1α, in vivo is associated with an increase 
in uptake of FDG (Chapter 3). In addition, hypoxia is known to be an important cause 
of treatment failure in many tumours. Overexpression of both HIF-1α and CAIX, a 
pathway regulating pH within the cell, has been related to a poor outcome71-75.   
Therefore, the correlation between a high uptake of FDG with a high expression of the 
hypoxia-related marker HIF-1 α, might explain the underlying mechanism of the 
relation between a high uptake of FDG and a poor outcome. 
 
Although the maximal uptake of FDG within a tumour is related to outcome, one has to 
realize that the uptake of FDG is heterogeneous within the tumour. This variation in 
uptake of FDG might reflect heterogeneity of ongoing pathophysiological processes. 
The identification of the intra-tumour heterogeneity for different tumour characteristics 
by non-invasive imaging techniques, like PET, would allow specific targeting76. One of 
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the possibilities is radiation surdosage of the areas with a high uptake of FDG. There-
fore, it would be of great interest to further investigate the biological background of the 
intra-tumour heterogeneity in NSCLC for FDG uptake on PET scan, applying the       
‘ex-vivo’ method described in Chapter 4. 
Repeated PET-CT scanning: before, during and after radiotherapy 
As described above, the PET(-CT) scan is increasingly used in radiation treatment 
planning of NSCLC. Although visual interpretation of PET-CT images is still dominating, 
auto-segmentation can contribute to a more standardized and improved use of PET in 
target volume delineation6,10-21. PET scan would be even of more clinical value, if it 
would enable prediction of response to radiation treatment early during the course of 
fractionated radiotherapy. The concept could be similar to early response measure-
ments during chemotherapy in other tumour sites and the monitoring of neo-adjuvant 
therapy in NSCLC77-80. Repeated PET scanning during radiotherapy might allow for early 
metabolic response prediction, and would give the opportunity to individually adjust 
ongoing treatment, which might consists of adapting the radiation dose or adding 
another form of treatment. Moreover, repeated CT scanning should be used to adapt 
target volume in case of an enlargement of volume during radiation, to avoid      
geographical misses. This enlargement of volume during fractionated radiotherapy is 
seen in about 15% of patients, as described in Chapter 6. Whether radiation fields 
should be adapted in case of a decrease in GTV is less clear. No information is available 
concerning the remaining (microscopic) tumour load left behind in the surrounding 
tissues, which were originally included in the GTV. 
 
Furthermore, PET can be used to assess treatment outcome after radiotherapy81-85. In 
a study performed by Wong et al. the change in maximal SUV after radiotherapy was 
more accurate in predicting local control than the change in CT-based tumour size82. 
We confirmed that patients showing a metabolic response on the post-radiotherapy 
scan showed a better overall survival compared with non-responders (Chapter 7)83. 
Dose escalation 
Applying radiation biology principles a higher radiation dose should result in a higher 
local control probability. It is estimated that a total tumour dose (TTD) of 84 Gy (2 Gy 
fractions, once daily) is needed to achieve about 50% tumour control probability86. 
Several clinical dose escalation trials have shown promising results87-92. Timmerman 
and colleagues performed a dose-escalation study in patients with medically inoper-
able, stage I disease using extra-cranial stereotactic radiotherapy88. Most other dose-
escalation studies have been performed in a combined group of patients with stage I to 
III disease and showed higher local control rates and/or a better overall survival in 
patients receiving the highest dose91,93. Dose escalation is limited by damage to normal 
tissues. The most critical organs in radiation treatment of NSCLC are the lungs, the 
spinal cord, but also mediastinal structures, like great vessels and main bronchi. 
Several dosimetric factors for normal lung tissue, such as relative V20 (volumes of lung 
receiving more than 20 Gy) and mean lung dose (MLD) have been shown to be useful 
to estimate the risk of radiation pneumonitis95,96. The use of (FDG) PET-CT scans for 
target volume delineation in NSCLC might further allow dose escalation, since its use 
decreased radiation exposure of the oesophagus and lung6,17. This decrease in    
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exposure of normal tissues indeed allowed for a significant radiation dose escalation, 
which lead to an increase in estimated tumour control probability6,17. Omitting elective 
irradiation of the mediastinum, and selectively irradiate pathologic lymphnodal areas, 
also allows for dose-escalation. At least 2 prospective studies have shown that it is safe 
to selectively irradiate the FDG-PET positive mediastinal nodes91,100. 
 
However, not only the TTD delivered, but also the overall treatment time in which the 
radiation treatment is given is an important determinant of outcome. In the CHART 
trial a hyperfractionated, accelerated scheme (54 Gy in 12 days, 1.5 Gy 3 times per 
day) was compared with a conventional scheme of 60 Gy in 6 weeks, 2.0 Gy once 
daily101. This trial showed a 2-year overall survival of 30% for the CHART schedule 
compared with 21% for the conventional scheme. Moreover, the recent CHARTWELL 
study confirmed the importance of overall treatment time102. 
 
Most of the above mentioned dose escalation studies have used strict inclusion criteria, 
e.g. invasion in the great vessels and/or involved supraclavicular nodes were not 
allowed91,93. Therefore, the results of dose escalation and accelerated schedules can 
only be applied to this selected subpopulation of NSCLC patients. Especially in case of a 
small tumour volume the TTD can be easily escalated up to higher doses, whereas the 
possibilities for larger tumour volumes are limited. Especially the more difficult cases, 
with tumours growing directly into the mediastinum or great vessels or tumours 
located in the direct proximity of the spinal cord are challenging. It is also important in 
these cases to achieve the best result possible for each individual patient. We therefore 
applied an individualized radiation schedule including the highest achievable TTD based 
on individualized normal tissue dose constraints and delivered in a short overall treat-
ment time. A theoretical gain in total tumour control probability of 25% can probably 
be achieved using a personalized maximal tolerable dose scheme, given in twice daily 
fractions of 1.8 Gy instead of a classic scheme of 60 Gy in 2.0 Gy fractions once daily. 
The results of our in silico trial were confirmed in our prospective clinical trial (Chapter 
8 and 9). 
General Conclusions 
Due to its high diagnostic accuracy in NSCLC, PET-CT scans have acquired their place 
in radiation treatment of NSCLC. The uptake of FDG on PET scan has also a prognostic 
value, since a high uptake is correlated with a poor survival. The amount of uptake of 
FDG as seen on pre-treatment scans is associated with the expression of hypoxia 
related markers, as tumours with a high SUVmax express in a higher proportion HIF-1α 
and GLUT-1 compared with tumours with a low uptake. 
 
PET-CT scans are increasingly used for target volume delineation. Furthermore, PET 
can be used for automatic segmentation. The source-to-background (SBR) automatic 
segmentation method has been validated in NSCLC and not only reduces the      
delineated volume of the GTV, but also reduces interobserver variation in target  
volume delineation. Therefore, auto-contouring should be used to standardize target 
volume delineation in multi-institutional studies and can be easily applied in daily 
practice. 
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PET-CT scans should however not only be used before start of radiation therapy, but 
repeated scanning during therapy is needed. This will allow adjustment of radiation 
fields according to changes in target volumes during radiotherapy, to avoid geographi-
cal misses. The repeated scans also provide information regarding the evolution of FDG 
uptake during fractionated radiotherapy, which may be prognostic for outcome. 
 
Finally, the use of FDG-PET scans for target volume delineation shows smaller target 
volumes. This leads to decreased radiation exposure of normal tissues and will there-
fore allow for dose-escalation. Applying an individualized dose prescription, delivering 
the maximal tolerable dose based on individual dose constraints, will ultimately lead to 
more favourable results of radiation treatment in NSCLC. 
Future perspectives 
Although the use of PET next to CT improves target volume delineation in NSCLC, 
several issues implementing PET(-CT) in radiation treatment remain unresolved. Some 
of these are related to respiratory tumour motion. In contrast to the fast acquisition of 
CT, the acquisition of a standard PET image takes 3 to 5 minutes. If a PET is performed 
during free breathing, it consists of an average image of multiple respiratory cycles. 
Therefore, it blurs the target volume and might result in an overestimation of the GTV. 
Methods to correct for this respiratory motion, such as respiratory-correlated PET   
(RC-PET) are developed to overcome this problem. The combined use of a respiration 
correlated CT and PET scan might further improve the estimation of the tumour volume 
and the exact localization of the tumour103,104. Moreover, applying RC-PET will also 
affect the measured level of SUV and can influence maximal uptake values in up to 
30% compared with static images38,103. If both respiration correlation and phased 
attenuation correction are applied, the determination of maximal SUV will be more 
reliable and thus better suited for tumour characterization and might also further 
improve PET based auto-segmentation. The assessment of individual tumour      
movement will also enable individualisation of the margins used for PTV, and thus 
reduce the risk of geographical miss. In case of limited tumour movement, individual 
margins for PTV might be condensed, allowing for further dose escalation. 
 
Other issues that need to be further addressed are the spatial resolution of PET and 
tumour edge definition. The current spatial resolution of PET (5 to 6 mm) is large 
compared with the spatial resolution of CT (about 1 mm). The limited spatial resolution 
of PET contributes to the blurring of the image and might therefore also influence the 
tumour edge definition. Although technical advances might improve the resolution of 
PET, it is likely to be limited to a resolution of 2 to 3 mm. 
 
18F-FDG is the most widely available and used tracer for PET in oncology. Although the 
uptake of FDG is correlated with outcome, FDG is not a very specific tracer. FDG is 
likely to be related to clonogenic density and might be seen as general tracer for the 
identification of tumour cells within the body. False-positive findings can be caused by 
inflammation or physiological uptake, whereas false-negative scans can occur in slowly 
growing tumours. However, more specific tracers are currently being evaluated49,105. 
One field of interest is the imaging of hypoxia. 18F-labeled Fluoromisonidazole         
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(18F-MISO) is the most widely examined nitroimidazole derivative, representing a non-
invasive method for the quantification of the oxygenation status. Although F-MISO is 
feasible for imaging, the clinical use is limited due to a low tumour-to-background ratio 
and the slow clearance from normoxic cells49,106. A more promising PET tracer for the 
visualization of tumour hypoxia might be the 18F-labeled nitroimidazole compound 
fluoroazomycin arabinoside (18F-FAZA), since this tracer has a higher tumour-to-
background ratio compared with 18F-MISO107,108. The hypoxia related tracers might also 
be useful in predicting response to treatment85,109. Moreover, specific tracers to image 
cellular proliferation and apoptosis are investigated. Another interesting field of   
research concerns the coupling of monoclonal antibodies to radioisotopes for PET110,111. 
This will enable the evaluation of the binding properties of the monoclonal antibodies 
and the visualization of the presence of receptors for these antibodies in vivo. Labeling 
of the Epidermal Growth Factor Receptor (EGFR) inhibitor Cetuximab to the positron 
emitter 89Zirconium, might give the opportunity to visualize the binding of Cetuximab 
in vivo and can therefore be used to specific target EGFR110. A similar approach might 
be applied to image hypoxia in vivo and to target CAIX112. 
 
One has to be aware that tumours are not homogenous, but actually heterogeneous for 
several biological characteristics113. It is the ultimate aim to visualize these tumour 
characteristics by imaging76. Potentially PET might be used to map these different 
areas within the tumour with specific characteristics. Selective targeting of the most 
radioresistant areas within a tumour might improve local control rates and therefore 
survival in the radiation treatment of NSCLC. One of the most essential questions to be 
addressed at the outset is whether areas with a high uptake of FDG remain stable 
during fractionated radiotherapy. Moreover, one has to get informed about the exact 
localization of residual disease and/or recurrence after radiotherapy. If recurrences are 
predominantly detected in the pre-treatment FDG hotspots and moreover, if these 
areas remain stable during fractionated radiotherapy, this would allow selective sub-
boosting of these specific areas. Therefore, we are currently investigating the stability 
of FDG uptake during radiotherapy and the localisation of residual disease114. One of 
the problems which need to be tackled is the comparison and matching of post- and 
pre-radiation scans correctly, since deformation is encountered for both normal tissues 
as well as tumour after radiation treatment. 
 
In conclusion, (radiation) treatment for NSCLC needs to be further individualized. First 
of all, the treatment modality of choice for an individual patient should not only be 
based on TNM-classification and the general condition of the patient. More dedicated 
tools are needed to predict outcome. A method to achieve this is the use of the so-
called computer assisted theranostics. The term theranostics refers to diagnostic tests 
that identify the suitability of a specific treatment for an individual patient. Treatment 
can be individually utilized according to test results. This concept is usually referring to 
targeted drugs, but might also be applicable to radiation treatment. Tools are needed 
to select individual patients for combined treatments, like chemo-radiation or a combi-
nation of radiotherapy and monoclonal antibodies and/or new molecules. The use of 
new tracers and labelled antibodies in molecular imaging might assist in this selection 
procedure. 
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Moreover, in case of radiotherapy the target volume and margins used need to be 
further individualized. Improvement in auto-delineation methods, combined with the 
use of more dedicated imaging, including RC-PET-CT will indeed improve target volume 
delineation and will allow determination of individual margins. 
 
Once treatment has started, therapy needs to be adapted according to treatment 
induced changes. For radiotherapy this means that radiation treatment planning should 
not only be based on pre-treatment scans, but individual changes in tumour volume, 
tumour movement and even metabolic changes during therapy should be taken into 
account. The shape and size of radiation fields, the total tumour dose, as well as the 
dose distribution within the tumour and even the combination of several treatment 
modalities need to be reconsidered during therapy. Treatment needs to be adapted 
according to the individual needs of both the patient, as well as the tumour. Further 
individualization will ultimately lead to an improvement of (radiation) treatment in 
NSCLC. 
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Introduction 
Chapter 1 contains a general introduction of the staging and treatment of non-small 
cell lung cancer (NSCLC). Moreover, the general role of the positron emission tomo-
graphy (PET) scan in staging of NSCLC cancer is discussed and the objectives of this 
thesis are described. 
 
The main questions addressed in this thesis are: 
 What is the biological meaning of FDG-uptake on PET scan? 
 Can FDG-PET-CT scan further improve the characterization and definition of the 
target volume? 
 Can the treatment of NSCLC be improved by individualization of radiotherapy? 
 
In Chapter 2 a review is given of the current role of PET(-CT) scan in radiation    
treatment of NSCLC. Until recently PET scan, mainly using 18F-Fluoro-deoxyglucose 
(FDG) as a tracer was primarily used for staging purposes in NSCLC, because of its 
high accuracy compared with CT. Its use has in individual patients resulted in a change 
in stage and treatment. Nowadays PET is also increasingly used to define target vol-
ume in radiation treatment planning for NSCLC. Although both an increase as well as a 
decrease in target volumes has been described, most studies have shown a mean 
decrease of 20 to 25%. Changes are mainly caused by a change in nodal target volume 
and the exclusion of atelectasis. Incorporation of PET seems to improve tumour cover-
age and spare normal tissues, which may lead to less toxicity or the possibility to 
escalate dose. Moreover, combining PET and CT reduces interobserver variability in 
target volume delineation compared with CT alone. However, more research is needed 
to assess the exact role of PET in radiation treatment of NSCLC. 
The biological meaning of FDG uptake in NSCLC 
 
The biological meaning of the uptake of 18F-fluoro-2-deoxy-glucose (FDG) as visualized 
on PET scan is discussed in Chapter 3 and Chapter 4. The maximal uptake of FDG in 
the primary tumour was consistently shown to be an independent prognostic factor for 
survival. But the actual mechanisms by which a high FDG uptake leads to a worse 
prognosis are not well known. Chapter 3 describes the results of a retrospective study, 
in which the relation between the maximal standardized uptake value (SUVmax) and a 
proliferation-related marker (Ki-67), glucose transporters (GLUT-1 and GLUT-3) and 
hypoxia related markers (HIF-1α and CAIX) was investigated. One hundred and two 
patients, scheduled for complete resection, received a diagnostic PET scan and their 
surgical specimens were used for immunohistochemical staining. It was shown that the 
actuarial survival was worse for patients having a tumour with a high SUVmax. More-
over, tumours with a high SUVmax expressed in a higher proportion HIF-1α and GLUT-1 
compared with tumours with a low SUVmax. Both markers are upregulated under  
hypoxic conditions. This study provides evidence that not only in vitro, but also in vivo 
hypoxia is associated with an increase in FDG uptake. 
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Tumours are heterogeneous for several biological characteristics; therefore it is the 
ultimate aim to visualize tumour characteristics by imaging. Variations in the FDG 
uptake within the tumour might reflect heterogeneity of ongoing pathophysiological 
processes. In Chapter 4 the feasibility to correlate intra-tumour heterogeneity as 
visualized on FDG PET with histology for NSCLC is evaluated. For this purpose we used 
an ex-vivo model. FDG was injected just before surgery and the surgical specimen 
were scanned. The procedure was feasible in all 5 patients. This method can also be 
applied to other tumour types and PET tracers, and can provide more insight infor-
mation in the biological correlates of intra-tumour heterogeneity. Finally, this would 
allow for specific targeting and hence improvement of treatment outcome in NSCLC. 
The role of FDG-PET scan in radiotherapy of NSCLC 
Chapters 5 to 7 deal with the role of PET-CT before, during and after radiation treat-
ment. First of all, before start of radiotherapy delineation accuracy can be improved 
using PET. The PET scan signal can be utilized to automatically delineate tumours. In 
Chapter 5 the Source-to-Background (SBR) based auto-contouring method is validated 
for NSCLC. The maximal tumour diameter of the SBR based auto-contour correlated 
strongly with the macroscopic diameter of primary tumours and was shown to be 
accurate for involved lymph nodes. Moreover, the influence on interobserver variability 
compared with manual PET-CT based gross tumour volume (GTV) delineation was 
investigated. The auto-contour based target volumes decreased the delineated target 
volumes and reduced the interobserver variability. Auto-contouring may therefore 
further improve the quality of target delineation in NSCLC patients. 
 
PET-CT scan also be used to assess changes in tumour volume, tumour motion and 
FDG uptake during a course of fractionated radiotherapy. The results of repeated    
PET-CT scans and Respiration Correlated CT scans prior to treatment and in the first 
and second week of radiotherapy are reported in Chapter 6. A striking heterogeneity of 
tumour volume changes was observed at all time points. Although for the majority of 
patients the tumour volume only changed slightly (<30%), in some patients (4/23) the 
volume decreased >30% and in others (3/23) the volume increased >30%. No signifi-
cant changes in average tumour motion or breathing frequencies were observed during 
fractionated radiotherapy. These findings underscore the need for repeated imaging 
during the course of radiotherapy, since an increase in volume without changing the 
radiation fields will lead to inadequate tumour coverage. 
 
In Chapter 7 we investigated changes in FDG uptake during fractionated radiotherapy 
in relation to metabolic response after radiation treatment. Like for tumour volumes, 
the evolution of SUVmax showed a large intra-individual heterogeneity. Whereas for 
metabolic responders no change in SUVmax was observed during radiotherapy,     
metabolic non-responders showed an 48% increase during first week followed by a 
decrease in the second week. Furthermore, non-responders had a higher SUVmax 
compared with responders at all time points investigated and showed a significantly 
worse overall survival compared to metabolic responders. The difference in time trends 
in SUVmax might reflect intrinsic tumour characteristics and might finally enable adjust-
ment of treatment. 
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Clinical implications: the role of individualized 
radiotherapy in NSCLC 
The use of PET-CT scan for target volume delineation may reduce the delineated target 
volume and might therefore give the possibility to escalate dose. Dose-escalation is 
one of the approaches to overcome the high number of local recurrences, which is one 
of the major problems after (chemo-)radiation in NSCLC. Therefore, for each individual 
patient the highest therapeutic ratio should be achieved by increasing the total tumour 
dose (TTD) to the limits of normal tissues; the so-called individualized maximal   
tolerable dose. 
 
Chapter 8 depicts the theoretical gain in estimated tumour control probability (TCP) 
that can be achieved when an individualized maximal tolerable dose (MTD) prescription 
is used. Five treatment plans were compared; the first two employed a classic    
fractionation of 2 Gy/day (5 days/week) to a total dose of 60 Gy (QDclassic) or deter-
mined by individualized MTD dependent upon normal tissue dose constraints for lung 
and spinal cord (QDMTD). The third scheme assumed a hypofractionated schedule of 
2.75 Gy fractions (QDhypofr), while the fourth and fifth scheme were based on hyperfrac-
tionation and acceleration (1.8 Gy twice daily, BIDclassic and BIDMTD). While both      
dose-escalation and hypofractionation resulted in an increase in mean estimated TCP 
compared with a classic fractionation to a total dose of 60 Gy, the combination of 
escalation and acceleration (BIDMTD) improved the mean estimated TCP with more than 
25%. 
 
In Chapter 9 we report the first results of a prospective feasibility trial applying the 
MTD prescription model. All 28 patients included in this study were irradiated using an 
individualized prescribed total tumour dose, based on normal tissue dose constraints 
(mean lung dose of 19 Gy and maximal spinal cord dose of 54 Gy) up to a maximal 
TTD of 79.2 Gy in 1.8 Gy fractions twice daily. The TTD was most often limited by the 
mean lung dose. Acute toxicity was in general mild, although 1 patient died due to 
pneumonitis. Concerning late toxicity, 2 patients had grade 3 toxicity. We showed that 
an individualized maximal tolerable dose irradiation, based on normal tissue dose 
constraints, is feasible and that initial results showing a median overall survival of 19.6 
months are promising. 
 
Finally, Chapter 10 contains a discussion of the results of this thesis with regard to the 
current standard of radiation treatment of NSCLC. Furthermore, it contains the general 
conclusions and future perspectives. 
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Introductie 
Hoofdstuk 1 bevat allereerst een algemene introductie met betrekking tot de stadiëring 
en de behandeling van longkanker. In Nederland bedraagt het aantal nieuwe patiënten 
met longkanker ongeveer 9000 per jaar. Longkanker is de tweede meest voorkomende 
kanker bij mannen en de derde bij vrouwen (www.ikcnet.nl). De prognose van long-
kanker is in het algemeen slecht met een 1-jaarsoverleving van ongeveer 40% en een 
5-jaarsoverleving van 15%.  
 
Longkanker kan worden onderverdeeld in het kleincellige (20%) en niet-kleincellige 
type (80%). De behandeling van niet-kleincellige longkanker is afhankelijk van het 
stadium van de ziekte en de algemene conditie van de patiënt. Patiënten met een 
vroeg stadium van longkanker, die in een goede algemene conditie zijn, komen in 
aanmerking voor chirurgische resectie. Patiënten met lokaal gevorderde ziekte komen 
in principe in aanmerking voor een gecombineerde behandeling van radiotherapie en 
chemotherapie. En in het geval van metastasen kan worden gekozen voor palliatieve 
chemotherapie en/of ondersteunende zorg. In dit stadium kan radiotherapie een 
belangrijke rol spelen bij de palliatie van pijnlijke (bot)metastasen. 
 
De positron emissie tomografie (PET) scan heeft een belangrijke rol in de diagnostiek 
van longkanker. De PET scan is een functionele beeldvormingstechniek, waarbij een 
radioactieve isotoop wordt ingebracht in de patiënt. Met behulp van een speciale 
camera kan de straling, uitgezonden door de radioactieve isotoop, gedetecteerd 
worden en kan er een afbeelding gemaakt worden van de verdeling van de isotoop in 
het lichaam. 18F-Fluoro-deoxyglucose (FDG) is de meest gebruikte radioactieve isotoop 
en geeft inzicht in het glucose metabolisme. 
 
In het eerste hoofdstuk worden eveneens de doelstellingen van dit proefschrift   
beschreven, waarbij een drietal vragen centraal staan: 
 Wat is de biologische betekenis van opname van FDG in de longtumor op de     
PET scan? 
 Wat is de rol van de PET scan in de radiotherapeutische behandeling van         
niet-kleincellige longkanker? 
 Kan de behandeling van niet-kleincellige longkanker verbeterd worden door de 
toepassing van geïndividualiseerde radiotherapie? 
 
In hoofdstuk 2 wordt een overzicht gegeven van de huidige rol van de PET scan in de 
radiotherapeutische behandeling van longkanker. De PET scan wordt veelal gebruikt 
voor de stadiëring van longkanker, omdat de PET scan accurater is dan de computer 
tomografie (CT). Op basis van de PET scan wordt in een aantal individuele gevallen een 
ander klinisch stadium vastgesteld, wat leidt tot een wijziging van de voorgenomen 
behandeling. De PET scan kan ook gebruikt worden om het doelvolume ten behoeve 
van de radiotherapieplanning te bepalen. Toevoeging van de PET scan informatie aan 
conventionele beeldvorming leidt in een aanzienlijk aantal patiënten tot een veran-
dering van het doelvolume. Deze verandering wordt voornamelijk bepaald door een 
verschil in het aantal aangedane lymfeklieren op basis van de PET scan in vergelijking 
met de CT scan. Daarnaast biedt de PET scan de mogelijkheid om onderscheid te 
maken tussen tumor en atelectase (een aandoening waarbij een deel van de long geen 
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lucht meer krijgt en daardoor samenvalt). Gemiddeld neemt het doelvolume door het 
gebruik van de PET scan 20 tot 25% af. Door het gebruik van de PET scan kan de 
tumor beter gevisualiseerd worden, waardoor de exacte positie van de tumor met een 
grotere nauwkeurigheid bepaald kan worden. Dit heeft als gevolg dat er een kleiner 
risico is op het geografisch missen van een deel van de tumor. Daarnaast kan de PET 
scan leiden tot een betere sparing van het omliggende gezonde weefsel, met als 
consequentie een afname van de bijwerkingen en/of de mogelijkheid tot het geven van 
een hogere radiotherapiedosis. Een ander voordeel van de combinatie van de PET en 
CT scan ten behoeve van de bepaling van het radiotherapie doelvolume, is dat de 
variatie van intekening tussen de verschillende artsen afneemt. Aanvullend onderzoek 
is echter nog nodig om de uiteindelijke rol van de PET scan in de radiotherapeutische 
behandeling van longkanker te bepalen.  
De biologische betekenis van de opname van FDG in 
longkanker  
De biologische betekenis van de opname van FDG, zoals deze gezien wordt op de    
PET scan, wordt besproken in hoofdstuk 3 en 4. De maximale opname van FDG in de 
primaire tumor is een prognostische factor met betrekking tot overleving. Over het 
onderliggende mechanisme, waarom een hoge FDG opname leidt tot een slechte 
prognose, is weinig bekend. In hoofdstuk 3 worden de resultaten van een retro-
spectieve studie, waarin de relatie tussen de maximale opname van FDG uitgedrukt als 
‘standardized uptake value’ (SUVmax) en de immuunhistochemische expressie van 
diverse markers beschreven. In het totaal ondergingen 102 patiënten met longkanker 
een PET scan voorafgaande aan een operatie. Biopten van de tumor genomen uit het 
longpreparaat werden gebruikt voor immunohistochemische kleuringen: een prolifera-
tie gerelateerde marker (Ki-67), glucose transporters (GLUT-1 and GLUT-3) en hypoxie 
gerelateerde markers (HIF-1α and CAIX). De overleving van patiënten met een tumor 
met een hoge SUVmax was beduidend slechter dan die van patiënten met een tumor 
met een lage SUVmax. Bovendien toonden tumoren met een hoge SUVmax in grotere 
mate aankleuring voor de markers HIF-1α en GLUT-1 in vergelijking met tumoren met 
een lage SUVmax. Beide markers komen in toenemende mate tot expressie onder 
hypoxische omstandigheden. Deze studie toont aan dat niet alleen in vitro, maar ook 
in vivo hypoxie geassocieerd is met een toename in opname van FDG.  
 
Tumoren tonen heterogeniteit voor diverse biologische kenmerken. Het zou daarom 
uiterst interessant zijn als deze heterogeniteit in beeld gebracht kan worden door 
middel van beeldvorming. Mogelijk geeft de variatie in opname van FDG binnen een 
tumor, zoals deze gezien wordt op de PET scan, heterogeniteit in biologische processen 
binnen de tumor weer. In hoofdstuk 4 wordt een ex-vivo methode beschreven, waarin 
de intra-tumor heterogeniteit in FDG opname wordt gecorreleerd met onderliggende 
pathofysiologische processen. Hiervoor werd bij 5 patienten FDG toegediend juist voor 
de operatie en werd de verwijderde tumor gescand in de PET scanner. Deze methode is 
bruikbaar en kan eveneens toegepast worden in andere tumoren en met behulp van 
andere PET tracers. De ex-vivo methode kan kan meer inzicht geven in de biologische 
achtergrond van intra-tumor heterogeniteit zoals gevisualiseerd op de PET scan. De 
informatie verkregen via deze methode geeft de mogelijkheid voor specifieke, doel-
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gerichte behandeling van de verschillende subvolumina binnen een tumor met als 
uiteindelijke doel de verbetering van de behandelingsresultaten van niet-kleincellige 
longkanker. 
De rol van de FDG-PET scan in de radiotherapeutische 
behandeling van niet-kleincellige longkanker  
Hoofdstuk 5 tot en met 7 beschrijven de rol van de PET-CT scan voorafgaande aan, 
gedurende en na afloop van de radiotherapeutische behandeling van niet-kleincellige 
longkanker. Voorafgaande aan de radiotherapie kan de PET scan gemaakt worden om 
het doelvolume van de radiotherapie te bepalen. Het PET signaal kan gebruikt worden 
om de tumor automatisch in te tekenen. In hoofdstuk 5 wordt de automatische in-
tekening van de tumor gebaseerd op de ‘Source-to-Background’ (SBR) methode ge-
valideerd voor niet-kleincellige longkanker. De maximale diameter van de primaire 
tumor vastgesteld door middel van de SBR methode toonde een goede correlatie met 
de macroscopische diameter zoals vastgesteld bij pathologisch onderzoek. Eveneens 
blijkt de SBR methode accuraat te zijn voor de intekening van aangedane lymfeklieren. 
In deze studie is ook gekeken naar de invloed van de automatische intekening op de 
variatie van intekening van de tumor door verschillende artsen. Als uitgangssituatie 
werd de intekening van 33 longtumoren door 5 artsen gebruikt. Vervolgens werd deze 
5 artsen gevraagd de 33 tumoren nogmaals in te tekenen, nu met de SBR auto-
contour als uitgangspunt. Hierdoor nam het gemiddelde ingetekende volume af en de 
variatie tussen de diverse intekeningen van de artsen nam eveneens af. De SBR 
automatische intekenmethode verbetert de kwaliteit van de intekening bij              
niet-kleincellige longkanker en dient te worden gebruikt als basis voor klinische studies 
en in de dagelijkse praktijk. 
 
De PET-CT scan kan eveneens gebruikt worden om veranderingen gedurende de 
radiotherapeutische behandelingen in beeld te brengen. In dit proefschrift worden de 
veranderingen in het tumor volume, de tumor beweging en de mate van opname van 
FDG beschreven. In hoofdstuk 6 worden de resultaten van herhaalde PET-CT scans en 
herhaalde ademhalingsgecorreleerde CT scans voorafgaande aan de radiotherapie en 
gedurende de eerste 2 weken van de radiotherapie gepresenteerd. Er werd een grote 
variatie in individuele tumorvolumeveranderingen gezien. Bij sommige patiënten 
(4/23) neemt het tumorvolume af (>30%), terwijl bij anderen (3/23) het tumorvolume 
met meer dan 30% toeneemt. Het merendeel van de patiënten toont echter geen 
evidente verandering in het tumorvolume gedurende de bestralingsperiode. Deze 
studie toonde geen significante veranderingen in gemiddelde tumorbeweging en/of 
ademhalingsfrequentie gedurende de bestraling. Echter gezien het feit dat een toe-
name in tumorvolume zonder aanpassing van de radiotherapievelden kan leiden tot 
een inadequate dekking van de dosis ter plaatse van de tumor, is het van wezenlijk 
belang om het tumorvolume gedurende de radiotherapie door middel van CT te   
controleren.  
 
In hoofdstuk 7 worden de veranderingen in opname van FDG gedurende en na afloop 
van de radiotherapie beschreven. De veranderingen in maximale FDG opname (SUVmax) 
in de tumor tonen een grote variatie tussen de verschillende patiënten. De PET-CT scan 
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zeventig dagen na de laastste fractie radiotherapie werd gebruikt om de mate van 
metabole respons te bepalen. Patiënten, die op dit tijdstip een complete of partiele 
respons toonde, leefden significant langer dan de zgn. metabole non-responders. 
Bovendien toonden deze 2 groepen patiënten verschillende patronen van SUVmax 
gedurende de bestraling. Terwijl er bij metabole responders sprake was van een 
stabiele SUVmax gedurende de radiotherapie, toonde de groep metabole non-responders 
een gemiddelde toename van 48% van de SUVmax gedurende de 1e week, gevolgd door 
een afname in de 2e week van de radiotherapie. Op alle onderzochte tijdstippen hadden 
de metabole non-responders een hogere SUVmax als de metabole responders. Het 
verschil in de hoogte van de SUVmax en het verschillende tijdsbeloop kan mogelijk 
veroorzaakt worden door intrinsieke tumorkarakteristieken. De veranderingen in 
volume dan wel opname van FDG zouden uiteindelijk gebruikt kunnen worden om de 
behandeling gedurende de radiotherapie aan te passen. 
Klinische implicaties: de rol van geïndividualiseerde 
radiotherapie van niet-kleincellige longkanker 
Het gebruik van de PET-CT scan voor de bepaling van het doelvolume kan leiden tot 
een afname van het doelvolume. Dit geeft de mogelijkheid om de radiotherapiedosis te 
verhogen, zonder dat daarbij een veranderd bijwerkingsprofiel van normale weefsels 
verwacht hoeft te worden. Na (chemo-)radiatie is het aantal patiënten, dat een lokaal 
recidief ontwikkelt echter nog erg hoog. Dosis-escalatie wordt gezien als één van de 
mogelijkheden om het aantal lokale recidieven te verminderen. Het is daarom van 
belang dat iedere individuele patiënt de hoogst mogelijke radiotherapiedosis (de zgn. 
totale tumor dosis, TTD) toegediend krijgt ter plaatse van de lokale tumor en de 
aangedane lymfeklieren. Hierbij dient de tolerantie van de gezonde weefsels wel in 
acht genomen te worden. Dit principe wordt de geïndividualiseerde maximaal     
tolerabele dosis genoemd.  
 
In hoofdstuk 8 wordt het theoretische model van de geïndividualiseerde maximaal 
tolerabele dosis beschreven en de mogelijke winst in tumor controle, die hiermee 
behaald kan worden. In dit hoofdstuk worden 5 radiotherapieschema’s met elkaar 
vergeleken: een conventioneel klassiek schema, een geaccelereerd radiotherapie-
schema (meerdere fracties per dag), een gehypofractioneerd schema (een hogere 
fractiedosis) en twee geïndividualiseerde schema’s (een schema in éénmaal dagelijkse 
fracties en een geaccelereerd schema). Deze planningsstudie laat zien dat er een grote 
winst is te verwachten met betrekking tot de kans op tumor controle bij de toepassing 
van een geïndividualiseerd, geaccelereerd schema in vergelijking met alle andere 
radiotherapieschema’s.  
 
In hoofdstuk 9 worden de eerste resultaten beschreven van een prospectieve, klinische 
studie waarin het geïndividualiseerde maximaal tolerabele dosis schema werd toege-
past. In totaal werden 28 patiënten geïncludeerd in de studie. De patiënten werden 
bestraald tot een maximaal tolerabele dosis gebaseerd op de normale weefsel-
tolerantie, te weten een gemiddelde longdosis van 19 Gy en een maximale dosis op het 
ruggenmerg van 54 Gy. De maximaal voorgeschreven dosis bedroeg 79,2 Gy gegeven 
in fracties van 1,8 Gy tweemaal daags. De totale bestralingsdosis werd het vaakst 
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beperkt door de gemiddelde longdosis. De acute bijwerkingen waren in het algemeen 
mild, hoewel 1 patiënt is overleden ten gevolge van een longontsteking. Met betrekking 
tot de bijwerkingen op lange termijn hadden 2 patiënten een graad 3 bijwerking. Deze 
studie heeft aangetoond dat radiotherapie op basis van een geïndividualiseerde  
maximaal tolerabele dosis, waarbij rekening wordt gehouden met de normale weefsel-
tolerantie, haalbaar is. De eerste resultaten zijn veelbelovend, en tonen een mediane 
overleving van 19,6 maanden en een 1-jaars en 2-jaars overleving van respectievelijk 
57,1% en 47,1%. 
 
Ten slotte, bevat hoofdstuk 10 de discussie van de resultaten beschreven in dit    
proefschrift ten aanzien van de huidige standaard behandeling en de recente literatuur. 
In dit hoofdstuk worden eveneens de toekomstperspectieven beschreven.  
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Nu het wetenschappelijke deel geschreven is, hoop ik weer meer tijd te krijgen voor 
mijn hobby’s, waaronder koken. Al lijkt het doen van onderzoek en het schrijven van 
een proefschrift wel op het bereiden van een menu. Ik wil u in dit dankwoord dan ook 
graag meenemen in de bereiding van mijn menu.  
 
De bereiding van een menu begint met het bedenken ervan. Gelukkig werd het menu 
mede opgesteld door Prof. Lambin, de promotor en Dr. De Ruysscher, de copromotor. 
Beste Philippe, ik ben je zeer erkentelijk voor de geboden kansen en het vertrouwen: 
de opleiding, de mogelijkheid om 3 jaar full-time onderzoek te doen en je bijdrage aan 
de artikelen en presentaties. Beste Dirk, mede door jouw begeleiding, sturend en 
steeds kritisch, is dit proefschrift tot stand gekomen. Je grenzenloze enthousiasme, de 
tijd die je nam om te discussiëren en je uitgebreide ervaring in het doen van onderzoek 
en het schrijven van wetenschappelijke artikelen hebben mede tot dit resultaat geleid.  
 
Daarnaast is net zoals bij koken een goede voorbereiding van essentieel belang. Het 
begint met een goede basis: goede omstandigheden en de juiste ingrediënten. 
 
Het is erg fijn om in een goede keuken te mogen koken. Zo is er het fantastische 
longteam, waar ik deel vanuit mocht maken. Beste Rinus, bedankt voor de vele in-
tekeningen en je klinische bijdrage. Beste Liesbeth, bedankt voor de vele leerzame 
discussies en je kritische beoordelingen van de manuscripten. Het is soms niet leuk om 
te zien dat je eigen recept wordt aangepast, maar als vervolgens het eindresultaat 
dusdanig verbeterd, geeft dat zeker een goed gevoel. 
 
Geert het was fijn dat we samen in dezelfde pan konden roeren. Jouw fysische toe-
voegingen hebben mijn medische recepten zeker verrijkt. Onze gezamenlijke inspan-
ningen hebben dan ook geleid tot een mooi zeven gangen menu. Hoewel Geert de 
grootste fysische bijdrage heeft geleverd, wil ik zeker ook een aantal andere fysici 
bedanken. André Minken, jammer dat je je nu toelegt op de Overijsselse keuken, maar 
bedankt voor je bijdrage aan de eerste PET-CT recepten. André Dekker, bedankt voor 
je kritische houding ten aanzien van de studieopzet, de analyse en de manuscripten. 
Hugo, bedankt dat je samen met mij in de ‘heterogene brei’ wilde roeren. Michel, onze 
‘PET fysicus’, bedankt voor je ondersteuning en je inspanningen voor de auto-
contouring. Wouter, bedankt dat je de recepten in Matlab hebt willen uitwerken.  
 
Ik heb voor het bereiden van dit menu ook gebruik mogen maken van de faciliteiten 
van aangrenzende keukens. De longartsen en longchirurgen van het azM, Atrium 
Medisch Centrum, Maasland Ziekenhuis Sittard, Laurentius Ziekenhuis Roermond en 
Sint Jansgasthuis Weert, wil ik bedanken voor hun medewerking aan de verschillende 
studies. In het bijzonder wil ik Monique Hochstenbag en Anne Marie Dingemans bedan-
ken voor hun bijdragen. Ook de afdeling pathologie heeft een groot aandeel gehad in 
de bereiding van het menu. Anique Janssen bedankt voor de introductie in immuno-
histochemie, en de groep arts-assistenten voor het uitsnijden van de vele longprepa-
raten. Beste Robert-Jan, bedankt voor het beoordelen van de vele coupes. Het was 
altijd leerzaam en bovendien gezellig om menig recept met je te delen en over   
begeleidende wijnen te discussiëren.  
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Lekker eten staat of valt natuurlijk ook bij het gebruik van goede, bij voorkeur verse 
ingrediënten. Het zal u niet zijn ontgaan dat het belangrijkste ingrediënt van dit menu 
de PET-CT scan is. Het gebruik van PET beelden voor de radiotherapie planning vereist 
een goede samenwerking tussen de afdeling Nucleaire Geneeskunde en de afdeling 
Radiotherapie. Ik wil dan ook de afdeling Nucleaire Geneeskunde van het azM bedan-
ken voor hun ondersteuning. Beste Marinus, bedankt voor je bijdrage aan de diverse 
protocollen en je aanvullingen op de manuscripten vanuit een nucleair oogpunt.  
 
Ingrediënten, die hier niet direct leverbaar waren werden in het buitenland ingeslagen. 
Beste Christophe Dooms, Johan Vansteenkiste, Erik Verbeken en Sigrid Stroobants 
(Leuven) bedankt voor de fijne samenwerking. Beste Søren Bentzen, bedankt voor je 
bijdrage aan de auto-contouring en de in silico studie.  
 
De inkoop van de beste ingrediënten is alleen mogelijk met een goed budget. Ik wil het 
onderzoeksinstituut GROW (UM) en Biocare (EC FP6) dan ook bedanken voor de 
geboden mogelijkheden: het doen van onderzoek, maar ook de kans om de resultaten 
in binnen- en buitenland te presenteren.  
 
En natuurlijk wil ik iedereen bedanken, die direct of indirect heeft bijgedragen aan een 
van de gangen van dit menu. Allereerst de patiënten, die bereid waren herhaalde PET-
CT scans te ondergaan. Daarnaast de co-auteurs en mijn directe collega’s: de radio-
therapeut-oncologen, de laboranten, de (secretariële) ondersteuning en niet te verge-
ten de groep arts-assistenten. Als onderzoekster mocht ik toch een kamer met ze 
delen en er was altijd een kop koffie en een luisterend oor. Cary en Ruud wil ik be-
danken voor de statistische ondersteuning, Bianca voor de bewerking van de foto’s en 
Rianne voor de secretariële ondersteuning van de promotie. 
 
Zoals ook met koken is de receptuur van dit proefschrift in de loop van de tijd regelma-
tig aangepast. In de beginfase was er nog de experimentele keuken: Kim, Ludwig en 
Jan bedankt voor jullie hulp bij de ‘in-vitro’ recepten. Goede ideeën en suggesties van 
collega’s hebben uiteindelijk geleid tot verdere verbeteringen van het menu, waardoor 
de gangen beter op elkaar zijn afgestemd.  
 
Lekker eten hoort natuurlijk begeleid te worden door een goed glas wijn. De wijn moet 
ten eerste op dronk en in evenwicht met het eten zijn. Daarnaast heb je natuurlijk nog 
de persoonlijke voorkeur: de één prefereert een Rioja, terwijl de ander de voorkeur 
geeft aan een Bourgogne wijn. Ik heb ook geleerd dat het belangrijk is om een fles 
wijn soms even te laten liggen om deze verder op dronk te laten komen. En dat geldt 
ook voor sommige ideeën in dit proefschrift: deze hebben even op het vat moeten 
rijpen voordat ze tot uitvoering zijn gebracht.  
 
Verder wil ik de beoordelingscommisie graag bedanken voor het voorproeven van dit 
menu: Prof. van Engelshoven, Prof. Grosu, Prof. Teule en Dr. ten Velde bedankt dat u 
de tijd heeft gevonden om dit menu te beoordelen en van waardevolle opmerkingen te 
voorzien.  
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Nu het menu bijna klaar is, dient het te worden opgediend en hierbij hoort natuurlijk 
een mooie opmaak van de gerechten. Patricia, bedankt voor het ontwerp en de profes-
sionele opmaak van de omslag.  
 
Het belangrijkste van een menu is echter het genieten ervan samen met familie en 
vrienden. Ik wil mijn ouders bedanken voor hun steun en hun vertrouwen in mij. Mede 
dankzij jullie voorbeeld om door te zetten, heb ik dit bereikt. Daarnaast wil ook alle 
familie en vrienden bedanken, waarmee ik regelmatig gezellig heb mogen tafelen. 
Tijdens deze etentjes kwam geregeld mijn onderzoek ter sprake: bedankt voor jullie 
interesse en enthousiaste reacties. In het bijzonder wil ik mijn paranymfen Saskia en 
Jeroen bedanken.  
 
Tenslotte lieve Marcel bedankt dat je de bereiding en het opdienen van dit menu 
samen met mij hebt willen delen. Bedankt voor je steun, je begrip en je liefde.  
 
Ik zou u nu graag allen willen uitnodigen om samen met mij aan tafel te gaan en te 
gaan genieten van dit menu.  
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Curriculum Vitae 
Angela van Baardwijk werd geboren op 23 september 1971 in Waalwijk en groeide op 
in Drunen. In 1989 voltooide zij haar VWO diploma aan het Dr. Mollercollege in   
Waalwijk en aansluitend startte zij met de studie Geneeskunde aan de Universiteit 
Maastricht. In september 1996 behaalde zij het artsexamen en werkte ruim 2 jaar als 
assistent geneeskunde niet in opleiding Heelkunde in het Maasland Ziekenhuis in 
Sittard. In februari 1999 werd gestart met de opleiding Heelkunde in het academisch 
ziekenhuis Maastricht (opleiders: Prof. G. Kootstra en Prof. M. Jacobs). In april 2001 
verwisselde zij op eigen initiatief de opleiding Heelkunde voor de opleiding tot radio-
therapeut-oncoloog in het Radiotherapeutisch Instituut Limburg (de huidige MAASTRO 
clinic) met als opleiders Dr. J. Jager en Prof. P. Lambin. Vanaf 2004 werd de opleiding 
gedurende 3 jaar onderbroken voor het promotie onderzoek, zoals beschreven in dit 
proefschrift. Dit onderzoek vond plaats binnen het onderzoeksinstituut ‘Growth and 
Development‘ van de Universiteit Maastricht onder directe begeleiding van Dr. D. De 
Ruysscher en Prof. P. Lambin als promotor. In juli 2007 hervatte zij de opleiding 
Radiotherapie binnen MAASTRO clinic, die zij in oktober 2008 verwacht af te ronden. 
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